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ABSTRACT

Messenger RNA Transport and Translation Regulated by the 3' UTRs of Dendritic mRNAs
and Abnormal Alternative Splicing of Neuroligin1 in the Fmr1 KO Mouse Hippocampus
by
Tianhui Zhu
Advisors: Dr. Paul Feinstein
Fragile X Syndrome (FXS) is one of the most commonly inherited mental retardations. It
is caused by the loss of functional fragile X mental retardation protein (FMRP). Loss of
functional FMRP is the most widespread single-gene cause of autism. The most prominent
phenotype of FXS patients is an IQ ranging from 20 to 70. FMRP is an RNA binding protein,
widely expressed in almost all tissues and highly expressed in brain. As a RNA binding protein,
85-90 % of FMRP in the brain is associated with polyribosomes. Approximately 4 % of total
mRNA is associated with FMRP, which functions in the stability, transport and translational
regulation of its targeted mRNAs.
The 3’ untranslated region (3’UTR) of mRNAs can be important for their subcellular
localization and translational regulation. Many genes contain localization elements in their
3’UTRs that enable transcripts to localize to dendrites for site-specific translation. FMRP
functions as a translational regulator in this process.
Local translation of certain proteins is crucial to synaptic plasticity. Synaptic plasticity is
the ability of a synapse to regulate its strength over time in response to stimuli. It is the basis of
learning and memory. The two forms of long-term plasticity are long-term depression (LTD) and
long-term potentiation (LTP). FXS patients and Fmr1 KO mice all show exaggerated LTD in the
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hippocampus, which is the center of emotion, memory, and the autonomic nervous system. In
addition, some types of abnormal LTP have been demonstrated in Fmr1 KO mice. These
evidences indicate that FMRP plays an important role in synaptic plasticity through translational
regulation of target mRNAs.
Neuroligin (NL) is a family of neural adhesion molecules. Neuroligins are transmembrane proteins located at the post-synaptic membrane and bind with pre-synaptic adhesion
molecules known as NEUREXIN (NRX). Neuroligins function in synaptogenesis, synapse
differentiation, and synapse maintenance. Importantly, they have been shown to be involved in
autism and other cognitive diseases.
Both neuroligins and neurexins are products of alternative splicing. The recognition
between neuroligins and neurexins is splice variant-dependent. This variant-specific binding
triggers different downstream signals for synaptogenesis and synapse differentiation. The work
presented here addresses the targeting of FMRP to the 3’ UTR of some dendritic mRNAs and
their translational regulation. And for the first time, we demonstrate that FMRP is involved in the
alternative splicing of mRNA. FRMP is found related to Neuroligin1 splicing in mice
hippocampus.

v

ACKNOWLEDGMENT
Accomplishing this doctoral dissertation is the most significant challenge I have ever
encountered in my life, in both academic aspect and life aspect. I was being offered kind and
generous help during my study. It is a great pleasure to share my appreciation to the people who
helped to make this achievement possible.
Most important of all, I am sincerely and heartily grateful to my mentor Dr. Paul
Feinstein for his support and guidance to finish this thesis. I want to thank him for being so
generous with his time to help me complete this thesis, for his encouragement to pursue my
dream, for his guidance to conquer the obstacles in life, and for sharing his knowledge and
wisdom in both science and life. I am so lucky to have shepherd Paul as my mentor to complete
my PhD study.
I want to thank Dr. Jason Dictenberg for his help in the experiments. His knowledge and
encouragement inspired and motivated me to finish the experiments.
I would like to express my deepest gratitude to the members of my committee, Dr.
Mitchell Goldfarb, Dr. Carmen V. Melendez-Vasquez, Dr. Jonathan Levitt, and Dr. Robert H
Singer, for their invaluable time, insightful advice and support. I would like to thank all my
second level exam committee members, Dr. Robert H. Singer, Dr. Diana P. Bratu, Dr. Frida E.
Kleiman, Dr. Francis S. Y. Lee and Dr. Samie Jaffrey, for their precious opinions about my
research.
I would also like to thank the support of the Biochemistry Ph.D. Program at the Graduate
Center of City University of New York. I am truly grateful and really appreciated for Dr. Edward

vi

Kennelly, Dr. Richard Magliozzo and Mrs. Judy Li for all the help in the past years. I could not
have got this done without your help.
I also want to give my best appreciation to my lab members, Marcus Ng, Sam Lau,
Christopher Ferrari, Charlotte D'Hulst, Valérie Drouet, Genoveva Uzunova and Astrid Musnier.
Especially, I would like to thank Hao Wu and Ivan Cohen, who are my “band of brothers” who
provided many insightful opinions to my research, also help me a lot in my life with their selfless
support and endless encouragement.
I would like to thank Aaron Greller, George Wallace, Franka Warner-Johnson and Jim
Kominski and many of you all who helped me a lot at Biology Department of Hunter College. I
would like to thank Lloyd Williams and Zhong Wang from the bio-image facility for their help. I
would like to thank all the people working in the animal facilities: Barbara Wolin, Sonia
Avevedo, Sally, Pat and all the other staff for taking care of our mice.
I want to thank my friends and colleagues Tomasz Rusielewicz, Prospero Lugo,
Magdalena Kiprowska, Mateusz Urbanski, Hu Wang, Marlon Jansen, Eugene Lempert, Jie Gao,
Qian Huang and every graduate student in Hunter College and Graduate Center who helped me. I
want to give my special thanks to Dr. Christine Cain, who gave tremendous effort in helping
editing the thesis, so I can get it done in time.
I would like to thank my family for their understanding, patience, and support. Thank you
all for endless love and tolerance so I could focus on my study. I wish I could have spent more
time with you. This thesis is dedicated to my most beloved grandmother, who passed away
during my PhD study.

vii

TABLE OF CONTENTS
TITLE .............................................................................................................................................. i
COPY RIGHT ................................................................................................................................. ii
ABSTRACT ................................................................................................................................... iv
ACKNOWLEDGMENT................................................................................................................ vi
TABLE OF CONTENTS ............................................................................................................. viii
LIST OF ABBREVIATIONS ....................................................................................................... xii
LIST OF FIGURES AND TABLES............................................................................................ xiii
CHAPTER

1

INTRODUCTION ............................................................................................. 1

1.1

Introduction of autism ...................................................................................................... 2

1.2

The Fragile X Syndrome (FXS) and FMRP..................................................................... 3

1.3

FMRP and mRNA transport............................................................................................. 7

1.4

Local translation and translational regulation by FMRP ............................................... 11

1.5

FMRP and synaptic plasticity ........................................................................................ 14

1.6

Neurexin and Neuroligin ................................................................................................ 20

1.7

FMRP and RNA processing ........................................................................................... 25

1.8

Specific aims .................................................................................................................. 30

Chapter 1 Figures ...................................................................................................................... 31
CHAPTER
2.1

2

MATERIALS AND METHODS .................................................................... 37

Hippocampal neuron culture .......................................................................................... 38

viii

2.2

Plasmid construction ...................................................................................................... 38

2.3

Neuron transfection ........................................................................................................ 40

2.4

Immunoprecipitation (IP) and western blot ................................................................... 40

2.5

Live imaging and Fluorescence recovery after photobleaching (FRAP) ....................... 41

2.6

Artificial synapse formation assay ................................................................................. 42

2.7

NEUREXIN-FC staining and surface GluA2 staining ................................................... 43

2.8

Immuno-Fluorescence and (IF) Fluorescent In Situ Hybridization (FISH) ................... 44

2.9

PCR ................................................................................................................................ 45

2.10 Luciferase assay ............................................................................................................. 45
Chapter 2 Figures ...................................................................................................................... 47
CHAPTER

3

FMRP BINDS TO THE 3’UTR OF FMR1 TO REGULATE MRNA

TRANSLATION IN THE DENDRITES OF HIPPOCAMPAL NEURONS .............................. 48
3.1

Introduction .................................................................................................................... 49

3.2

FMRP binds Fmr1 mRNA in its 3’ UTR ....................................................................... 51

3.3

Dendritic localization of Fmr1 3’ UTR and co-transport of Fmr1 3’ UTR with FMRP in

processes.................................................................................................................................... 54
3.4

Translational regulation through Fmr1 3’ UTR ............................................................. 56

3.5

deTagRFP-Fmr1 3’ UTR expression in neurons and FRAP of deTagRFP-Fmr1 3’ UTR

in dendrite.................................................................................................................................. 60
3.6

Conclusion...................................................................................................................... 62

ix

Chapter 3 Figures ...................................................................................................................... 66
CHAPTER

4

FMRP BINDS TO THE 3’UTR OF NEUROLIGIN1 TO REGULATE

mRNA TRANSLATION IN THE DENDRITES OF HIPPOCAMPAL NEURONS.................. 81
4.1

Introduction .................................................................................................................... 82

4.2

FMRP binds Nl1 3’ UTR in its 3’ UTR ......................................................................... 82

4.3

Dendritic localization of Nl1 3’ UTR and its co-localization/co-transport with FMRP 83

4.4

Post-synaptic localization of Nl1 3’ UTR ...................................................................... 84

4.5

Translation regulated through Nl1 3’ UTR .................................................................... 87

4.6

Local translation regulated through Nl1 3’ UTR ........................................................... 89

4.7

Local translation at artificial synapse ............................................................................. 90

4.8

Conclusion...................................................................................................................... 91

Chapter 4 Figures ...................................................................................................................... 93
CHAPTER

5

ABNORMAL NEUROLIGIN1 MRNA ALTERNATIVE SPLICING IN

FMR1 KO MICE HIPPOCAMPUS............................................................................................ 111
5.1

Introduction .................................................................................................................. 112

5.2

Abnormal alternative splicing in Fmr1 KO mice......................................................... 113

5.3

PCR of Nl1 +A+B variants .......................................................................................... 115

5.4

Discovery of new alternative splicing variant of Nl1 +SSA1+SSA2+SSB ................. 116

5.5

Neuron rescue by Nl1 variant expression ..................................................................... 116

5.6

β-NRX-FC staining of WT and Fmr1 KO hippocampal neurons. ............................... 118

x

5.7

Conclusion.................................................................................................................... 119

Chapter 5 Figures .................................................................................................................... 122
CHAPTER

6

DISCUSSION ................................................................................................ 133

FMRP and Fmr1 3’ UTR ........................................................................................................ 136
FMRP and Neuroligin1 3’ UTR .............................................................................................. 140
The role of FMRP in splicing:................................................................................................. 144
Further directions: ................................................................................................................... 149
Discussion Figures .................................................................................................................. 154
REFERENCE .............................................................................................................................. 155

xi

LIST OF ABBREVIATIONS
AMPAR α-amino-3-hydroxy-5-methyl-4-

KHC kinesin heavy chain

isoxazolepropionic acid receptor

KLC kinesin light chain

BDNF brain-derived neurotrophic factor

MAP2 microtubule associate protein 2

CaMKIIα cam kinase II α

MBP maltose-binding protein

CHX cycloheximide

MCP MS2 coat protein

CPE cytoplasmic polyadenylation element

NL Neuroligin

CPEB CPE binding protein

NMDAR N-methyl-D-aspartate receptor

DHPG 3, 5-dihydroxyphenylglycine

NRX Neurexin

DIC Differential interference contrast

PABP poly (A) binding protein

DIV days in vivo

PI protease inhibitor

FISH fluorescent in situ hybridization

RBP mRNA binding protein

FL full length

RFP red fluorescent protein

FMRP fragile X mental retardation protein

RNAi RNA interference

FRAP Fluorescence recovery after

RI RNAase inhibitor

photobleaching

RNP ribonucleoprotein

GABA gamma-aminobutryic acid

RRM RNA recognition motif

GFP green fluorescent protein

siRNA small interfering RNA

HEK human embryonic kidney

UTR untranslated region

hnRNP heterogeneous nuclear

vGAT vesicular GABA transporter

riboncucleoprotein

vGLUT vesicular glutamate transporter

IF immunofluorescence

ZBP1 zipcode-binding protein

KH K Homology domain

xii

LIST OF FIGURES AND TABLES
Figure 1-1

FMRP schematic ..................................................................................................... 31

Figure 1-2

FMR1-family proteins ............................................................................................ 31

Figure 1-3

Polyribosomes clusters at the base of dendritic spines ........................................... 31

Figure 1-4

RNA transport and local translation in neuron ....................................................... 32

Figure 1-5

FMRP phosphorylation and translational regulation .............................................. 32

Figure 1-6

Hippocampus, LTP and LTD .................................................................................. 33

Figure 1-7

mGluR theory of FXS ............................................................................................. 33

Figure 1-8

Neuroligin-Neurexin binding and alternative splicing of Neuroligin ..................... 34

Figure 1-9

Biochemical mechanism of splicing ....................................................................... 35

Figure 1-10

Alternative splicing patterns................................................................................ 35

Figure 1-11

A-I editing and recognition of I as G .................................................................. 36

Figure 1-12

RNA editing in splice site alters splicing ............................................................ 36

Figure 2-1

MS2-MCP system ................................................................................................... 47

Figure 3-1

FMRP binds Fmr1 3’ UTR in HEK293 cells ......................................................... 66

Figure 3-2

The Fmr1 3’UTR localizes to dendrites and co-transports with FMRP ................. 69

Figure 3-3

FMRP is transported and co-localized with the Fmr1 3’ UTR ............................... 71

Figure 3-4

Neuron specific synapsin-promoter vector ............................................................. 72

Figure 3-5

Translational regulation through Fmr1 3’ UTR...................................................... 74

Figure 3-6

Global and local translation of deTagRFP-Fmr1 3’ UTR ...................................... 79

Figure 4-1

FMRP binds Nl1 3’ UTR in HEK293 cells ............................................................ 93

Figure 4-2

Nl1 3’ UTR transport in dendrites .......................................................................... 94

Figure 4-3

Co-localization and co-transport of Nl1 3’ UTR with FMRP................................. 97

xiii

Figure 4-4

Post-synaptic localization of Nl1 3’ UTR ............................................................... 97

Figure 4-5

Artificial synapse formation assay .......................................................................... 98

Figure 4-6

Nl1 3’ UTR accumulate at artificial synapse ........................................................ 101

Figure 4-7

Neuron specific luciferase assay of Nl1 3’ UTR. ................................................. 103

Figure 4-8

myr-deTagRFP-Nl1 3’ UTR expression in HEK293 and neuron ......................... 104

Figure 4-9

FMRP mutants in translational regulation ............................................................ 105

Figure 4-10

FRAP of deTagRFP-Nl1 3’ UTR ...................................................................... 107

Figure 4-11

Post-synaptic expression of deTagRFP-Nl1 3’ UTR ........................................ 108

Figure 4-12

Local translation of myr-deTagRFP Nl1 3’ UTR at artificial synapse ............. 109

Figure 5-1

NL1 expression in synaptosomes of hippocampus ............................................... 122

Figure 5-2

Nl1 primer design, PCR of A1B A2B ................................................................... 123

Figure 5-3

Nl1 A1B A2B PCR ............................................................................................... 125

Figure 5-4

Nl2 variants are not affected in Fmr1 KO mice .................................................... 127

Figure 5-5

New variant: A1A2B ............................................................................................ 128

Figure 5-6

Nl1 variants expression affect synapse number and size differently .................... 129

Figure 5-7

Nl1 variants affect surface GluA2 amount............................................................ 130

Figure 5-8

NRX-FC staining of WT and KO neuron ............................................................. 131

Figure 5-9

All possible variants of Neuroligin1 ..................................................................... 132

Figure 6-1

FMRP targets local translation model................................................................... 154

xiv

CHAPTER

1

INTRODUCTION

1

1.1

Introduction of autism
Autism is a neural development disorder characterized by impaired social interaction and

communication, as well as repetitive and stereotyped behavior patterns. The term "autism" was
first used the by Swiss psychiatrist, Paul Eugen Bleuler, in the 1912 American Journal of
Insanity (Greydanus & Toledo-Pereyra, 2012). The name is derived from the Greek word “autos”
which means "self."
The Diagnostic and Statistical Manual of Mental Disorders (DSM), published by the
American Psychiatric Association, is the standard classification of mental disorders used by
mental health professionals in the United States. It contains a listing of diagnostic criteria for
every psychiatric disorder recognized by the U.S. healthcare system. Based on the classification
in DSM-5 (2013), autism is but one type of Autism Spectrum Disorder (ASD). The other two
types of ASD are Asperger’s Syndrome, and pervasive developmental disorder not otherwise
specified (PDD-NOS). Autism and mental retardation are not necessarily associated with each
other. Mental retardation is a possible comorbid disorder of the autism spectrum at more severe
level.
In 1943, Leo Kanner described three girls and eight boys between 2 and 8 years of age
who exhibited an extreme preference for solitude and patterns such as repetitive behaviors,
persistent interests, and deficits in both language and communication (Kanner, 1943). It was the
first time that a male predominance was noticed in autism disorder. In 1944, Austrian
pediatrician, Hans Asperger, published observations of patients who exhibited similar symptoms.
Both researchers observed autistic traits in the families of affected individuals, which lead them
to believe there was a possible genetic link with the disease.
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In 1977, the first twin study was performed comparing autistic patients with their
identical or fraternal twins. Identical twins develop from one fertilized ovum and are genetically
identical, while fraternal twins develop from two different ova and have unidentical genomes.
Results from twenty-one twin pairs revealed that the co-occurrence of autism in identical twins
was much higher than in fraternal twins (Folstein & Rutter, 1977), indicating that genetic factors
may play a crucial role in autism.
Although a great number of genes are associated with autism, a clear genetic basis has
not been found. Current data, however, shows that 10-15 % of autism cases are monogenic,
arising from defects in a single gene. Studying these monogenic cases of autism is the best way
to understand autism pathogenesis and cognition at the molecular and cellular level.

1.2

The Fragile X Syndrome (FXS) and FMRP
Data from the mid-1990’s show that 1.49 % of the US population is affected by mental

retardation and/or a developmental disability (Larson et al., 2001). Amongst all mental
retardations, Fragile X Syndrome (FXS) is the most widespread single-gene cause of autism and
the most frequent cause of inherited mental retardation. Martin and Bell studied several
generations in one family and described members with intellectual deficits and social withdrawal.
In addition, they were able to demonstrate a male-linked genetic pattern (J. P. Martin & Bell,
1943). Fragile X Syndrome occurs at a rate of 1:5,000 in males and a rate approximately half that
in females (1/10,000) (Coffee et al., 2009). These rates may be underestimated since some
reports show an even higher occurrence at 1:1,500 in males and 1:2,500 in females (Rousseau et
al., 1994). Autism and FXS do not necessarily overlap with each other. The prevalence of autism
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in FXS is 15-30 % and the rate of FXS in total autism is 2-7 % (Rogers, Wehner, & Hagerman,
2001) (Kaufmann et al., 2004) (Harris et al., 2008).
The most prominent symptom of FXS is mental retardation. Approximately 85 % of
males and 25-30 % of females with full mutation FXS (full mutation will be talked soon) have a
Full Scale Intelligence Quotient (FSIQ) lower than 70, with an average of 40 in males (Rousseau
et al., 1994) (Merenstein et al., 1996) (Loesch, Huggins, & Hagerman, 2004) (Loesch et al.,
2004). Other symptoms of FXS include short-term memory loss and defects in visuospatial
ability (Crowe & Hay, 1990). The physical characteristics of affected people include a long
narrow face, prominent forehead, jaw and ears, and enlarged testicles in male patients. There are
also a variety of connective tissue abnormities such as hyper-extensible finger joints, flat feet,
soft skin and a high-arched palate (Chudley & Hagerman, 1987) (Lachiewicz & Dawson, 1994).
In the 1970s, an association between mental retardation and abnormal synapse
dysmorphogenesis was first described (Marin-Padilla, 1972; Purpura, 1974). Dendritic spines
display an immature phenotype in FXS patients, with the spines being longer and thinner
compared to unaffected people (Bagni & Greenough, 2005). FXS patients also have high
dendritic spine density. This abnormality in spine structure can be found in other types of ASD
(Aldinger, Plummer, Qiu, & Levitt, 2011). This indicates a potential pathological basis of the
disease. This neurological phenotype has led FXS research to focus on synapses, with an
emphasis on synapse structure, function, and especially plasticity.
Fragile X Syndrome is caused by the loss of functional fragile X mental retardation
protein 1 (FMRP). The “X” refers to the X chromosome where the gene is located. In 1991, a
trinucleotide repeat expansion (CGG) was found in the 5' UTR of the fragile-X mental
retardation gene 1 (FMR1) in FXS patients. This repeat expansion leads to hypermethylation of
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the FMR1 promoter and its resultant silencing (Fu et al., 1991) (Pieretti et al., 1991) (Verkerk et
al., 1991). Unaffected individuals have between 5-54 CGG trinucleotide repeats in FMR1, with
an average of 30 repeats. Expansion of these repeats to 55-200 (pre-mutation) does not cause
FXS but rather fragile X-associated tremor/ataxia syndrome (FXTAS), characterized by
cognitive decline, autonomic dysfunction, ataxia, and Parkinsonism (Iwahashi et al., 2006). In
females, decreased ovarian function can be present which is known as fragile X-associated
primary ovarian insufficiency (FXPOI). This causes infertility and early menopause in some
female pre-mutation carriers (Oostra & Willemsen, 2009). If the number of repeat units exceeds
200, it is referred to as a full mutation and results in hypermethylation and transcriptional
silencing of FMR1 (Oberle et al., 1991). The severity of the disease varies based on the level of
mutation. Transcriptional silencing of FMR1 is the primary cause of FXS. However, other
mutations in FMR1 can also cause FXS. For example, one patient was found to have a point
mutation leading to an amino acid change (I340N) in FMRP that changed protein function (De
Boulle et al., 1993) (Y. Feng, Absher, et al., 1997). Another patient with an R138Q mutation in
FMRP has also been identified (Collins et al., 2010).
In 1994, an Fmr1 knockout (KO) mouse was generated by the insertion of a neomycin
cassette into exon 5 of the mouse Fmr1 gene (Consort, 1994). The Fmr1 KO mouse model has
been an essential tool in the study of FMRP and FXS. Neurons from Fmr1 KO mice show highly
similar phenotype as FXS patients, including long and thin dendritic spines (Galvez &
Greenough, 2005) (Grossman, Aldridge, Weiler, & Greenough, 2006).
To understand the etiology of FXS, it is important to study the function of FMRP. FMRP
is an RNA-binding protein (RBP) believed to be involved in RNA processing, transport and
translational regulation, especially in dendrites (Santoro, Bray, & Warren, 2011) (Bhakar, Dolen,
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& Bear, 2012). FMRP is widely expressed in virtually all cell types, with particularly high levels
in neurons but low levels in glial cells (Y. Feng, Gutekunst, et al., 1997).
As an RNA binding protein, FMRP binds specific RNAs as opposed to having a general
affinity for total RNA. Sequence analysis of FMRP has revealed several common RNA binding
domains: two hnRNP K-homology (KH) domains known as KH1 and KH2, and one Arg-GlyGly (RGG) box (Figure 1-1) (Ashley, Wilkinson, Reines, & Warren, 1993). The KH domain
binds to "kissing-complex" tertiary RNA motifs (Darnell et al., 2005). The RGG box binds Gquartet loops (Blackwell, Zhang, & Ceman, 2010) and SoSLIP (Sod1 mRNA Stem Loops
Interacting with FMRP) motifs (E. G. Bechara et al., 2009). Messenger RNAs (mRNA) with Urich sequences but no specific corresponding RNA binding domains in FMRP have also been
reported as FMRP targets (Chen, Yun, Seto, Liu, & Toth, 2003) (Fahling et al., 2009).
The aforementioned point mutation leading to the amino acid change I340N in FMR1
affects the KH2 domain of FMRP and causes disease (De Boulle et al., 1993) (Y. Feng, Absher,
et al., 1997). This indicates that the RNA binding ability of FMRP is important to its function.
Although other RNA motifs have been identified as FMRP targets, no common FMRP targeting
motif has been found (Darnell et al., 2011). Experiments using high-throughput sequencing
combined with crosslinking immunoprecipitation (HITS-CLIP) found that FMRP can target
mRNAs in their coding regions (66 %), 3' UTRs (19 %) and 5' UTRs (5 %) (Darnell et al., 2011).
Interestingly, one FMRP target is its own gene product, FMR1 mRNA (C. T. Ashley, Jr. et al.,
1993).
There are three highly homologous members in the FMRP RNA-binding protein family:
FMRP, Fragile X-related proteins 1 and 2 (FXR1P and FXR2P, respectively) (Figure 1-2)
(Tamanini et al., 2000) (Ascano et al., 2012). The expression of FMR1 is under the regulation of
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alternative splicing (C. T. Ashley et al., 1993). The full-length isoform, isoform 1, encodes a 71
kDa protein. The major isoform, isoform 7, encodes a 69 kDa protein (Figure 1-2) (C. T. Ashley
et al., 1993) (Verkerk et al., 1993) (Ascano et al., 2012). A stoichiometric study of FMRP-RNA
binding with in vivo transcribed fetal human brain mRNAs estimated that FMRP targets 4 % of
total mRNAs (C. T. Ashley, Jr. et al., 1993). This data has been confirmed in mice by microarray
(Brown et al., 2001) and by HITS-CLIP (Darnell et al., 2011).
The International Human Genome Sequencing Consortium (IHGSC) of the Human
Genome Project (HGP) has placed an estimate of 20,000 to 25,000 genes in the human genome
(International Human Genome Sequencing, 2004). It has been reported that 84 % of all genes are
expressed in the human brain (Hawrylycz et al., 2012). Based on these facts, FMRP should
potentially target 670-840 genes. The HITS-CLIP study identified 842 targets in the mouse brain,
which fits the original estimate (Darnell et al., 2011). These mRNA targets are physically bound
by FMRP, not all of their translation are known to be regulated by FMRP. 28 of them are also
candidates for autism as determined by the SFARI database of autism candidate genes. These
include the well-studied autism genes such as NEUROLIGIN3, NEUREXIN1, and SHANK3
(http://gene.sfari.org). As more autism candidate genes are identified, there are likely to be more
FMRP targets found in this pool such as the other two members of NEUREXIN family:
NEUREXIN 2 and NEUREXIN 3. In a recent study, exome sequencing of 343 families with an
ASD child showed that one-fifth of candidate autism genes with de novo mutations are FMRP
targets (Iossifov et al., 2012). This surprising overlap strengthens the link between FMRP and
autism.

1.3

FMRP and mRNA transport
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For many years it was believed that mRNAs and their translation machinery were only
found near the nucleus in the cell body. Classical dogma is that protein translation occurs in the
soma. If proteins are required elsewhere, they will be transported to the destined subcellular
locations. However, considering the morphology of neurons, with distant dendritic and axonal
compartments, as well as the relatively slow speed of protein translation/transport from soma,
researchers were forced to consider local translation as a mechanism neurons might use to work
around these morphological challenges. Messenger RNA transport combined with local protein
synthesis is a more responsive mechanism for cells to respond to extracellular signals than
retrograde signaling followed by anterograde microtubule-dependent protein transport.
As visualization techniques advanced, mRNAs and components of the translational
machinery were eventually identified in dendrites and axons (Figure 1-3) (Steward & Levy, 1982)
(Koenig & Giuditta, 1999). Since one copy of mRNA can be used as template for several rounds
of protein translation, local translation is economical for the cell. Furthermore, not only the
mechanism of local translation provides a faster response to stimuli, but also functions in the
establishment of cell polarity and the definition of cellular compartments (Besse & Ephrussi,
2008) (Becalska & Gavis, 2009).
Transport of mRNAs is a required component of local translation. Messenger RNAs do
not diffuse randomly in cytoplasm but are sorted and transported to specific sites based on the
requirements of their protein products. Instead of being transported as single molecules, mRNAs
associate with RNA binding proteins to form cytoplasmic messenger ribonucleoprotein particles
(mRNPs) complexes. There are three major types of mRNP complexes in the cytoplasm: stress
granules (SGs), processing bodies (P-bodies) and ribonucleoprotein particles (RNPs) (Bramham
& Wells, 2007).
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Stress granules and processing bodies share some components. But in general, the major
difference is that stress granules function in RNA storage, whereas P-bodies function in RNA
degradation (Anderson & Kedersha, 2006). Stress granules appear in the mammalian cell
cytoplasm when cells experience environmental stress such as UV, heat, or oxidation
(Krichevsky & Kosik, 2001). Stress granules contain stalled translation pre-initiation complexes
as well as many early translation initiation factors. Several well-known RNA binding proteins
are found in stress granules, like FMRP, the cytoplasmic poly-A element binding protein (CPEB)
(Napoli et al., 2008) and Staufen (Anderson & Kedersha, 2006). P-bodies are RNA granules that
contain the mRNA decay machinery (Bashkirov, Scherthan, Solinger, Buerstedde, & Heyer,
1997).
RNPs are formed in the nucleus following RNA transcription and processing. To be
specific, mature mRNA transcripts complex with RNA binding proteins to form messenger
RNPs. Messenger RNPs are then exported to the cytoplasm where they are remodeled and
delivered to their destinations (Figure 1-4). In neurons, mRNPs are found in both dendrites and
axons and local translation occurs in both sites (Besse & Ephrussi, 2008).
Cytoskeletal and motor proteins are required for proper mRNP transport. Microtubules
are oriented in distal dendrites with their minus ends at the proximal side and plus ends at the
distal side. In proximal dendrites, microtubules exist in both orientations. All three types of
motors (kinesin, dynein and myosin) are implicated in mRNA transport (Jansen, 2001). Kinesin
family motor proteins associated with microtubules move from minus end to plus end, whereas
dynein family motors move from plus end to minus end. In addition, there are myosin family
motors that move on actin. The FMRP-induced mRNA transport in dendrites is dependent on
microtubules, but not on actin (Antar, Dictenberg, Plociniak, Afroz, & Bassell, 2005).
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In the majority of cases, however, RNAs are transported on microtubules by kinesins
(Kiebler & Bassell, 2006). Kinesin superfamily proteins (KIFs) are classified into 15 kinesin
families (Kinesin1 to Kinesin 13, Kinesin 14A and Kinesin 14B). The kinesin1 family contains
KIF5A, KIF5B, and KIF5C. The KIF5s are motors for the anterograde transport of mRNPs in
dendrites (from proximal cell body to distal dendrites) (Hirokawa, 2006). RNA granules directly
interact with the KIF5 C-terminal tail (heavy chain) (Hirokawa & Takemura, 2005). The kinesin
motor does not bind to mRNA directly. RNA binding proteins target cis element in mRNAs and
serve as adaptors between RNA granules and kinesin. One example is the β-actin zip code
binding protein 1 (ZBP1) which recognizes a 54 nucleotide sequence (so called zip code), in the
3' UTR of β-actin mRNA for transport to dendrites (Kislauskis, Zhu, & Singer, 1994).
Many studies have suggested an mRNA transport function for FMRP. Both nuclear
localization signals (NLS) and nuclear export signals (NES) are found in FMRP (Eberhart,
Malter, Feng, & Warren, 1996). FMRP also forms complexes with mRNAs and the kinesin light
chain (KLC) of KIF5 (Dictenberg, Swanger, Antar, Singer, & Bassell, 2008). Taken together,
these findings imply a nuclear-cytoplasmic shuttling function of FMRP, carrying target mRNAs
out of nucleus.
FMRP interacts specifically with an mRNA nuclear export factor, nuclear RNA export
factor 2 (NXF2) (Lai, Sakkas, & Huang, 2006). FMRP also binds to nuclear mRNAs, a nuclear
exporter protein (Tap/NXF1), and transcribing pre-mRNAs (Kim, Bellini, & Ceman, 2009).
Binding of FMRP with transcribing pre-mRNAs raises the possibility that FMRP may be
involved in RNA processing. The missense mutation (R138Q) in the NLS of FMRP causes
development delays in patients, indicating an important role for FMRP in the nucleus or in
nuclear-cytoplasmic shuttling (Collins et al., 2010).
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The majority of FMRP (95 %) is found in the cytoplasm where it localizes to the soma,
axons, dendrites and post-synaptic sites (Devys, Lutz, Rouyer, Bellocq, & Mandel, 1993). In the
cytoplasm, FMRP has been visualized as part of dynamic RNA granules, trafficking to dendrites
and axons (De Diego Otero et al., 2002) (Antar, Afroz, Dictenberg, Carroll, & Bassell, 2004)
(Antar et al., 2005). FMRP was found to co-localize and co-sediment with Staufen (Ohashi et al.,
2002) (Ferrari et al., 2007), which regulates mRNA transport to dendrites (Tang, Meulemans,
Vazquez, Colaco, & Schuman, 2001).
In some cases, FMRP trafficking to dendrites can be stimulated by neuronal activities
(Antar et al., 2004) (Gabel et al., 2004). Several specific mRNAs are transported to dendrites in
response to neuronal activities (Mayford, Baranes, Podsypanina, & Kandel, 1996). Surprisingly,
FMRP-targeted mRNAs can be correctly localized to their destinations in the absence of FMRP
(Bhakar et al., 2012). Thus, FMRP is more likely to be a passive passenger in mRNPs. Many
RNA binding proteins possess the same feature and are thought to be dispensable for RNA
transport, but required for granule assembly, stability and translation (Kiebler & Bassell, 2006).
The translation of mRNAs in FMRP-containing mRNPs is widely accepted to be
repressed during transport. One convincing piece of evidence supporting this is that microtubuleassociated FMRP is restricted to mRNPs that do not contain ribosomes (Wang et al., 2008).
Stimulation by activity at the base of dendritic spines may signal a relief of translational
repression (Sutton & Schuman, 2006).

1.4

Local translation and translational regulation by FMRP
In 1982, Steward and Levy visualized polyribosomes localized at the base of dendritic

spines during synaptogenesis (Figure 1-3) (Steward & Levy, 1982). Synaptogenesis is the
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formation of synapses between neurons. This observation strongly suggested that local
translation of proteins is important for synaptogenesis. Together, the RNA binding ability of
FMRP and its dendritic localization suggest that FMRP may regulate the local translation of its
target mRNAs at the synapse.
Synaptic plasticity, the ability of a synapse to respond to stimulation by changing its
strength, is an important aspect of learning and memory. It is associated with the local translation
in neuron processes. To elucidate the possible roles of FMRP in synaptic plasticity, its
association with polyribosomes was investigated. FMRP was found associated with
polyribosomes by ultracentrifugation in a sucrose density gradient (Y. Feng, Absher, et al., 1997).
In general, FMRP is recognized as a translational repressor. in vivo experiments using
recombinant FMRP added to rabbit reticulocyte lysates showed a dose-dependent reduction of
brain mRNA translation, but not rabbit reticulocyte lysate mRNA (Li et al., 2001). A study
comparing protein synthesis in wild type and Fmr1 KO hippocampal slices showed a significant
increase of basal translation in Fmr1 KO mice compared to WT mice (Qin, Kang, Burlin, Jiang,
& Smith, 2005) (Dolen et al., 2007). Some genes, such as hASH1 (human aschaete-scute
homologue 1) (Fahling et al., 2009) and Sod1 (superoxide dismutase 1) (E. G. Bechara et al.,
2009) (Bechara et al., 2009) exhibited enhanced FMRP-mediated translation. FMRP has also
been shown to stimulate the translation of the K+ ion channel, Kv4.2, by binding to the 3’UTR
of Kv4.2 mRNA (Gross, Yao, Pong, Jeromin, & Bassell, 2011).
Translational inhibition can be achieved both by blocking the initiation of ribosome
assembly and stalling the elongation of actively translating ribosomes (Darnell et al., 2011).
Binding of the translation initiation factor eIF4E to the 5’-7 methyl guanosine cap (5’ cap) of
mRNA is the rate-limiting step of translation initiation (Hiremath, Webb, & Rhoads, 1985)
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(Duncan, Milburn, & Hershey, 1987). The finding that FMRP co-sediments with the cytoplasmic
FMRP interacting protein (CYFIP1), the 80S ribosome complex and translation initiation factors
suggests that FMRP can repress translation at the initiation phase (Napoli et al., 2008).
Considering that the majority of FMRP is found bound with polyribosomes, it is widely
accepted that the primary way FMRP regulates translation is during the translation elongation
step. Samples from the patient with the FMRP

missense mutation showed that this mutation

abolishes the interaction of FMRP with polyribosomes (Y. Feng, Absher, et al., 1997). The
I304N mutation localizes in the second KH domain of FMRP, indicating that the RNA binding
ability and association of FMRP in polyribosomes is crucial to the normal function of FMRP.
The presence of FMRP in all three types of RNA granules also suggests that FMRP may be
involved in translational inhibition in many phases (Shiina & Tokunaga, 2010).
FMRP also binds to RNAi/microRNA machinery proteins, such as endoribonuclease
Dicer (Dicer, also called helicase with RNase motif) (Caudy, Myers, Hannon, & Hammond,
2002) (Ishizuka, Siomi, & Siomi, 2002) and Argonaute 2 (Ago2) (Jin et al., 2004) in Drosophila.
Dicer is an endoribonuclease in the RNase III family that produces miRNA. Ago2 is the catalytic
component of RNA-induced silencing complex (RISC). Besides the RNAi/microRNA machinery
proteins, small RNA molecules like miR-125b and miR132 were found to associate with FMRP
(Muddashetty et al., 2011). A region in non-coding RNA, brain cytoplasmic RNA1 (BC1), has
been shown to bind CYFIP1 and translation initiation factors, providing one example of RNA
based translational regulation by FMRP (Zalfa et al., 2003).
FMRP exists predominantly in its phosphorylated form (Narayanan et al., 2007). A serine
residue (human ser500, murine ser499) is crucial to the phosphorylation of FMRP. The
phosphorylation of this serine residue can trigger subsequent phosphorylation of specific nearby
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residues and switch the translational regulation status of FMRP. Two FMRP mutants have been
constructed to mimic phosphorylated FMRP (S499D) and dephosphorylated FMRP (S499A)
(Figure 1-5) (Ceman, O'Donnell, et al., 2003). With the help of these mutants, it has been
demonstrated that the phosphorylation status of FMRP does not affect its RNA binding ability
but does affect its association with polyribosomes (Ceman, O'Donnell, et al., 2003)
(Muddashetty et al., 2011). Wild-type FMRP and the S499D mutant show resistance to ribosome
run-off after sodium azide treatment, representing stalled polyribosomes (Ceman, O'Donnell, et
al., 2003). Unphosphorylated FMRP is associated with actively translating polyribosomes. The
phosphorylation and dephosphorylation of FMRP are catalyzed by ribosomal S6 kinase (S6K)
and protein phosphatase 2A (PP2A), respectively (Santoro et al., 2011). Thus, translation of
FMRP target mRNAs may be regulated by phosphorylation and dephosphorylation via S6 and
PP2A.

1.5

FMRP and synaptic plasticity
It is important for the correct protein to be expressed in the correct site at the right time in

cells, especially to avoid ectopic expression of deleterious proteins. Local translation of specific
mRNAs targeting at specific regions is important for spatial restriction of specific protein. Now
it is widely accepted that specific mRNAs can be localized to dendrites and locally translated. In
general, locally translated proteins can be classified into structural proteins (like actin) and
regulatory proteins (like kinases and phosphatases). The translational regulation of these mRNAs
can cause morphological changes in neurons like dendritic spine shape, and physiological
changes like synaptic plasticity.
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Synaptic plasticity is the foundation of learning and memory. It is the ability of synapses
to change the strength of signal transmission between neurons, which bequeaths synapse
“processing” power. Neurons would merely be connected “electrical wires” without synaptic
plasticity. Based on timescales, plasticity can be classified as short-term (tens of milliseconds to
minutes) and long-term (minutes or longer). Long-term potentiation (LTP) and long-term
depression (LTD) are two types of long-term plasticity, which occur at excitatory synapses
(Gerrow & Triller, 2010).
Cellular synapses can be classified as excitatory synapse and inhibitory synapse based on
their ability to change the post-synaptic potential. This depends on the receptor type on the postsynaptic terminal. Excitatory synapses are a type of synapses in which an action potential (AP)
from a pre-synaptic neuron depolarizes the post-synaptic neuron, raises the resting membrane
potential towards the threshold potential, and eventually makes an action potential more likely to
happen at the post-synaptic neuron. Inhibitory synapses do the opposite, lowering the membrane
potential, making it more difficult for a post-synaptic neuron to fire an AP.
These two types of synapses can be identified based on the neurotransmitters used. In
mammals, the major excitatory synapses in the central nervous system (CNS) are glutamatergic
synapses. The major inhibitory synapses in the CNS are GABAergic synapses. The amino acid
L-glutamate is the primary excitatory neurotransmitter in the mammalian CNS, but there are also
catecholamines, which include epinephrine, norepinephrine and dopamine. In the peripheral
nervous system (PNS), the most typical excitatory neurotransmitter is acetylcholine, which
works at neuromuscular junctions.
There are two types of glutamate receptors: ionotropic glutamate receptors (iGluRs),
which are ligand-gated ion channels, and metabotropic glutamate receptor (mGluRs). There are
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three types of iGluRs: the N-methyl-D-aspartate receptor (NMDA receptor or NMDAR), the αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor or AMPAR)
and kainate receptors with nomenclature based on their agonists (Ronald, Larsson, Anckarsater,
& Lichtenstein, 2011). There are eight different types of mGluRs, labeled mGluR1 to mGluR8.
They are classified into three groups, Group I, II, and III (Gp1, Gp2, Gp3) based on receptor
structure and physiological activity (Ohashi et al., 2002). Group I mGluRs contain mGluR1 and
mGluR5; Group II mGluRs contain mGluR2, mGluR3 and mGluR4; Group III mGluRs contain
mGluR4, mGluR6, mGluR7 and mGluR8.
It is known that activation of the Gp1 mGluRs (mGluR1 and mGluR5) can stimulate
translation in biochemical preparations of enriched cortical synapses (Weiler & Greenough,
1993). Polyribosomes can accumulate rapidly in dendrites after stimulation of metabotropic
glutamate receptors (mGluRs) using the Gp1 mGluRs agonist 3, 5-dihydroxyphenylglycine
(DHPG). Protein translation involving FMRP can also be triggered by DHPG at dendrites
(Weiler et al., 1997). This rapid response of local translation to stimuli through mGluR is
important for synaptic plasticity (Huber, Kayser, & Bear, 2000).
LTP was first observed in the hippocampus. This region has been extensively studied
with regards to synaptic plasticity although both LTP and LTD are found in other regions too.
The hippocampus is important for inhibition (for example, animals with hippocampal damage
tend to be hyperactive (Nadel, 1975 #1807)), memory, and spatial recognition. The hippocampus
is divided into several regions, such as dentate gyrus (DG) and Cornu Ammonis - horn of (the
ancient Egyptian god) Amun. Cornu Ammonis is divided into four regions: CA1, CA2, CA3,
CA4 (only CA1 and CA3 are shown in the figure) (Figure 1-6) (Riedemann, Patchev, Cho, &
Almeida, 2010). The DG contains granule cells. The CA areas of hippocampus are full of
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pyramidal neurons. The term “hippocampus proper” refers to the four CA regions. The term
“hippocampal formation” refers to the hippocampus proper plus DG and subiculum. In the
hippocampus, there are three principal information pathways. First, the perforant path from the
entorhinal cortex to granule cells in the DG; second, the mossy fiber path (which is the axon of
granules cells) from the granule cell of the DG to the pyramidal cells in the CA3; and third, the
Schaffer collateral-commissural (SCC) path from the CA3 to CA1. LTD and LTP were induced
by placing electrodes in the Schaffer collateral-commissural (SCC) pathway and recorded from
the CA1 (Figure 1-6) (Riedemann et al., 2010).
Both LTP and LTD could be dependent on NMDARs or mGluRs. LTP is an
enhancement of signal transmission between neurons. It can be stimulated by tetanic stimulation,
which consists of high frequency stimulation. It is widely accepted that LTP is induced by
increasing neurotransmitter release, or increasing AMPAR numbers on the post-synaptic
terminal, or increasing the conductance of ion channels. The NMDAR-dependent LTP in the
CA1 region of adult hippocampus is the most widely studied (Castillo, 2012).
There are three phases of LTP: LTP 1, LTP 2 and LTP 3. LTP 1 is known as early-form
LTP (E-LTP), and is independent of protein translation. LTP 2 is dependent on protein
translation. LTP 3 is dependent on both RNA transcription and protein translation. Together,
LTP 2 and LTP 3 are called late LTP (L-LTP). In E-LTP, AMPARs become permeable to Na+
by L-glutamate stimulation. The Na+ influx results in excitatory post-synaptic potentials (EPSP),
which release the Mg2+ block in NMDAR to make them permeable to Na+ and Ca2+. Ca2+ influx
triggers downstream signaling in post-synaptic neuron. In E-LTP, the calcium-calmodulin
dependent protein kinase II (CaMKII) is activated due to phosphorylation caused by an increase
in Ca2+ concentration. Activated CamKII phosphorylates AMPARs to increase their conductance.
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It also phosphorylates other proteins to induce AMPAR membrane insertion, which increase
AMPAR density at the post-synaptic terminal. Late LTP is dependent on gene transcription and
translation, which are stimulated by the extracellular signal regulated kinase (ERK). The ERK
pathway can be activated by kinases like protein kinase C (PKC), protein kinase A (PKA),
CamKII and phosphoinositide 3-kinase (PI-3K) (Malenka & Bear, 2004).
LTD is the weakening of CNS synapse strength, whereby the effectiveness of synaptic
transmission is decreased on an activity-dependent basis (Santoro et al., 2011). There are many
types of LTD depending on the type of neurons: in the CA1 region of hippocampus, there are
NMDAR-dependent LTD and mGluR- dependent LTD. The change in membrane potential
adjusts the concentration of Ca2+ in the cell following neurotransmitter release and determines
whether the post-synaptic neuron will undergo LTP or LTD following stimulation. If Ca2+
concentrations is below threshold, activation of phosphatase dephosphorylates kinase, results in
LTD. Further research found that not only the post-synaptic Ca2+ concentration but also the
amplitude and duration of Ca2+ concentration elevation is essential to inducing of LTP or LTD
differentially (Mizuno, Kanazawa, & Sakurai, 2001).
DHPG can trigger LTD via mGluR (Palmer, Irving, Seabrook, Jane, & Collingridge,
1997). This mGluR-LTD is a major form synaptic plasticity and is translation-dependent in
dendrites (Huber et al., 2000). In contrast, NMDAR-dependent LTD is independent on
translation. NMDAR-dependent LTD can be triggered by internalization of AMPARs, which is
induced by stimulation of Gp1 mGluR using DHPG (Snyder et al., 2001). In the hippocampus,
the major mGluR located on dendrites in the stratum radiatum is mGluR5, while mGluR1
localizes predominantly on cell bodies (Luscher & Huber, 2010). Knowing that FMRP
translation is enhanced at dendrites by DHPG stimulation (Weiler et al., 1997) and that FMRP
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happens to be a translation inhibitor, it is natural to suspect that FMRP is involved with mGluR5
and mGluR-LTD. Interestingly, DHPG-induced LTD is exaggerated in the hippocampus of
Fmr1 KO mice (Huber, Gallagher, Warren, & Bear, 2002).
FMRP is essential for translational activation following neurotransmitter release. The
Fmr1 KO mouse shows deficits in activating protein synthesis induced by DHPG (Weiler et al.,
2004). Since FMRP is widely accepted as a translational repressor, FMRP targets may be over
expressed in the absence of FMRP, including proteins responsible for AMPAR internalization.
Excessive AMPAR internalization results in exaggerated LTD in Fmr1 KO mice.
New protein synthesis is not necessary for mGluR-LTD. This could be because these
LTD proteins are already present, or they are overexpressed. This significant discovery led to the
“mGluR theory of FXS" (Figure 1-7) (Bear, Huber, & Warren, 2004). This theory was validated
by reducing mGluRs in Fmr1 KO mice by creating mGluR+/- heterozygous mice (Dolen et al.,
2007). Antagonists of mGluR5 can also rescue some deficits in Fmr1 KO mice (de Vrij et al.,
2008). Based on this theory, mGluR5 antagonists have been used in patients to treat autism.
Some drugs have been in clinical trials since 2009 (http://clinicaltrials.gov). In conclusion, the
symptoms of FXS may be caused by both exaggerated mGluR-LTD, and inability of enhancing
local protein translation at post-synaptic terminal to respond new stimulations.
LTP in Fmr1 KO mice was considered normal for years (Godfraind et al., 1996; Paradee
et al., 1999). However, new protocols designed to induce LTP by glycine bath of hippocampal
tissue slices shows that this form of LTP is decreased in Fmr1 KO mice (Shang et al., 2009).
One form of LTP is known as spike timing dependent long-term potentiation (STD-LTP). This
STD-LTP does not require FMRP to be expressed, but the absence of FMRP results in a higher
threshold (Meredith et al., 2007). Therefore, FMRP is involved in both LTD and LTP.
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The HITS-CLIP result shows that 18 out of 58 NMDAR complex genes, 20 out of 32
mGluR5 complex genes, 1 out of 3 AMPAR complex genes are targets of FMRP (Darnell et al.,
2011) (Sidorov, Auerbach, & Bear, 2013). Taken together, FMRP may be involved in synaptic
plasticity induction, expression and maintenance in more than one pathway by translational
regulation of “plasticity-related-proteins.”

1.6

Neurexin and Neuroligin
Synapse is the key site of information transmission between neurons. Most

communications

between

neurons

at

synapse

is

achieved

via

neurotransmitters.

Neurotransmitters are released by pre-synaptic neuron to activate ion channels or receptors on
the post-synaptic terminal. The basis of this transmission is synaptogenesis and synapse
maintenance. Synaptogenesis is the process of formation, specification and maturation of
functional synapses between neurons. There are three steps involved in synaptogenesis: initial
recognition, synaptic junction formation and final maturation (Sudhof, 2008). There are growing
evidences to show the adhesion molecules at both pre-synaptic and post-synaptic terminals play
important roles in synapse formation and synapse function. Neurexins (NRXs) and Neuroligins
(NLs) are currently the most widely studied synaptic adhesion molecules. Neurexins localize to
the pre-synaptic terminal and neuroligins are the corresponding ligands on the post-synaptic
terminal (Ichtchenko et al., 1995). They form a trans-synaptic complex in the synaptic cleft.
Both Neurexin and Neuroligin contain several isoforms and all isoforms are under
alternative splicing (Figure 1-8). To make it clear, in this thesis, isoforms are defined as different
genes of the same family that are transcribed from different promoters and variants are defined
as different alternative splicing products of one isoform. Neurexin was first found to be the
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receptor of α-latrotoxin, which is a toxin from the black-widow spider (Ushkaryov, Petrenko,
Geppert, & Sudhof, 1992). Neurexins are type 1 membrane proteins. There are three neurexin
genes in mammals: Nrx1, Nrx2, and Nrx3. Each neurexin gene encodes an α-form neurexin
(longer isoform) and a β-form neurexin (shorter isoform) by transcription from different
promoters (Tabuchi & Sudhof, 2002). Both α-NRX and β-NRX share the same C-terminus. In
total, there are six types of neurexin isoforms in α-Nrx1, β-Nrx1, α-Nrx2, β-Nrx2, α-Nrx3, and βNrx3.
There are four Neuroligin isoforms (Nl1-4) in rodents and five NEUROLIGIN isoforms
(NL1-5) in humans (Sudhof, 2008). NL1-3 are highly homogeneous and they are mainly
expressed in CNS, while NL4 is expressed in both CNS and PNS (Hoon et al., 2011). NL1
preferentially localizes to excitatory synapses (Song, Ichtchenko, Sudhof, & Brose, 1999). NL2
preferentially localizes to inhibitory synapses (Varoqueaux, Jamain, & Brose, 2004). NL3 was
found to localize to both types of synapses (Budreck & Scheiffele, 2007).
The alternative splicing diversity of Neurexin and Neuroligin provides the physical basis
of recognition between pre-synaptic terminal and post-synaptic terminal. In Neurexin, there are
five splice sites (SS 1-5) in α-Nrx, which can result in more than 1000 potential variants in
different combination. There are two splice sites (SS 4, SS 5) in β-Nrx, which can produce four
variants (Ichtchenko et al., 1995) (Shen et al., 2008). All Nl isoforms have a splice site A (SS A)
and Nl1 has one additional splice site (SS B). It is widely accepted that there are four Nl1
variants: +A+B, +AΔB, ΔA+B, and ΔAΔB. Delta (Δ) means the following splice site is missing.
For example, the major variant of Nl1, ΔA+B, contains splice site B but not splice site B. All the
splice sites of neurexin and neuroligin are localized in the extracellular domain. Including or
excluding the splice sites bequeaths binding specificity to NRX and NL. The major NRX binding
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partner of NL1 is β-neurexin ΔSS4 (Sudhof, 2008). Neurexins do not only bind to NLs, but also
to dystroglycan and neuroexophilins (Craig & Kang, 2007).
Previous studies found that splice site B (SS B) of the NL1 variant is a key switch
affecting NRX recognition. For NRX1 and NL1 interaction, NL1 variants with SS B bind
specifically to β-NRX without SS 4 (not to α-NRX or β-NRX with SS 4). NL1 without SS B is
able to bind all α and β-NRX variants, which is independent on SS 4 of NRX. NL2-4 behave in
the same way as NL1 without SS B, since there is no SS B in these isoforms (Baudouin &
Scheiffele, 2010).
The presence or absence of splice sites on NRX and NL makes possible the specific
recognition between the two types of molecules. This molecular recognition and binding may
further influence the recognition and binding between pre-synaptic terminal and post-synaptic
terminals during synaptogenesis and may also influence synapse maintenance and signal
transmission in mature synapses. Since SS B is only a 9 AA sequence, it is amazing that this
short peptide can switch the recognition and binding affinity of NL1 with NRXs. Protein crystal
structure shows that SS B of NL1 is on the binding interface with neurexin, while SS A of NL1
and SS 4 of NRX1 are nearby (Arac et al., 2007) (Figure 1-8). This is consistent with the key
role these splice sites play in Neuroligin/Neurexin recognition and binding (Koehnke et al., 2008)
(Shen et al., 2008). As the only Nl isoform that contains SS B, NL1 is distinct from all the other
NLs. It has different binding affinity with NRX and different functions. The SS A of all
neuroligins regulates the binding to NRX with much smaller effect (Comoletti et al., 2006).
Co-culture experiments with non-neuronal cells expressing NL on cell membrane and
neurons has shown formation of pre-synaptic terminals in neurons (Scheiffele, Fan, Choih, Fetter,
& Serafini, 2000). Complimentary experiments with non-neuronal cells expressing neurexin co-
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cultured with neurons showed formation of post-synaptic terminals in neurons at the position of
contact with ectopically expressed neurexin (Graf, Zhang, Jin, Linhoff, & Craig, 2004; Takei et
al., 2004). It has also been shown that overexpression of NL in cultured neurons increases
synapse number (Dean et al., 2003) (Chih, Afridi, Clark, & Scheiffele, 2004) (Graf et al., 2004)
(Prange, Wong, Gerrow, Wang, & El-Husseini, 2004) (Levinson et al., 2005) (Nam & Chen,
2005).
Overexpression of NL1 can increase excitatory synapse number (Prange et al., 2004) and
overexpression of NL2 can increase inhibitory synapse number (Chih, Engelman, & Scheiffele,
2005). The balance of expression of distinct neuroligins regulate the excitatory/inhibitory
balance (Levinson & El-Husseini, 2005). On the other side, RNAi knockdown of NL1-3 shows
decreased synapse number (Chih et al., 2005). It suggests that NL plays a role in synapse
formation. However, gene knockout experiments in mice show that knockout of any one of Nl1-3
is not fatal, only the triple knockout is fatal. Mice lacking Neuroligin1-3 died at birth because of
breath failure. The analysis of the triple knockout neurons showed that the synapse number and
morphology are all normal, but the electrophysiology is impaired (Varoqueaux et al., 2006).
Taken together, these data suggest that Neuroligins are essential to synapse function but not to
synapse formation (Chubykin et al., 2007; Varoqueaux et al., 2006).
Neurexins and Neuroligins all have a PDZ binding site in the intracellular part of the
protein, binding and interacting with other PDZ-containing proteins like scaffold and signaling
proteins. The name PDZ come from the first letter of post synaptic density protein 95 (PSD95),
Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein (zo-1) (Kennedy,
1995). Neuroligin1 binds to PSD95 (Irie et al., 1997) and S-SCAM (Chen et al., 2000) by their
PDZ binding domain in the post-synaptic terminal. These proteins relate NL1 to the glutamate

23

receptor recruitment mechanism directly or indirectly, affecting synaptic plasticity (Dean &
Dresbach, 2006).
Changes in synapse activity by overexpression of Nl1 in cultured neurons were explained
by the observed increases in synapse numbers (Graf et al., 2004) (Chih et al., 2005). However,
more recent evidence showed that NL1 is actually involved in synaptic plasticity. NL1 plays a
subtype-specific role in LTP in young CA1 and adult DG at the hippocampus. In fact, knocking
out Nl1 changes the AMPAR/NMDAR ratio in neurons (Chubykin et al, 2007; Shipman, 2012),
diminishing LTP in the CA1 region (Blundell et al., 2010) and completely eliminating LTP at
DG cells (Shipman & Nicoll, 2012). However, NL3, which does not contain SS B, appears in
excitatory synapses, and is not essential to support LTP in CA1 (Shipman & Nicoll, 2012).
Overexpression of the extracellular domain of NL1 can enhance NMDAR-mediated current. The
SS B of NL1 is essential for these effects. NL1 with SS B has a stronger synaptogenic phenotype
(Boucard, Chubykin, Comoletti, Taylor, & Sudhof, 2005). It is more prone to form excitatory
synapse (Chih, Gollan, & Scheiffele, 2006). The manipulation of NL1 levels could affect
synapse number as well as the ratio of NMDAR/AMDAR in synapses. The ratio of
NMDAR/AMDAR may affect Ca2+ influx following neurotransmitter release and eventually
affect synaptic plasticity. But the all-or-none results of the LTP deficit in the neuroligin KO mice
shows that there is more than just the NMDAR change.
There has been accumulative evidence showing that NRXs and NLs are involved in
autism. Copy number variation and mutation in Nl1, Nl3, Nl4 and Nrx1-3 are associated with
autism (Jamain et al., 2003) (J. Feng et al., 2006) (Sudhof, 2008). (http://gene.sfari.org). Nl1 KO
mice also showed ASD like behavior (Chubykin et al., 2007) (Blundell et al., 2010).
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Interestingly, Nl1, Nl2 and Nl3 and all three Nrxs (Nrxs1-3) are FMRP targets (Dahlhaus & ElHusseini, 2010; Darnell et al., 2011).

1.7

FMRP and RNA processing
Although FMRP is localized to both the nucleus and cytoplasm, most research has been

focused on its behavior and function in cytoplasm where it is predominantly located. However,
the importance of a protein cannot be judged simply by its abundance. FMRP does not only bind
mRNAs in the cytoplasm but also nucleus (Kim et al., 2009). Based on the fact that both NES
and NLS exist in FMRP, FMRP has been observed shuttling in and out of nucleus. So one
proposed behavior of FMRP is shuttling out of the nucleus with its target mRNA. However, the
major focus of FMRP research has been on its role in the cytoplasm, especially in dendritic
spines. It is possible FMRP is playing a different role in the nucleus, which happens before target
RNAs reach the cytoplasm and certainly before cytoplasmic transport and translation. More and
more discoveries about the role of FMRP in the nucleus have been made in recent years.
Binding to other proteins to form functional complexes fulfills the functions of FMRP.
Finding a nuclear-localized FMRP binding protein would help to understand its functions in the
nucleus. Several FMRP binding proteins such as FXR1P, FXR2P, nucleolin and heterogeneous
nuclear ribonucleoprotein A1 (hnRNP A1) have been discovered using co-immunoprecipitation
(Ceman, Brown, & Warren, 1999). Recently, FMRP was reported as a chromatin binding protein
which functions in the DNA damage response (DDR) (Alpatov et al., 2014).
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a family of RNA-binding
proteins that bind to pre-mRNAs and are involved in RNA processing, including 5’ capping, 3’
polyadenylation, RNA editing and RNA splicing. One of the most abundant and studied
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members of this family is hnRNP A1. It is a “Swiss army knife” playing a role in many
processes involved in gene expression, like constitutive splicing, alternative splicing, and
translation. It also plays a role in nuclear export, telomere maintenance and telomerase activity
(Jean-Philippe, Paz, & Caputi, 2013).
The role of hnRNP in splicing is the most important and was the first of its functions
discovered. RNA splicing is the removal of intron and joining of exons to form mature RNA.
This can happen in tRNAs, rRNAs and mRNAs. Splicing is one major event in eukaryotic RNA
processing. In mRNA, the splicing action is performed by the spliceosome, which is an RNAprotein complex composed of five small nuclear RNAs (snRNAs U1, U2, U4, U5, and U6) and
several protein factors. The mechanism of splicing includes two nucleophilic attacks (Figure 1-9)
(Patel & Steitz, 2003). Its function is fulfilled through cis-acting elements and trans-acting
proteins (activators and repressors). Based on their effect and location, cis-acting elements can
be classified as intronic splicing silencers (ISS), exonic splicing silencers (ESS), intronic splicing
enhancers (ISE), and exonic splicing enhancers (Jamain et al.). The predominant splicing
repressors are hnRNPs, such as hnRNP A1.
Most activator proteins are members of the serine-rich (SR) protein family that contain
RNA recognition motifs and arginine and serine-rich (RS) domains (Matlin, Clark, & Smith,
2005). Alternative splicing is RNA splicing in which particular exons of a gene may be included
or excluded from the same pre-mRNA to form different transcripts, which eventually translate to
different proteins. There are several alternative splicing patterns that depend on one exon
included or excluded (Figure 1-10). Alternative splicing increases the diversity of genome. For
example, the same Nl and Nrx pre-mRNA can produce several variants. More than 80 % of
human genes are alternatively spliced (Kampa et al., 2004). In fact, abnormal alternative splicing
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can cause many diseases. For example, tauopathies are diseases caused by abnormal ratio of tau
isoforms (I used variant in this thesis) produced from deregulated alternative splicing in the
central nervous system (Tazi, Bakkour, & Stamm, 2009).
A nuclear protein reported to have interaction with the Drosophila fragile X homolog
(dFMR1) is Drosophila adenosine-to-inosine RNA-editing enzyme (dADAR). Its activity is
modulated by dFMR1 (Bhogal et al., 2011). The dADAR is responsible for adenosine-to-inosine
RNA editing (A-I editing). The inosine is recognized as guanosine by the cellular machinery due
to a similarity in molecular structure (Figure 1-11) (Basilio, Wahba, Lengyel, Speyer, & Ochoa,
1962). RNA editing is an event whereby RNA molecules undergo nucleotide sequence changes
after the RNA has been transcribed, hence the term “editing”. It is one process of eukaryotic premRNA processing. It has been observed in eukaryotes, viruses, archaea and prokaryotes. In
eukaryotic cells, it happens not only to mRNA but also to tRNA, rRNA, and even miRNA
(Mehler & Mattick, 2007). There are generally two types of editing: by insertion or deletion, and
by deamination (Gott & Emeson, 2000). Deamination can transform the cytidine base to uridine
(C-U editing) or change adenosine to inosine (A-I editing). All of them change the primary
sequence of RNA, which may affect any biological process involving RNA sequence or structure.
By changing RNA sequence, RNA editing allows cells great molecular diversity.
A-I editing is the major RNA editing form in mammals (Danecek et al., 2012). All A-I
editing occurs in a double stranded RNA (dsRNA) region. A-I editing is classified as a specific
type and a promiscuous type. Specific editing occurs in short complexes like the double strand
formed between intronic sequences and its complimentary exon. Promiscuous editing happens in
long complexes. If an intronic sequence is involved to form the double strand, it means this
editing process must happen prior to splicing or at least simultaneously. If it is a pre-splicing
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procedure, then the nucleotide change at splice sites would affect splicing. Altered editing on the
branch site or splice site could cause many types of effects on splicing, including abolished
splicing or changed splice site choice (Figure 1-12) (Valente & Nishikura, 2005). If the changes
in nucleotides happen in the coding region, it may alter the primary sequence of the encoded
protein, introduce a stop codon producing a shorter peptide, or introduce additional ATGs,
enabling the expression of a new transcript. Changes in the non-coding region may cause a
corresponding effect based on the changes.
Since RNA editing can change the information encoded by the mRNA, it is not surprising
that it has many physiological functions and related diseases. Many disorders are related to
abnormal RNA editing (Maas, Kawahara, Tamburro, & Nishikura, 2006) (Slotkin & Nishikura,
2013). It has been shown that A-I editing is very prominent in nervous system (Bass, 2002)
(Valente & Nishikura, 2005). RNA editing, especially A-I editing, participates in almost all
aspects of development, homeostasis, synaptic plasticity, and neural network (Mehler & Mattick,
2007). Among the diseases caused by abnormal A-I editing, many of them are nervous system
diseases. Some neurotransmitter receptors in CNS are regulated by A-I editing, like GluR2 of
AMPAR. More than 99.9 % of GluR2s undergo A-I editing resulting in a Q to R change which
makes sure the AMPAR permeability is low to Ca+ at basal state (Barbon & Barlati, 2011).
Inhibition of editing or knockout of ADAR2 causes epileptic seizures in transgenetic mice due to
excessive Ca+ infuse, and early death (Reenan, 2001). Research using deep sequencing to
compare A-I editing sites in neurotypical and autistic postmortem cerebella showed a correlation
between A-I editing and autism (Eran et al., 2013).
In conclusion, FMRP may get involved in RNA editing through ADAR2, get involved in
RNA splicing through hnRNP A1, or get involved in RNA splicing indirectly through ADAR2.
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It is possible that there are other hnRNPs and RNA editing enzymes regulated by FMRP directly
or indirectly.
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1.8

Specific aims

The experiments described in this thesis have following specific aims:
First, study the protein-RNA interaction FMRP and its potential target Fmr1 3’ UTR.
Investigate the subcellular localization of Fmr1 3’ UTR. At the translation level, study the
translational regulation of FMRP through Fmr1 3’ UTR and local translation regulated through
Fmr1 3’ UTR.
Second, study the protein-RNA interaction FMRP and its potential target Nl1 3’ UTR.
Investigate the subcellular localization of Nl 3’ UTR. Eventually, At the translation level, study
the translational regulation of FMRP through Nl1 3’ UTR and local translation regulated through
Nl1 3’ UTR.
Third, analyze the abnormal alternative pattern of Nl1 mRNA in Fmr1 KO hippocampus.
Study the role FMRP plays in alternative splicing of Nl1 mRNA. Rescue abnormal neuron
properties of Fmr1 KO hippocampus with specific Nl1 variant.
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Chapter 1 Figures

Figure 1-1
FMRP schematic
The FMRP schematic, showing the NLS and NES of FMRP, also the three RNA binding
domains: KH1, KH2, and RGG box. (Cheever & Ceman, 2009). RNA 15(3): 362-366.

Figure 1-2
FMR1-family proteins
The FMR1 family of proteins contains FMR1, FXR1 and FXR2. They all contain three RNA
binding domains: two hnRNP K-homology (KH) domains (blue), and one arginine–glycine-rich
(RG/RGG) box (yellow). The full-length FMR1 isoforms 1 (iso1) (71 kDa) and predominant
isoform 7 (iso7) (69 kDa) vary by the presence of exon 12 (black) within KH2. I304N mutation
localizes in KH2 (red star). (Ascano et al., 2012). Nature 492(7429): 382-386.

Figure 1-3
Polyribosomes clusters at the base of dendritic spines
Polyribosomes of dentate granule cell localize throughout cytoplasm. The spine is indicated by
“S”, dendritic shaft is indicated by “den”. Arrow points to clustered polyribosomes at the base of
spine. (Steward & Levy, 1982). J Neurosci 2(3): 284-291.
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Figure 1-4
RNA transport and local translation in neuron
Dendritic and axonal RNAs are transported in mammalian neurons. Yellow arrow stands for
retrograde signal triggered by transsynaptic stimuli, sending from synapse to cell body and
nucleus. RNPs are assembled in the cytoplasm and transported along cytoskeleton. RNPs get
recruited at target site and then locally translated. (Tiedge, Bloom, & Richter, 1999). Science
283(5399): 186-187.
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Figure 1-5
FMRP phosphorylation and translational regulation
(A) FMRP phosphorylation and translational regulation. Phosphorylated FMRP bind target
mRNA and repress its translation. Dephosphorylated FMRP release binding to target mRNA and
release translation. (B) Schematic of the domain structure of FMRP showing phosphorylation
site. Serine is shown in bold. Arrows point to the four possible sites of phosphorylation. (Ceman,
O'Donnell, et al., 2003). Hum Mol Genet 12(24): 3295-3305.
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Figure 1-6
Hippocampus, LTP and LTD
Schematic representation of induction and recording of long-term potentiation (LTP) and longterm depression (LTD). LTP and LTD can be induced by electrodes placed in the Schaffer
collateral-commissural (SCC) pathway and recorded from the CA1 subfield as shown in upper
panel. Lower panel shows excitatory post-synaptic potentials (EPSP) of LTD and LTP
(Riedemann et al., 2010). Riedemann, T., et al. (2010). Mol Brain 3: 2.

Figure 1-7
mGluR theory of FXS
Activation of group I mGluRs stimulate translation of FMRP target mRNAs while FMRP inhibit
FMRP targets translation. Absence of FMRP increase FMRP targets translation, which will
cause FXS. Antagonist or Gp1 mGluR decrease target mRNA transcription translation. (Dolen,
Carpenter, Ocain, & Bear, 2010). Pharmacol Ther 127(1): 78-93.
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Figure 1-8
Neuroligin-Neurexin binding and alternative splicing of Neuroligin
Upper panel shows splice site A (including A1 and A2) and B of NL1. Upper right shows the
isoelectric point of A1 (positive) and A2 (negative). The structure of NL1 and β-NRX1 shows
their interacting interface. Splice sites are shown in yellow. Modified from (Dean & Dresbach,
2006). Trends Neurosci 29(1): 21-29.
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Figure 1-9
Biochemical mechanism of splicing
Splicing reaction is done by two nucleophilic attack reactions between nucleotides. The 2’ OH of
branch point nucleotide in the intron perform nucleophilic attacks on the first nucleotide of the
intron on the 5’ to form a lariat intermediate (lariat means loop). Then the 3’ OH of the 5’ exon
attacks the last nucleotide of intron at the 3’ splice site. Finally the exons get joined and the
intron get released (Patel & Steitz, 2003). Nat Rev Mol Cell Biol, 4(12), 960-970. doi:
10.1038/nrm1259.

Figure 1-10 Alternative splicing patterns
(A) Included or excluded. (B) Mutually exclusive exons. (C) Alternative 5’ splicing. (D)
Alternative 3’ splicing. (E) Alternative promoter/ alternative 5’ splicing. (F) Alternative Poly A
site/ alternative 3’ splicing. (G) A retained intron. (H) Multiple alternative splice sites in one premRNA. (Black, 2003). Annu Rev Biochem 72: 291-336.
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Figure 1-11 A-I editing and recognition of I as G
(A) Hydrolytic deamination convert adenosine to inosine. (B) Inosine is recognized as guanosine.
(Valente & Nishikura, 2005). Annu Rev Biochem 72: 291-336.

Figure 1-12 RNA editing in splice site alters splicing
(A) Regular splicing without editing. (B) Splicing is abolished when RNA editing removes
branch site. (C) 5’ alternative editing site is created. (D) 3’ alternative editing site is created. (E)
Splicing is abolished when 3’ splice site is destroyed. (F) Created splice site is destroyed.
(Valente & Nishikura, 2005). Prog Nucleic Acid Res Mol Biol 79: 299-338.

36

CHAPTER

2

MATERIALS AND METHODS
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2.1

Hippocampal neuron culture
Following mouse strains were purchased from the Jackson Laboratory: WT (FVB.129P2-

Pde6b+Tyrc-ch/AntJ) and Fmr1-KO (FVB.129P2-Pde6b+Tyrc-ch Fmr1tm1Cgr/J). The protocol
was approved by the Institutional Animal Care and Use Committee (IACUC). Animals were
housed in the Hunter College Animal Facility, approved by the Association for Assessment and
Accreditation of Laboratory Animal Care International (AALAC). Mice were raised in a
controlled environment.
Hippocampal cell cultures were prepared from P0 (postnatal) mice. Whole brains were
removed from newborn pups and the hippocampi from 5~7 mice were dissected. Hippocampal
tissue was digested in plating medium (MEM, 10% FBS, 10 mM HEPES, 33 mM glucose) with
trypsin for 15 min at 37°C. Cells were gently dispersed with a glass Pasteur pipette (opening
narrowed to proper size by flame before use). Dispersed hippocampal neurons were then plated
at low density (25,000 cells/cm2) on poly-L-lysine pre-coated (0.1 mg/ml) glass chambers
(Thermo) or coverslips. Cultures were incubated at 37° C with 4 % CO2. Plating media was
replaced with maintenance medium (astrocyte-conditioned Neurobasal/B27/GlutaMAX) 2 hours
after plating. AraC (1-β-D-arabinofuranosylcytosine) was added to a final concentration of 2.5
μM two days after plating to curb glial proliferation. Transfection was performed on cultured
neurons on DIV (day in vivo) 6~7.

2.2

Plasmid construction
The dual luciferase vector pmirGLO (Promega) is designed to evaluate microRNA

activity on target 3’ UTRs. The pmirGLO-Fmr1 3’ UTR vector and pmirGLO-Nl1 3’ UTR
vector were constructed by cloning the Fmr1 3’ UTR and Nl1 3’ UTR from cDNA of the
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appropriate (KO or WT) mouse brain into the SacI and SalI sites of the multiple cloning site
(MCS) of pmirGLO, downstream of Firefly luciferase. The flag-FMRP construct was prepared
by adding a FLAG tag to the 5’ of mouse FMRP and cloning the flag-FMRP into pcDNA3
vector. Vector pBS+ and pBS- were constructed by replacing CMV promoter of pcDNA3.1+ and
pcDNA3.1- by the Synpasin promoter cloned from mouse genomic DNA. The “+” and “-” vector
have that the same multiple cloning sites in reverse orientations. The dual synapsin promoter
vector, pDS- vector was constructed based on pBS- vector by adding another synapsin promoter.
The multiple cloning site was split into two parts: MCS1 and MCS2. The SV40 polyA signal
sequence from pmirGLO vector was added to downstream of MCS1. A bovine growth hormone
polyadenylation signal sequence (BHG polyA) was added to downstream of MCS2. These two
polyA signal sequence were used to stop transcription of the first and the second transcript
respectively. Vector pDS_GFP-FMRP_LifeAct-TagRFP was constructed by cloning GFP-FMRP
into MCS1 and LifeAct-TagRFP into MCS2.
The MCP-MS2 system was used to visualize mRNA subcellular localization (Figure 2-1).
Some changes were made to the traditional system. The MCP-TagRFP vector in both
pcDNA3.1+ and pBS+ were constructed to increase signal/noise ratio instead of GFP. The MS2
vector backbone used for MS2 vector construction was derived from the Rous sarcoma virus
(RSV) promoter-LacZ-MS2-β-actin 3’ UTR vector. The MS2-Fmr1 3’ UTR vector, MS2-Nl1 3’
UTR vector and MS2-Gapdh 5’UTR-CDS-3’ UTR vector were constructed by replacing the βactin 3’ UTR to make new constructs. The myristoylated-destabilized-TagRFP vector was
constructed by adding a myristoylation consensus sequence at the 5’ end of TagRFP. A
destabilization signal was the added to the 3’. Next, Fmr1 3’UTR or Nl1 3’ UTR were added to
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the MCS at downstream of the coding sequence (myr-RFP-destabilization AA). Plasmids were
amplified in E.coli and extracted using PerfectPrep EndoFree Plasmid Maxi Kit (5 Prime).

2.3

Neuron transfection
Neuron culture medium was exchanged with pre-warmed antibiotic free conditioned

medium at least 2 hours before transfection. For each chamber or coverslip (one well of a 12well plate), 2~2.5 μg plasmid was diluted in 50 μl Opti-MEM (Life Technologies) with 0.75 μl
Plus reagent (Life Technologies). This was mixed with 2.25 μl Lipofectamine LTX diluted in 50
μl Opti-MEM, incubated for 5 min at RT, and plated.
Stealth siRNAs (400 nM) targeting mouse Fmr1 were transfected into neuronal cultures
in 12 well plates. Lipofectamine RNAiMAX (Life Technologies) was used for siRNA
transfection as per instructions.

2.4

Immunoprecipitation (IP) and western blot
HEK293 cells were trypsinized and split into 6 well plates to ensure a density of 70~80 %

at the time of transfection on the second day. Co-transfection was performed using LipoD293TM
DNA in vivo Transfection Reagent (SignaGen® Laboratories) as per instructions. The following
combinations were used: FLAG-FMRP and pcDNA3, FLAG-FMRP and pmirGLO (blank
vector), FLAG-FMRP and pmirGLO-Fmr1 3’ UTR, FLAG-FMRP and pmirGLO-Nl1 3’ UTR.
Cells were incubated for 36-48 hours. Following incubation, cells were washed with phosphate
buffered saline (PBS) and treated with IP buffer (50 mM Tris-Cl [pH 7.3], 100 mM NaCl, 2 mM
MgCl2, 1 mM EDTA, 5 % glycerol, 0.1 % Triton X-100, protease inhibitor, and RNase
Inhibitors) on ice for 15 min and followed by 4°C centrifugation (16,000 X g) for 10 minutes.
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Each supernatant was immune-precipitated using ANTI-FLAG® M2 magnetic beads overnight
at 4°C. Beads were washed 3 times with 10 bead volumes of IP buffer. Beads were then split
into two equal halves. One half was resolved in 2X SDS-PAGE loading buffer, heated at 95 °C
and the supernatant was electrophoresed on a 4-12 % gradient Bis-Tris gels. Gels were
transferred to nitrocellulose membranes with iBlot® 7-Minute Blotting System (Life
Technologies). The membrane was probed with mouse anti-FLAG antibody (mouse, clone M2)
and scanned with ODYSSEY® Infrared Imaging System (LI-COR Bioscience). Quantification
was performed using Image J (NIH). The other half of the sample was treated with Trizol (Life
Technologies) to extract mRNA for reverse transcription and PCR. Taq DNA Polymerase (New
England Biolabs) was used for amplification. The cDNA derived from the IP was used to
detect/amplify Firefly luciferase, Renilla luciferase and the N19 region of Fmr1 by PCR. NL1
antibody (clone 4C12) (SYSY, Synaptic Systems) was used to probe NL1 in synaptosomes from
hippocampus.

2.5

Live imaging and Fluorescence recovery after photobleaching (FRAP)
All transfections for live imaging were performed on DIV 6-7 hippocampal neurons. In

the MS2-MCP experiment, the two constructs (MCP-RFP and MS2-Fmr1 3’ UTR, or MCP-RFP
and MS2-Nl1 3’ UTR, or MCP-RFP and MS2-Gapdh mRNA) were transfected with MCP-RFP
and MS2-3’-UTR at a 1:9 ratio to maximize mRNA labeling efficiency based on our experience.
Triple plasmid transfections of GFP-FMRP, MCP-RFP and MS2-3’-UTR were done with a ratio
of 1:1:9. Two plasmids transfection of Cerulean and myr-deTagRFP vectors were performed at a
ratio of 1:9. For all DHPG treatments, neuronal cultures were treated with 100 µM (RS)-3, 5DHPG (TOCRIS Bioscience) for 15 minutes. Because of slight physiological differences

41

between (RS)-3, 5-DHPG and (S)-3, 5-DHPG, we used (RS)-3, 5-DHPG (Wisniewski et al.,
2002). For all brain-derived neurotrophic factor (BDNF) treatment, neuronal cultures were
treated with 50 ng/ml BNDF for 1h. Differential interference contrast (DIC) images were taken
to visualize live cell morphology.
All live images were captured using a Nikon ECLIPSE Ti inverted fluorescence
microscope with following lenses: Nikon 40 X/1.30 Plan Fluor Oil object lens (DIC H/N2 ∞/
0.17 WD 0.2), Nikon 60 X/1.49 Apo TIRF Oil object lens (∞/0.13-0.21 DIC N2), Nikon 100
X/1.49 Apo TIRF Oil object lens (∞/0.13-0.20 DIC N2).
For live imaging experiments, transfected neuron chambers were scanned with the 40 X
lens to localize transfected neurons. 60 X and 100 X lenses were used for live imaging. Laser
was provided by a Laser Diode Control Unit (LDCU8) (Power Technology). Lasers were
adjusted through MicroPoint (Andor). Images and videos were deconvolved with AutoQuant
(Media Cybernetics) before quantification to enhance the quality of images.

2.6

Artificial synapse formation assay
HEK293 cell culture was trypsinized and split into 24 well plates with HEK culture

medium (DMEM with 6 mM L-glutamine and 10% BGS). Transfection of the Neurexin-GFP
vector was performed on the second day at a density of 70~80 % using LipoD293TM DNA in
vivo Transfection Reagent (SignaGen® Laboratories) as per instructions. The corresponding
neuronal culture for co-culture experiments was transfected on the same day with the Neuroligin
(A2B) vector, PSD95-TagRFP vector, the MS2-MCP system, or deTagRFP-3’ UTR plasmids.
Co-cultures were prepared on the third day (one day after transfection). Neurexin-GFP
transfected HEK293 cells were briefly treated with trypsin to get cells off bottom without too
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much digestion of the NEUREXIN-GFP on the HEK cell surface. Pre-warmed HEK cell culture
medium was used to neutralize trypsin. Cells were centrifuged at room temperature at 100 x g for
1 min. Then trypsin containing medium was removed and cells were diluted with pre-warmed
neurobasal medium (GIBCO, Life Technologies). Neurobasal medium (200 μl) was used to
dilute cells from one well of a 24 well plate and 100 μl of the diluted HEK cells were added to a
chamber of transfected hippocampal neurons. Images and videos were taken either immediately
after co-culture started, or one hour later depending on the aim of experiment.

2.7

NEUREXIN-FC staining and surface GluA2 staining
Rattus Neurexin1 beta was cloned into a FC-IgG vector in a scheme of hemagglutinin of

Influenza A virus-Rattus Neurexin1 beta-hFc IgG in the plasmid with psecTag2 vector (Life
Technologies) backbone. The hemagglutinin of Influenza A virus at N terminal of protein is
capable to secrete the recombinant protein out of cell. Human Fc region (fragment crystallizable
region) is the tail region of an antibody, which is capable to bind protein A (a 56 kDa surface
protein originally found in the cell wall of the bacterium Staphylococcus aureus). HEK293 cells
were split and cultured in 100 mm Nunclon® cell culture dishes. Transfection was performed the
second day at a density of 70~80 % by calcium phosphate transfection method. Medium was
collected and replaced with fresh culture medium every day since transfection for 3days. Hepes
(pH 7.4, 1.0 M) was added to collected medium with a ratio 1:40 to a final concentration 25 mM
and preserved in 4 °C. 3~5 collections were done before purification. Collected medium was
centrifuged in 50 ml polypropylene tubes at 3000 rpm, 15 min, 4 °C to pellet suspended cells.
The supernatant was then filtered by 0.45 µm cellulose acetate (CA, membranes provide fast
flow rates and low protein binding and are good for filtering cell culture media), polystyrene
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nonpyrogenic filter system (Corning) (CA). Protein A Dynabeads magnetic beads (Life
Technologies) was washed with fresh culture medium before incubation with filtrated medium.
0.5~0.7 µl Protein A magnetic beads were added to 1 ml filtrated medium and rotated in 50 ml
polypropylene tubes in 4°C cold room overnight. The beads were concentrated by spinning down
at 700 rpm, 4 min, 4°C and purified from medium by magnet. The beads were washed 4 times
with 1 ml Hepes (pH 7.4, 25 mM) on ice and suspended to final concentration as 33 % bead
volume/buffer volume in ice-cold Hepes (pH 7.4, 25 mM). The beads with NEUREXIN-FC were
preserved in 4°C. To dilute NEUREXIN-FC from the beads, 100 µl glycine buffer (pH 2.2, 100
mM) was used on 100 µl beads. The concentration of eluted NEUREXIN-FC was measured with
a Qubit fluorometer as per instructions (Life Technologies).

2.8

Immuno-Fluorescence and (IF) Fluorescent In Situ Hybridization (FISH)
For IF imaging, neurons were fixed on the day after transfection in fixative (4 %

paraformaldehyde (PFA) in 1 X PBS with 4 % glucose) for 20 minutes at room temperature.
PBS-T (1X PBS, 0.1 % Trition X-100) was used to penetrate cell membranes. Then neurons
were blocked with blocking buffer PBS-TB (PBS-T, 3 % BSA). Primary and secondary
antibodies were diluted in blocking buffer. Neurons were incubated with diluted antibodies for
40 min to 1h and 20-30 min respectively. Rinsing was performed 3 times using PBS-T between
primary antibody and secondary antibody incubations. After staining, coverslips were mounted
with ProLong® Gold Antifade Reagent overnight. The following antibodies were used in the IF:
MAP2 (mouse, clone HM-2, Sigma), synapsin I (rabbit; S 193, Sigma), Vglut1 (rabbit, BNP1,
Synaptic Systems) and VGat (rabbit, 131002, Synaptic Systems).
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Neurons were transfected with MS2-Nl1 3’ UTR for the FISH experiment. IF was done
before FISH following the same procedure as mentioned. An additional 4 % PFA fixation was
performed to fix antibodies before doing FISH. Anti-sense MS2 probes were used to detect
MS2-mRNA subcellular location following a previously described protocol (Bassell et al., 1998).
Probes (30 ng) were used per slide. Slides were incubated at 37°C for 5 hours before rinsing.
The coverslip was mounted similarly to those in IF.
All imaging of immunofluorescence slides were captured using Nikon ECLIPSE TE200U inverted fluorescence microscope with a Nikon 60 X 1.40 Oil Plan Apo VC lens. Imaging was
performed by using NIS-elements. Images were deconvolved with AutoQuant (Media
Cybernetics). Quantification Analysis of Fluorescence images was performed using NISelements software (Nikon).

2.9

PCR
Phusion High-Fidelity DNA Polymerase (New England Biolabs) was used for cloning.

Taq DNA Polymerase (New England Biolabs) was used to perform semi-quantitative PCR. 1 kb
Plus DNA Ladder (Life Technologies) was used as a marker in all DNA agarose gel
electrophoresis experiments. Quantification of DNA bands was performed using Image J (NIH).

2.10

Luciferase assay
Luciferase assays in HEK293 cells were performed by transfecting HEK293 cells with

pmirGLO (blank) and pmirGLO_Fmr1 3’ UTR vector. HEK293 cells were split into 48 well
plates to ensure a 70-80 % density the next day. Transfection was performed with LipoD293TM
DNA in vivo Transfection Reagent (SignaGen® Laboratories) as per instructions. Cells were
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lysed with lysis buffer included in the kit and collected 24 h after transfection. Luciferase assays
were performed using the Dual-Glo Luciferase Assay System (Promega) and GloMax 96
Microplate Luminometer (Promega). Firefly luciferase and Renilla luciferase amounts were
reported. The ratio of Firefly luciferase to Renilla luciferase was calculated.
For all DHPG treatments, neuronal cultures were treated with 100 µM (RS)-3, 5-DHPG
(TOCRIS Bioscience) for 15 minutes. Hippocampal neurons were cultured on poly-L-lysine
coated 24 well plates. Plasmid constructs of pDS-LUC and pDS with different 3’ UTRs were
transfected on DIV 6-7 with Lipofectamine LTX (Life Technologies) as described previously.
Neurons were lysed and collected for luciferase assays as described previously. Luciferase assay
was performed as described previously. Firefly luciferase and Renilla luciferase amounts were
recorded. The ratio of Firefly luciferase to Renilla luciferase was calculated.
In the analysis of luciferase assay, any translational effect on the target 3’ UTR will be
reflected by the amount of firefly luciferase. The Renilla luciferase serves as an internal control.
Compared to the blank pmirGLO vector which serves as a internal control and the ratio of Firefly
luciferase to Renilla luciferase shows the translational effect on the target 3’ UTR.
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Chapter 2 Figures

Figure 2-1
MS2-MCP system
(1) DNA and RNA polymerase in nucleus. (Bemben et al.) Tandem repeat of MS2 fused to
mRNA of interest. (3) MCP-GFP with a NLS is translated in cytoplasm and accumulate in
nucleus, also lower the concentration of MCP-GFP in the cytoplasm. (4) MCP-GFP bind MS2mRNA of interest and export to cytoplasm. (5-6) MCP-GFP + MS2-mRNA of interest complex
localize to the biological destination of mRNA of interest. (7) The complex got dissembled
mRNA of interest get degraded. (Weil, Parton, & Davis, 2010). Trends Cell Biol 20(7): 380-390.
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CHAPTER

3

FMRP BINDS TO THE 3’UTR OF FMR1 TO REGULATE MRNA TRANSLATION IN
THE DENDRITES OF HIPPOCAMPAL NEURONS
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3.1

Introduction
The fragile X mental retardation protein (FMRP) binds its own mRNA with high affinity

(C. T. Ashley, Jr. et al., 1993). Previous reports focused on an FMRP binding sequence located
in the coding region of Fmr1 mRNA, specifically a G-quartet motif within an Arg-Gly-Gly
(RGG) box (Schaeffer et al., 2001). A subdomain named N19 ( 1470-1896 nt, the 427 last
nucleotides of the coding region of FMR1 mRNA) derived from the FMR1 mRNA which
corresponds to the RGG box is often used as a positive control for FMRP targeting and binding
(Schaeffer et al., 2001) (E. Bechara et al., 2007).
However, for many mRNAs, the 3’ untranslated region (3’ UTR) is the target of RNA
binding proteins that facilitate mRNA transport and translational regulation. Many genes have
cis-acting localization signals in their 3’ UTRs(K. C. Martin & Ephrussi, 2009). One example is
the 3’ UTR of β-actin, which contains a 54 nt “zipcode” localization element. This sequence
contains enough information to guide the entire transcript to its destination (Kislauskis et al.,
1994). It is arguable whether the 3’ UTR of Fmr1 serves as a major binding site for FMRP
(Brown et al., 1998) (Sung, Conti, Currie, Brown, & Denman, 2000) (Schaeffer et al., 2001).
Besides this question, there remains some other questions: Does the 3’UTR of Fmr1 localize the
mRNA to specific region in the neuron? If it does, is the translation regulated by FMRP? Is the
translation globally or locally in dendrites? Moreover, how does FMRP regulate the translation
upon stimulation?
The technique of imaging RNA subcellular localization has advanced over the years.
Fluorescent in situ hybridization (FISH) was routinely used to visualize RNA molecules in fixed
cells. With the development of green fluorescent protein (GFP) fusion proteins, researchers can
visualize proteins in live cells. The visualization of RNA in live cells using GFP is possible, but
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this requires an adaptor to tether the RNA to the GFP reporter. Interestingly, RNA binding
proteins containing specific RNA targeting motifs fit the requirements of a tether.
The MS2-MCP system was developed to detect the subcellular localization of target
RNAs in living cells. It has been used in hippocampal neurons for the live imaging of mRNA
granules (Rook, Lu, & Kosik, 2000). This two plasmid system consists of one MCP-GFP
plasmid expressing GFP fused the MS2 capsid protein (MCP), and a MS2-RNA plasmid
expressing the target RNA sequence fused with several repeats of a stem-loop structure RNA
derived from bacteriophage MS2 (Bertrand et al., 1998). MCP is capable of binding to the stemloop structure of MS2 mRNA. Independent of where the target MS2-RNA fusion transcript
localizes, the MCP-GFP fusion protein is able to bind the MS2 stem loops of RNA. This stem
loop binding of MCP-GFP allows the entire complex to be visible in cells, depicting the location
of target RNA molecules. Recently, MS2-MCP has been used to visualize single molecule of
RNA in live mouse brain (Park et al., 2014).
The MS2-MCP system is implemented by transfecting live cells with the MS2 plasmid
and the MCP-GFP plasmid. Live imaging is possible using this method, which is a great
advantage compared to FISH (Fluorescent In Situ Hybridization), in which cells must be fixed
and provide only static images. Although a strong signal may be obtained by microinjection of in
vivo synthesized and fluorescently labeled RNA into living cells, the MS2-MCP delivery causes
less trauma to cells because the microinjection uses a needle to penetrate the plasma membrane
and inject exogenous material into cells. The MS2-MCP system uses much milder plasmids
transfection. The endogenous RNA transcription and protein translation machinery provide
signals. In addition, microinjection can sometimes deliver too much injected RNA to the cell,
which may overwhelm RNA processing and transporting mechanisms and lead to false positive
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results. Lastly, the MS2-MCP method provides cells with more “natural” mRNAs since it is
transcribed in nucleus by endogenous RNA polymerase II, modified by adding a 5’ m7G cap and
a 3’ poly A tail, also correctly folded. Since the secondary and tertiary structure of RNA is
important to its function, proper RNA folding is crucial. Since RNA expressed in MS2-MCP
system experiences the same mRNA transcription, RNA processing, modification and transport
as endogenous mRNA, the MS2-MCP system can highly mimic endogenous mRNA expression.
This gentle delivery method for mRNAs into live cells is a great advantage for in vivo study.
Here we show that FMRP binds to the 3’ UTR of Fmr1 in HEK293 cells. We also show
that the Fmr1 3’ UTR is integrated into ribonucleoprotein (RNP) granules that localize to
dendrites of hippocampal neuron. The FMRP co-localizes with the Fmr1 3’ UTR in these RNP
granules and co-transports to hippocampal processes. Using the luciferase assay, we found that
the translation of luciferase reporter is regulated through the Fmr1 3’ UTR by FMRP. We have
also observed local translation of myristoylated-destabilized-RFP reporter fused with Fmr1
3’UTR expressing in dendrites by Fluorescence recovery after photobleaching (FRAP).

3.2

FMRP binds Fmr1 mRNA in its 3’ UTR
We wanted to study the interaction of FMRP and the 3’ UTR of Fmr1 without the

influence of the Fmr1 5’ UTR and coding region. This is primarily because the coding region of
Fmr1 has been previously identified as an FMRP target (C. T. Ashley, Jr. et al., 1993). The
mouse Fmr1 coding region was cloned to pcDNA3 to express FMRP (Figure 3-1, A). The mouse
Fmr1 3’ UTR was cloned from wild type mouse brain cDNA to pmirGLO vector (Promega)
(Figure 3-1, B and C). The pmirGLO vector is a dual luciferase reporter vector designed for 3’
UTR study. The amount of two different luciferases, Firefly luciferase and Renilla luciferase, can
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be quantified differentially in the luciferase assay. The dual promoter vector was implemented
through a dual promoter design. The human phosphoglycerate kinase (PGK) promoter drives the
expression of Firefly luciferase which is at upstream of a multiple cloning site (MCS). The Fmr1
3’ UTR was cloned to the multipole cloning site. An SV40 late poly (A) signal sequence is
downstream of the MCS to efficiently terminate transcription by the PGK promoter. The second
promoter is an SV40 early enhancer/promoter that drives the expression of Renilla luciferase.
There is a synthetic polyadenylation signal at the 3’ end of Renilla luciferase to terminate
transcription. The two transcripts, Firefly luciferase_Fmr1 3’ UTR mRNA and Renilla luciferase
mRNA are expressed independently.
To begin our experiments, we first wanted to confirm the expression of our plasmid
constructs. The pmirGLO vector containing a control vector with no insert (pmirGLO, Figure
3-1, B) or the Fmr1 3’ UTR (Figure 3-1, C) were co-transfected with Flag-FRMP (Figure 3-1, A)
into HEK239T cells. Flag-FRMP was also transfected with blank pcDNA3 as a positive control
of FMRP-RNA binding since it reportedly targets the coding region of its own transcript.
RNA from cell lysates was extracted from cells 24 hours after transfection for RT-PCR
to confirm the expression of Firefly luciferase, Renilla luciferase and N19 region of Fmr1
mRNA (Figure 3-1, D). Primer pairs produced a 500 bp amplicon for Firefly luciferase (Lanes 1
and 3), a 308 bp product for Renilla luciferase (Lanes 2 and 4) and a 379 bp product for N19 of
Fmr1 (Lane 5). This result confirmed the expression of our plasmid constructs, also shows that
our primers are specific, producing a single band of the expected size for each amplification.
To determine if FMRP binds to the Fmr1 3’ UTR, Flag-FMRP and its targeting RNAs
were immunoprecipitated from lysate of transfected HEK293 cell using magnetic beads
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conjugated with anti-FLAG antibody. RNA was extracted from the beads for RT-PCR using the
same primers described above (Figure 3-1, E).
The N19 fragment of Fmr1, which has been previously identified as an FMRP target, is
robustly amplified from IP samples derived from Flag-FMRP transfection alone (Figure 3-1,
Lane 5). This confirms that the coding sequence of Fmr1 is a target of FMRP in this experiment,
which proves the validity of the system. The co-transfection of the empty control vector
pmirGLO and Flag-FMRP produced no visible bands for either Firefly or Renilla luciferase
(Lanes 3 and 4). This is an expected result since neither luciferase transcripts interact with FMRP
and therefore would not be pulled down. Only when the Fmr1 3’UTR is present in the pmirGLO
vector does Flag-FMRP bind and co-immunoprecipitate with Firefly luciferase mRNA (Figure
3-1, Lane 1). As shown in Lane 4, a signal for Renilla luciferase is absent after the pull-down of
Flag-FMRP under these conditions, since Renilla luciferase is not a target of FMRP (Figure 3-1,
Lane 2).
FMRP is widely expressed in almost all cell and tissue types. We attempted to exclude
endogenous FMRP in HEK293 cells by using FLAG-tagged FMRP and anti-FLAG antibody
instead of FMRP antibody. To assess the efficiency of our pull-downs, we performed western
blot for FLAG-FMRP under the conditions of our IP binding experiments (Figure 3-1, F). Using
anti-FLAG antibody, we could detect FLAG-FMRP in our input samples and following IP under
all conditions tested.
Taken together, these results strongly suggest that FMRP binds the 3’UTR of Fmr1. We
expressed Flag-FMRP and the 3’UTR of Fmr1 fused to Firefly luciferase in HEK293 cells and
performed IPs using anti-FLAG antibody. By extracting RNA from the pull-down samples,
preparing cDNA and using specific primer sets for PCR, we were able to detect the Firefly
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luciferase amplicon only when the 3’UTR of Fmr1 was present. When the same procedure was
performed on samples where no Fmr1 3’UTR was present, no bands were observed upon
amplification. This result is specific since all of our constructs are expressed in these cells and
our primer sets produce strong, single bands for each for transcript prior to IP. These results
demonstrate that FMRP specifically binds the Fmr1 3’ UTR HEK293 cells.

3.3

Dendritic localization of Fmr1 3’ UTR and co-transport of Fmr1 3’ UTR with

FMRP in processes
Fmr1 3’ UTR was cloned into MS2 vector to replace the β-actin sequence in the original
vector we have got (Figure 3-2, A). TagRFP was cloned to replace GFP in MCP-GFP vector to
make MCP-RFP because it provides a better signal/noise ratio under the microscope for this
experiment. TagRFP also has relative stable photostability which allows certain amount
bleaching time for Fluorescence Recovery After Photobleaching (FRAP) experiment. A Nuclear
localization signal (NLS) in the MCP-RFP construct can accumulate MCP-RFP in the nucleus to
minimize the free MCP-RFP in the cytoplasm, since MCP-RFP not binding to MS2-target 3’
UTR RNA would be transported to nucleus. This design is necessary, without the NLS, the RNA
binding MCP-RFP would be insignificant because the whole cell would be filled with free MCPRFP. Hippocampal neurons were cultured in L-Lysine-coated glass chamber. The two constructs
(MCP-RFP and MS2-Fmr1 3’ UTR) were transfected on days-in-vitro (DIV) 6-7 at a 1:9 ratio to
maximize mRNA labeling. Photos and videos were taken 18~24 hours after transfection. Results
showed RFP highlighted granules localized in dendrites (Figure 3-2, B), while there were much
less RFP highlighted granules shown in dendrites with only MCP-RFP transfection without
MS2-Fmr1 3’ UTR (Figure 3-2, C). No matter the RFP positive granule numbers or overall RFP
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signal detected in neuron processes is significantly higher in the co-transfection than the MCPRFP only transfection (Figure 3-2, D, E). Although there was no dendritic marker used in this
live imaging experiment, fixed transfected neurons were stained by dendritic marker MAP2
(microtubule-associated protein 2) to show their dendrite identity (unpublished data). Plus in this
live imaging result, typical pyramidal neuron contains one axon and several dendrites. It is
obvious there are many cell processes (dendrites and axon) containing the moving RFP
highlighted granules. So Fmr1 3’ UTR transport in dendrites although axon is not excluded in
this experiment. Videos were taken to show RNP granules containing Fmr1 3’ UTR transporting
in dendrites (unpublished data). Not all mRNA localize to dendrites, for example, Gapdh mRNA
localizes in neuron soma specifically (Tubing et al., 2010). Here we cloned full Gapdh mRNA
(including 5’ UTR, CDS and 3’ UTR) to MS2 vector to make MS2-Gapdh vector as a control.
The transfection of MS2-Gapdh vector with MCP-RFP vector shows Gapdh mRNA is retained
in the soma as expected (Figure 3-2, F).
In order to visualize the Protein-RNA interaction of FMRP and Fmr1 3’ UTR in neuron,
pcDNA3_GFP-FMRP vector was co-transfected with MCP-MS2 system. If FMRP binds Fmr1 3’
UTR granule, the co-localization of them should be visible (GFP-FMRP in green, Fmr1 3’ UTR
in red by MCP-RFP). Triple transfection of GFP-FMRP, MCP-RFP and MS2-CamKII 3’ UTR (a
known FMRP target, dendritic localized) on days-in-vitro (DIV) 6-7 hippocampal neurons
showed that granules containing both FMRP (green) and CamKII 3’ UTR (red) localized in
dendrites (Figure 3-3, A). Yellow color shows the co-localization in the merged photo of Cy3
(red) and GFP (green). The green and red particle in the image does not completely overlap with
each other in some granules. This is because the image was taken from live neurons so the
particles may be moving when the photo was taken. It takes time for the microscope to switch its
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Cy3 and GFP laser. So when the second fluoresce was taken, the granule may has already moved.
This delayed image will produce a final merged photo of multi-channel like the live imaging
photos presented in this thesis, which looks like incomplete overlap in merged photo. Then we
used this validated method on Fmr1 3' UTR (Figure 3-3, B). Many GFP-FMRP granules localize
at the base of spine or the base of dendrite branch, where the translation machinery localizes
(Figure 3-3, B). The result shows Fmr1 3' UTR is transported to dendrites, and co-localizes with
FMRP in granules at dendrites. But the co-localization of GFP-FMRP and Fmr1 3' UTR in the
static photo is possibly a result of independent transport and eventually co-localization at the
destination. Time lapse frames show they are co-transported (Figure 3-3, C, D). GFP-FMRP
transfection with MS2-β-actin 3’ UTR (not an FMRP target) with MCP-RFP showed many GFPFMRP granules do not localize with β-actin 3’ UTR granules (Figure 3-3, E).

3.4

Translational regulation through Fmr1 3’ UTR
It is necessary to figure out how translation is regulated through Fmr1 3’ UTR, and

whether or not FMRP regulate translation through Fmr1 3' UTR since the binding has been
proved by previous results. The pmirGLO vector is a dual luciferase assay vector designed to
quantify translational regulation through 3’ UTR inserted MCS. Luciferase assay of
pmirGLO_Fmr1 3’ UTR was performed in HEK293 cells with co-transfection of GFP-FMRP
(Hawrylycz et al.), GFP-FMRP (S499D) and GFP-FMRP (S499A). These mutants do not show
significant difference in binding affinity to some known FMRP targets (Ceman, O'Donnell, et al.,
2003). The normalized expression ratio of luciferase assay is calculated as the formula in Figure
3-5, C. Since all results have been normalized to expression ratio of pmirGLO in the same type
of transfection, the normalized expression ratio represents the translational regulation done
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through the 3’ UTR. The differences between columns show the translational regulation of
FMRP on reporter gene through target 3’ UTR. It shows the FMRP has a decrease of reporter
translation, and both the S499D and S499A have a stronger inhibition effect, just the
phosphorylation mimic mutant S499D have the strongest inhibition (Figure 3-5, D).
To investigate translational regulation through the target 3’ UTR, most luciferase assays
are performed in cell lines like HEK293 cells. But FMRP is the widely expressed in almost all
cell types in most organs. So the endogenous FMRP in HEK293 cells will influence the results,
although the co-transfected vector expressing FMRP with a strong CMV promoter leads to a
dominance of exogenous FMRP in transfected cells. To reveal the relative translational
regulation through Fmr1 3’ UTR in the presence or absence of FMRP, WT and Fmr1 KO mice
hippocampal neurons were used for this experiment. We did transfection and luciferase assay on
WT and Fmr1 KO hippocampal neurons with pmirGLO vector and pmirGLO-Fmr1 3’ UTRs.
But the repeats in one condition show very different ratio. One well (of 24 well plate) with the
same treatment could give a ratio ten times different to other wells. The reason could be that the
universal promoter PGK and SV40 of pmirGLO vector can express in both neurons and glia cells
in the cell culture, while there are always glia cells in the neuron culture although AraC was
applied to limit glia proliferation. Both reporters (Firefly luciferase and Renilla luciferase) using
universal promoters (PGK and SV40) can be expressed in transfected glia cells, which disturbs
the results since we only focus on the neurons. Considering the relative big size of glia cells, the
luciferase assay reading contributed by glia cells could be significant. The transfection efficiency
varies from well to well, the translational regulation varies in neurons and glia cells, then the
reading of Firefly luciferase/Renilla luciferase ratio could be very different from one well to
another.
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In order to measure the FMRP translation in neurons only, a neuron specific expression
system was established to restrict luciferase assay to neurons only. SYNAPSIN-1 (SYN1) is a
pre-synaptic protein which is involved in neural transmitter release (Evergren, Benfenati, &
Shupliakov, 2007). Synapsin promoter has been found to be active in neuron only but not glia
cells (Kugler, Kilic, & Bahr, 2003). Neuron specific vectors (pBS3.1- and pBS3.1+) were
constructed by cloning mouse Synapsin promoter from mouse genomic DNA to replace CMV
promoter in pcDNA3.1- and pcDNA3.1+ vectors o make pBS+ and pBS- vectors. LifeAct is a
17-amino-acid peptide, which is able to bind filamentous actin (F-actin) in eukaryotic cells
(Riedl et al., 2008). It was fused to fluorescent protein to highlight the morphology of transfected
neurons for live imaging. A pBS_LifeAct-TagRFP vector was constructed by cloning LifeActTagRFP into the Synapsin promoter vector pBS+. TagRFP is the brightest monomeric red
fluorescent protein available by the time of this experiment (148% brightness of EGFP),
possessing excitation/emission peak at 555 and 584 nm. Multimeric fluorescent proteins are even
brighter but very toxic to cells. TagRFP was generated from wild-type RFP (from sea anemone
Entacmaea quadricolor). A co-transfection of hippocampal neuron (which always has glia cells
in the culture) with pBS_LifeAct-TagRFP and pEGFP has been done to show the neuron specific
expression by Synpasin promoter (Figure 3-4, E). Immunofluorescent staining of MAP2 (neuron
dendritic marker) distinguishes neuron from glia. Fluorescent imaging shows the Synapsin
promoter exclusively expresses LifeAct-TagRFP in neurons, while CMV promoter expresses in
both neuron and glia cells.
In order to perform neuron specific luciferase assay, pDS vector (dual Synapsin promoter)
was designed to express two genes simultaneously in neuron (Figure 3-4, A). It is a neuronal
version of pmirGLO vector which used backbone of pcDNA3.1- with some key elements from
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pmirGLO (SV40 pA, BGH pA) and mus Synapsin promoter. Vector pDS_GFP-FMRP_LifeActTagRFP was constructed to test the validity of this vector (Figure 3-4, B). Both GFP-FMRP and
LifeAct-TagRFP were expressed in neuron by this single vector (Figure 3-4, C, D), but not in
glia cells.
A pDS-LUC (dual Synapsin promoter-Luciferase) vector was constructed by cloning
Firefly luciferase and Renilla luciferase at downstream of the first and second Synpasin promoter
of pDS vector separately (Figure 3-5, A). Vector pDS-LUC_Fmr1 3’ UTR was constructed by
cloning Fmr1 3’ UTR to the MCS1 following the first Synapsin promoter, and Renilla luciferase
following the second Synpasin promoter (Figure 3-5, B). Neuron specific luciferase assay of
Fmr1 3’ UTR was performed by transfecting WT hippocampal neurons and Fmr1 KO
hippocampal neurons with empty pDS-LUC vector and pDS-LUC_Fmr1 3’ UTR vector on DIV
6~7. Cultures were collected 24h later for luciferase assay. Synapsin promoters restrict the
expression of both Firefly luciferase and Renilla luciferase in neuron cells, excluding the effect
of glia cells. DHPG stimulation was applied for 15 min on neuron culture in stimulation
experiment before collection. Signals of Firefly luciferase was normalized by Renilla luciferase
within sample first, then this Firefly/Renilla ratio of Fmr1 3’ UTR data were normalized to the
Firefly/Renilla ratio of pDS-LUC blank vector in the same way as the pmirGLO luciferase assay
in HEK293 (Figure 3-5, C).
Neuron specific luciferase assay of Fmr1 3’ UTR showed the translation of reporters is
regulated through Fmr1 3' UTR in a FMRP dependent manner (Figure 3-5, E). The relative
translational regulation of Firefly luciferase is enhanced in WT neurons after DHPG stimulation,
while there is no such increase in Fmr1 KO neurons. The absence of FMRP may make the cells
“insensitive” to DHPG stimulation. The basal level expression regulated through Fmr1 3' UTR is
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higher in KO neurons than WT neurons, because the translation is relieved due to the lack of
FMRP.

3.5

deTagRFP-Fmr1 3’ UTR expression in neurons and FRAP of deTagRFP-Fmr1 3’

UTR in dendrite
After mRNA has arrived at its destination in dendrite, local translation may occur when
proper stimulation is applied to the translation machinery. Local translation is crucial to synaptic
plasticity. The luciferase assay by using dual Synapsin promoter in hippocampal neurons shows
global translational regulation through Fmr1 3’ UTR. Since the dendritic localization of Fmr1 3'
UTR and translation regulation by FMRP has all been proved, the next step is to look into the
translation of reporter genes regulated through Fmr1 3' UTR locally in dendrites.
A myristoylated-destabilized-RFP-based translation reporter was constructed to perform
Fluorescence Recovery After Photobleaching (FRAP) experiments to show local translation. The
N-myristoylation consensus AA sequence would bind plasma membrane, so its diffusion in the
cytoplasm can be reduced. A destabilized peptide from ornithine decarboxylase which is a target
of protein degradation machinery is added to C terminal (Marcora, Cejas, Gonzalez, Carrillo, &
Algranati, 2010) (Figure 3-6, A). New fluorescence appeared at the bleached site represents
newly translate protein at local (Figure 3-6, B). Myristoylated-destabilized-TagRFP (myrdeTagRFP) vectors with target 3’ UTRs were constructed by cloning the target 3’ UTRs to the
MCS at downstream of the myr-deTagRFP, just like myr-deTagRFP-Fmr1 3’ UTR (Figure 3-6,
A). Myr-deTagRFP_Nl 3’ UTR, Myr-deTagRFP_CamK II 3’ UTR, and Myr-deTagRFP_β-actin
3’ UTR were constructed in the same way.
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HEK293 cells were transfected with regular TagRFP vector and the myr-deTagRFP
vectors with target 3’ UTRs (Figure 3-6, C). All vectors have the same pcDNA3 backbone, the
same CMV promoter. It is obvious that the all myristoylated-destabilized-TagRFP express much
less fluorescence. HEK293 cells were transfected by the same protocol discussed before. RFP
fluorescence of single cell was quantified and compared (Figure 3-6, D). Except the
destabilization AA sequence strongly decreased the TagRFP amount, we can also tell differences
between myr-deTagRFP vectors with different 3’ UTR (Figure 3-6, D). Compared to blank myrdeTagRFP, Fmr1 3’ UTR, Nl 3’ UTR and CamK II 3’ UTR all decreased myr-deTagRFP level
while β-actin 3’ UTR did not significantly change myr-deTagRFP expression level.
The myr-deTagRFP blank or myr-deTagRFP-Fmr1 3' UTR vector was co-transfected
with pcDNA-Cerulean to DIV6-7 hippocampal neurons. Live imaging was done ~48 hrs after
transfection. Photos of the same neurons were taken before and after stimulation with brainderived neurotrophic factor (BDNF). Both myr-deTagRFP and Cerulean expression got
increased in both WT and Fmr1 KO neurons by BDNF stimulation (Figure 3-6, E). The
normalized expression ratio was calculated in a way similar to luciferase assay, all ratios from
myr-deTagRFP-Fmr1 3’ UTR (TagRFP/Cerulean) were normalized to myr-deTagRFP ratios
(TagRFP/Cerulean). Cell body and neuron processes were calculated separately (Figure 3-6, F).
In the cell body, the deTagRFP-Fmr1 3’ UTR has a high expression in KO neurons at the basal
state. After BDNF stimulation, there is no significant relative expression change in WT neurons,
but a decrease in KO neurons. In the cell processes, the other trends are similar, however, the
TagRFP also decreases in WT after stimulation.
For the FRAP experiment, once a transfected cell was identified, images were acquired
for 1min (-01 min) and then a region of a dendrite was photobleached by 405nm light for 2 sec
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and a photo was taken per minute (Figure 3-6, G). Local translation in this region was assayed by
observing recovery of fluorescence for >30 min after photobleaching. Time lapse images of a
representative experiment of myr-deTagRFP-Fmr1 3' UTR with BDNF treatment and deTagRFP
blank vector with BDNF treatment were taken. Five fames of each bleaching condition are
presented by rainbow contrast pictures, representative of before bleaching, after bleaching and
the recovery. The hot spots are the local translation sites, pointed by arrows. The hot spots of
myr-deTagRFP-Fmr1 3’ UTR were bleached out but recovered in 30 min. There are no such hot
spots in myr-deTagRFP blank vector transfected neurons and the fluorescent just smear back,
without showing up as hot spots.
The analysis presented by heat map is shown for the corresponding FRAP experiment
(Figure 3-6, G, bottom panel). X axis represents location along the dendrite in the time lapse
photo, Y axis represents time. In myr-deTagRFP-Fmr1 3' UTR with BDNF treatment, the hot
spot recovered after photobleaching. In the blank myr-deTagRFP FRAP experiment; the hot spot
was bleached permanently in the experiment.

3.6

Conclusion
The results presented here show that the Fmr1 3’ UTR can be pulled down by FLAG-

FMRP from lysate of co-transfected HEK293 cells. With the help of the non-invasive MS2-MCP
system, we observed the Fmr1 3’ UTR RNP granules transported and localized in dendrites,
while MCP-RFP accumulated in the nucleus and the Gapdh mRNA stayed in the soma. We also
observed RNP granules containing both Fmr1 3’ UTR and GFP-FMRP transporting in dendrites
in the co-transection experiment. Most of the Fmr1 3’ UTR signal observed in dendrites coexisted with GFP-FMRP signal in the same granule, which transports in the neuron processes.
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These data do not provide solid evidence of direct binding between Fmr1 3’ UTR and FMRP. To
investigate whether they bind directly to each other, UV-cross linking must be performed in
further research.
Although this RNA-protein binding could be direct or indirect, we did observe
translational regulation of reporter gene trough Fmr1 3’ UTR by FMRP. The relative translation
level of reporter regulated through target 3’ UTR was quantified by a dual luciferase assay
system. The translational regulation of wt GFP-FMRP and its phosphorylation/nonphosphorylation mimic mutants on Fmr1 3’ UTR was tested on HEK293 cells.
GFP-FMRP decreased the relative expression level of reporter through Fmr1 3’ UTR the most
among all FMRP plasmids. This is consistent with the widely accepted idea that FMRP is a
translational repressor. The translational regulation of FMRP on its target gene, at least partially,
is regulated through its phosphorylation. The key phosphorylation of S499 in the murine FMRP
will lead to the phosphorylation of several amino acids nearby. The phosphorylation mimic
mutant GFP-FMRP (S499D) and the non-phosphorylation mimic mutant GFP-FMRP (S499A)
both showed a stronger inhibition on relative expression of the reporter with Fmr1 3’UTR.
S499D mutant gave the strongest inhibition as expected because phosphorylated FMRP is the
inhibition form. The even lower expression of the non-phosphorylated form S499A compared to
wt GFP-FMRP was unexpected, because it is the relief form. This could be due to the lack of
translational regulation because of the inability to change phosphorylation status, while FMRP
has also been reported as translation enhancer in some cases.
To exclude the influence of endogenous FMRP in the HEK293 cells, we wanted to
perform the luciferase assay on WT and Fmr1 KO hippocampal neurons. A neuron specific dual
luciferase vector was invented using Synaptic promoter. The neuron specific promoter made it
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possible to perform neuron specific luciferase assay excluding the influence of glia cells. Result
showed the relative expression level of reporter with Fmr1 3’ UTR had higher expression in
Fmr1 KO neurons. The lack of FMRP regulation relieved the translation of reporter with Fmr1 3’
UTR. This is consistent with the results in the HEK293 cells, in which transfection without
FMRP resulted in higher reporter expression. After DHPG stimulation, there was an increase of
reporter expression in WT neurons, but no change in KO neurons. Our explanation of this result
is the Fmr1 KO mouse lost the regulation by FMRP through Gp1 mGluR pathway.
To further look into the local translation regulated through Fmr1 3’ UTR, myr-deTagRFP
vector was constructed to visualize new protein synthesis in dendrites. The global translation of
myr-deTagRFP was examined first in HEK293 cells. Most of these target 3’ UTRs decreased
reporter translation except β-actin 3’ UTR due to its nature as a housekeeping gene. Plus it is
widely accepted that β-actin is not a FMRP target since no such finding has been published so
far. The amount of myr-deTagRFP in the neurons cell body and cell processes were quantified
separately. BDNF enhanced translation in general. We saw the basal level relative expression of
reporter with Fmr1 3’ UTR was lower in WT, no matter the cell body or the processes, since the
FMRP in WT can inhibit translation of reporter with Fmr1 3’ UTR. After BDNF stimulation, the
relative expression cell body did not change in WT but greatly decreased in Fmr1 KO. The myrdeTagRFP level in Fmr1 KO decreased after BDNF stimulation in both WT and KO in processes.
To quantify the local expression of reporter, FRAP experiment was performed in cell
processes. Although myristoylation consensus AA sequence has been added to the N terminal of
TagRFP, there is tremendous level of diffusion of the myr-deTagRFP after bleaching, either in
the cytoplasm or on the cell membrane. The diffusion happened fast. The myr-deTagRFP started
to refill the bleached region in seconds after the reporter was bleached. So what we looked into
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were the hot spots, which are the potential translation sites in dendrites. The neurons were treated
with BDNF to increase translation in general. The hot spots of myr-deTagRFP-Fmr1 3’ UTR got
recovered within 30 min after bleaching. While in neurons transfected with myr-deTagRFP
blank vector, there were not so many hot spots visible in neuron processes and the fluorescence
did not recover after bleaching.
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Chapter 3 Figures
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Figure 3-1
FMRP binds Fmr1 3’ UTR in HEK293 cells
(A) Plasmid map of Flag-FMRP. Fmr1 coding region was cloned from wt mouse brain cDNA.
A flag tag was added to the 5’ to the FMRP coding region.
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(B) Plasmid map of pmirGLO. The blank pmirGLO vector (Promega). The PGK promoter
express the Firefly luciferase, the SV40 promoter/enhancer express the Renilla luciferase.
(C) Plasmid map of pmirGLO-Fmr1 3’ UTR. The Fmr1 3’ UTR was cloned from wt Fmr1 3’
UTR to the MCS of pmirGLO vector at downstream of Firefly luciferase.
(D) PCR confirmation for expression of transfected constructs in HEK293 cells. Following
transfection of plasmid combinations into HEK293 cells, RNA was extracted for RT-PCR.
Following amplicon were Firefly luciferase (FF; 500 bp), Renilla luciferase (REN; 308 bp) and
N19 in the Fmr1 coding sequence (379 bp). In each case, primer pairs produced single bands of
the expected size.
(E) PCR of FLAG-FMRP associated RNAs from pull downs of HEK293 transfected cells.
Plasmid combinations were transfected intoHEK293cells and Flag-FMRP was
immunoprecipitated using anti-Flag antibody conjugated to magnetic beads. RNA was extracted
from beads, cDNA prepared and used for PCR with primer sets for Firefly luciferase, Renilla
luciferase and N19. A strong signal for the N19 amplicon was obtained from Flag-FMRP single
transfections (Lane 5). N19 represents the coding region of Fmr1. When samples were prepared
from cells transfected with empty pmirGLO plasmid and Flag-FMRP, no signal was obtained for
either Firefly (FF) or Renilla (REN) luciferases (Lanes 3 and 4). When pmirGLO containing the
3’UTR of Fmr1 was co-transfected with Flag-FMRP, a band was observed for Firefly luciferase
(Lane 1) but not Renilla luciferase (Lane 2) due to the inability of the Renilla transcript and
FMRP to interact.
(F) Western blot of FLAG-FMRP. A Western blot using anti-FLAG antibody shows
significant amounts of FLAG-FMRP is pulled down under each of our IP conditions.

67

A

NLS

MCP

RFP

MCP-TagRFP
UbC

NLS

MCP

MS2-Fmr1 3’ UTR
RSV

NLS

RFP

MCP

RFP

8 MS2
Fmr1 3’ UTR

lacZ

C
LifeAct-Cerulean
MCP-RFP

MS2-Fmr1 3' UTR sum/length

0.02

40000
30000
20000
10000
0

M
S2

-F
m
r1

P
M
C

3'
U

TR

O
nl
y

0.00

****

O
nl
y

0.04

50000

P

0.06

TR

****

M
C

E

-F
m
r1
M
S2

D

Average granule number /um2

MS2-Fmr1 3' UTR count

3'
U

LifeAct-Cerulean
MS2-Fmr1 3’ UTR

Average Light Intensity (AU)/ um2

B

68

F
Gapdh mRNA-ms2

Figure 3-2
The Fmr1 3’UTR localizes to dendrites and co-transports with FMRP
(A) Schematic of the MS2-Fmr1 3’ UTR vector and the MCP-TagRFP. The MS2-Fmr1 3’
UTR vector was constructed by placing the Fmr1 3’ UTR downstream of the MS2 stem-loop
sequence (8 repeats). MCP-TagRFP vector was constructed by replacing GFP in MCP-GFP with
RFP. The two plasmids were co-transfected into wild-type hippocampal neurons at DIV 6-7.
Ubiquitin C promoter, (UbC) and Rous sarcoma virus promoter, (RSV).
(B) Live image of MS2-Fmr1 3’ UTR localization hippocampal neuron dendrites.
Representative image of hippocampal neurons transfected with MS2-Fmr1 3’ UTR vector and
MCP-TagRFP. LifeAct-Cerulean was co-transfected to highlight neuron morphology. Image
shows RFP positive granules in cell bodies and localized to dendrites. Photo shows merge of Cy3
(RFP, red) channel and CFP (cyan) channel. Rectangular region is a magnified selected region.
Scale bar is 10 μm.
(C) MCP-RFP transfection without MS2 vector. Representative image of hippocampal neuron
transfected with MCP-RFP vector and LifeAct-Cerulean. Most MCP-RFP accumulates in the
cell body. Rectangular region is a magnified selected region. Scale bar is 10 μm.
(D) Quantification of RNA granules in dendrites. Graph reflect the mean values of RNA
granule numbers in dendrites of >12 cells and at least 3-5 processes per neuron (±SEM). ****p <
0.0001 (Student’s t test).
(E) Quantification of Cy3 light intensity in dendrites. Graph reflects the mean value of light
intensity in processes of >12 cells at least 3-5 processes per neuron (±SEM). ****p < 0.0001
(Student’s t test).
(F) MS2-Gapdh mRNA does not localize to hippocampal processes. Representative image of
a hippocampal neuron transfected with MS2-Gapdh vector as a control for localization (live
imaging). Gapdh mRNA stays in soma and does not localize to processes. Rectangular region is
a magnified selected region. Photo shows merge of Cy3 (red) channel and DIC channel. Scale
bar is 5 μm.
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Figure 3-3
FMRP is transported and co-localized with the Fmr1 3’ UTR
(A) FMRP-GFP co-localizes with the MS2 CamK2 3’ UTR. Hippocampal neurons were cotransfected with GFP-FMRP, MS2-CamK2 3’UTR and MCP-TagRFP. Upper left panel shows
Cy3 signal, upper right panel shows FITC signal and bottom left are merged images. The merged
image shows most GFP-FMRP positive granules co-localized with CamK2 3’UTR granules in
neuronal processes. Bottom left is the DIC channel. Arrows point to granules in which GFPFMRP and Fmr1-3’ UTR co-localize. Scale bar is 5 μm.
(B) GFP-FMRP co-localizes with Fmr1 3’ UTR in dendrites. Hippocampal neurons were cotransfected with GFP-FMRP, MS2-Fmr1 3’ UTR, MCP-TagRFP and LifeAct-Cerulean on DIV
6-7. Results show most Fmr1 3’ UTR granules are co-localized with GFP-FMRP granules in
neuronal processes. Lower right photo shows a merge of Cy3, GFP, CFP, and DIC channels.
Scale bar is 5 μm.
(C) Co-transport of MS2-Fmr1 3’ UTR and GFP-FMRP. Hippocampal neurons were cotransfected with GFP-FMRP, MS2-Fmr1 3’ UTR and MCP-TagRFP on DIV 6-7. Time-lapse
photography was performed the second day. Timeframe photos show co-transport of GFP-FMRP
and Fmr1-3’ UTR granules in hippocampal processes. Scale bar is 2 μm.
(D) Velocity of Fmr1 3’ UTR/GFP-FMRP granules. Moving left is arbitrarily assigned as
positive. Each bar is granule velocity in μm/s, calculated as the distance moved between two
frames divided by the time duration between two frames.
(E) β-actin-3’ UTR does not co-localize with GFP-FMRP. Hippocampal neurons were cotransfected with GFP-FMRP, MS2-β-actin-3’ UTR, and MCP-TagRFP on DIV 6-7.
Representative photo show they do not co-localize. Scale bar is 2 μm.
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Figure 3-4
Neuron specific synapsin-promoter vector
(A) Plasmid map of pDS vector. pDS vector was constructed by cloning two Synapsin
promoters to the pBS- backbone.
(B) Plasmid map of pDS_GFP-FMRP_LifeAct-TagRFP. pDS_GFP-FMRP_LifeAct-TagRFP
was constructed by cloning GFP-FMRP and LifeAct-TagRFP to downstream of the two
Synapsin promoter separately.
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(C) pDS_GFP-FMRP_LifeAct-TagRFP express in hippocampal neuron. pDs_GFPFMRP_LifeAct-TagRFP transfected neuron expressing both GFP-FMRP and LifeAct-TagRFP
independently. Scale bar is 10 μm.
(D) Subcellular localization of GFP-FMRP granule. A region of neuron in (C) shows
preferential subcellular localization of GFP-FMRP granule to the base of spine or process branch.
(E) Synapsin promoter is neuron specific (IF). Hippocampal neurons were co-transfected with
pcDNA3_Cerulean (CMV promoter) and pBS+_LifeAct-TagRFP (Synapsin promoter) one
DIV6. Neurons were fixed for immunofluorescence staining of MAP2. Both neuron and glia
cells are expressing Cerulean (first frame, green, YFP channel). But only neuron is expressing
LifeAct-TagRFP (second frame, red, CY3 channel). Dendritic marker MAP2 staining highlights
neurons only (frame3, blue, Cy5 channel). Only the transfected neuros were pointed by arrows.
Scale bar is 10μm.
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Figure 3-5
Translational regulation through Fmr1 3’ UTR
(A) Plasmid MAP of pDS-LUC vector. pDS-LUC vector was constructed by cloning Firefly
luciferase and Renilla luciferase to downstream of the first Synapsin promoter and second
Synapsin promoter separately.
(B) Plasmid MAP of pDS-LUC_Fmr1 3’ UTR. The Fmr1 3’ UTR was cloned to the
downstream of the Firefly luciferase.
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(C) Normalized expression formula of luciferase assay. Each normalized expression is
calculated as Firefly luciferase/Renilla luciferase in each transfection. The final normalized
expression ratio is calculated as ratio of normalized pDS-target 3’ UTR expression
ratio/normalized pDS blank vector.
(D) Normalized expression ratio of luciferase assay in HEK293 cells. Luciferase assay was
performed by transfecting HEK293 cells using pmirGLO or pmirGLO_Fm1 3’ UTR with
pcDNA3 (control) GFP-FMRP (Hawrylycz et al.), GFP-FMRP-S499D, and GFP-FMRP-S499A
respectively to HEK293 cells. Cells were collected for luciferase assay 24h after transfection.
Results shows mean of relative expression of pmirGLO_Fm1 3’ UTR were normalized to
pmirGLO vector expression, n=3 (±SEM)). * p<0.05, *** p<0.001, n=3, (±SEM) (Student’s t
test).
(E) Neuron specific luciferase assay of Fmr1 3’ UTR. WT and Fmr1 KO hippocampal neurons
were transfected with pDS-LUC vector and pDS-LUC_Fmr1 3’ UTR on DIV 6-7. Neurons were
collected 24h after transfection for luciferase assay. Results shows mean of relative expression of
pDS-LUC_Fmr1 3’ UTR normalized to pDS-LUC vector, n=3 (±SEM). Stimulated samples
were treated with DHPG 20 min before collection. ns(non-significant) p≥0.05, ** p<0.01
(Student’s t test).
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Figure 3-6
Global and local translation of deTagRFP-Fmr1 3’ UTR
(A) Plasmid map of pcDNA3.1+ Myr-deTagRFP vector. Myr-deTagRFP was constructed by
fusing myristoylation consensus sequence to 5’ of TagRFP and destabilizing sequence to 3’.
Fmr1 3’ UTR was placed downstream of myr-deTagRFP.
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(B) Model of Myr-deTagRFP local expression.
(C) Expression of Myr-deTagRFP and regular TagRFP in HEK293 cells. Representative
photos of HEK293 cells transfected with pcDNA-TagRFP, Myr-deTagRFP-blank, MyrdeTagRFP-Fmr1 3’ UTR, Myr-deTagRFP-Nl1 3’ UTR, Myr-deTagRFP-CamKII 3’ UTR, MyrdeTagRFP-β-actin 3’ UTR vectors. Upper panel is taken with Cy3 filter, lower panel is merge of
Cy3 and DIC channel. Scale bar is 10μm.
(D) Comparison of myr-deTagRFP and regular TagRFP expression in HEK293 cells.
Quantification of average light intensity of TagRFP vectors. Results shows mean of more than
10 cells (±SEM). ns (non-significant) p≥0.05, *p<0.05, **p<0.01 (Student’s t test).
(E) Expression of myr-deTagRFP and myr-deTagRFP-Fmr1 3’ UTR in hippocampal
neuron. myr-deTagRFP or myr-deTagRFP-Fmr1 3’ UTR vector was co-transfected with
pcDNA_Cerulean. Neuron culture was stimulated with 50ng/ml BDNF 1h before imaging. Scale
bar is 10μm.
(F) Relative expression ratio of myr-deTagRFP Fmr1 3’ UTR in neuron cell body and
processes. Light intensity ratio TagRFP/Cerulean of myr-deTagRFP Fmr1 3’UTR was
normalized to myr-deTagRFP blank vector. Results shows mean of more than 12 neurons, 3-4
dendrites per neuron (±SEM). ns (non-significant) p≥0.05, ** p<0.01, *** p<0.001, ****
p<0.0001 (Student’s t test).
(G) FRAP of myr-deTagRFP-Fmr1 3'UTR and myr-deTagRFP blank vector. 405nm laser
was applied to chosen region of dendrites in transfected neuron. Fluorescence recovery was
recorded and presented as rainbow photos. In deTagRFP-Fmr1 3’ UTR transfected neuron,
bleached region has hot spot recovered. Representative photos on 1 min before bleach, 1 min, 11
min, 21 min, 31 min and 36 min after bleaching are on the left. The recorded recovery of hot spot
started in 11 min after bleaching. There is no such hot spot recovery in deTagRFP blank vector
transfected neuron (representative photos on the right). Lower panel shows accumulative
recovery over length of process during the whole FRAP experiment. X axis represent length and
position of the whole process, Y axis represents time. Red arrows point to the bleaching point,
which was performed on 00 min.
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CHAPTER

4

FMRP BINDS TO THE 3’UTR OF NEUROLIGIN1 TO REGULATE mRNA
TRANSLATION IN THE DENDRITES OF HIPPOCAMPAL NEURONS

81

4.1

Introduction
Pre-synaptically localized neurexins (NRX) and post-synaptically localized neuroligins

(NL) form a trans-synaptic complex between the pre-synaptic and post-synaptic terminals
(Ichtchenko, Nguyen, & Sudhof, 1996). The recognition and binding between the two molecules
are crucial to synaptogenesis, synapse maturation, differentiation, and maintenance. Mutation or
copy number variations in some members of the neurexin and neuroligin families, specifically
Nl1, Nl3, Nl4 and Nrx1-3, are related to autism (Jamain et al., 2003). In addition, some neurexin
variants are FMRP targets as shown by high throughput sequencing crosslinking
immunoprecipitation (HITS-CLIP) (Darnell et al., 2011).
Nl1 mRNA was not identified as an FMRP target by HITS-CLIP but by other method,
which predicted G quartet regions in the 5’ UTR of Nl1 as potential FMRP target sequences
(Dahlhaus & El-Husseini, 2010). We found two quadruplex forming G-rich sequences (QGRS)
in

the

Nl1

3’

UTR

using

QGRS

Mapper,

a

QGRS

prediction

program

(http://bioinformatics.ramapo.edu/QGRS/index.php) (Figure 4-1, A). Similar experiments to
those described in Chapter 3 were designed to assess FMRP-Nl1 3’ UTR binding, subcellular
localization of the Nl1 3’ UTR, translational regulation by FMRP through the Nl1 3’ UTR and
local translation of reporter-Nl1 3’ UTR in dendrites.

4.2

FMRP binds Nl1 3’ UTR in its 3’ UTR
To assess whether FMRP binds Nl1 3’UTR, we cloned the Nl1 3’ UTR from mouse brain

cDNA and inserted it into the pmirGLO vector (Figure 4-1, B). This construct, pmirGLO-Nl1 3’
UTR, was co-transfected with Flag-FMRP into HEK293 cells for co-immunoprecipitation to pull
down mRNA. Because the Nl1 3’UTR was transcribed with Firefly luciferase (FF) by the PGK
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promoter, and the Renilla luciferase (Ren) was transcribed by the SV40 promoter, we can assess
the presence of Nl1 3’UTR by amplifying each luciferase with PCR. HEK293 cells were cotransfected with both pmiRGLO-Nl1 3’UTR and Flag-FMRP (lane 1 and 2). A band of
approximately 500 bp was amplified using FF primers (amplifying Firefly luciferase) (Figure 4-1,
C, lane 1). The Ren primers (amplifying Renilla luciferase, 308bp amplicon if amplified, lane 2)
amplified no band. In the co-transfection of the empty pmirGLO vector with Flag-FMRP (Lanes
3 and 4), neither amplicon was amplified. Our positive control for FMRP binding, the Fmr1 N19
sequence, produces a strong band at the expected size (Lane 5). This experiment demonstrates
that FMRP binds the Nl1 3’UTR.

4.3

Dendritic localization of Nl1 3’ UTR and its co-localization/co-transport with FMRP
We used the MCP-MS2 system to determine subcellular localization of the Nl1 3’ UTR.

The Nl1 3’ UTR was cloned into the MS2 vector and co-transfected into hippocampal neurons
with MCP-TagRFP (described previously in Chapter2 material and methods, also in Chapter3).
RNP granules containing Nl1 3’ UTR localized in pyramidal neuron processes. Time-lapse
images showed moving granules (Figure 4-2, A). The moving velocity of a representative
granule was measured (Figure 4-2, B). The measured granule shows both retrograde and
anterograde movement, but in general it is an anterograde to the terminal of dendrites.
The dendritic localization of the Nl1 3’UTR was confirmed using fluorescent in situ
hybridization (FISH). Anti-sense MS2 probes was used on MCP-GFP/MS2-Nl1 3’UTR
transfected neurons. MS2-Nl1 3’ UTR co-localize with MCP-GFP in dendrites (Figure 4-2, C).
Dendrites were highlighted by dendritic marker microtubule-associated protein 2 (MAP2).

83

Co-transfection of MS2-Nl1 3’ UTR, MCP-TagRFP and GFP-FMRP shows colocalization of Nl1 3’ UTR and GFP-FMRP in RNP granules (Figure 4-3, A). Time-lapse frames
show co-transport of Nl1 3’ UTR and GFP-FMRP over time (Figure 4-3, B). The arrow points to
one representative moving granule at different time points.
Phosphorylation and dephosphorylation of FMRP is a key switch of its translational
regulation function. Two FMRP phosphorylation mutants FMRP (S499A) and FMRP (S499D)
were constructed to mimic dephosphorylated and phosphorylated FMRP at ser499 (Ceman,
O'Donnell, et al., 2003). The phosphorylation and dephosphorylation of this amino acid triggers
the phosphorylation/dephosphorylation of nearby sites (496S, 501T, and 503S) that are outside
of the RNA binding domains of FMRP (KH1 206-280, KH2 281-422, RGG 534-552).
To determine if the phosphorylation status of FMRP at ser499 affects its RNA binding
ability, we co-transfected hippocampal neurons with the FMRP mutants and both MS2-MCP
constructs (MS2-Nl1 3’ UTR and MCP-TagRFP). Our results show that the phosphorylation
status of FMRP does not affect its binding, co-localization or co-transport with the Nl1 3’ UTR
(Figure 4-3, C).

4.4

Post-synaptic localization of Nl1 3’ UTR
To assess the subcellular localization of Nl1 3’ UTR in dendrites, we used a marker of

post-synaptic density, post-synaptic density protein 95 (PSD95). Post-synaptic density protein 95
specifically localizes to the post-synaptic terminal of excitatory synapses. We co-transfected
PSD95-GFP with the Nl1 3’ UTR MS2-MCP system. Merged Cy3, GFP and DIC images show
co-localization of Nl1 3’ UTR, FMRP and PSD95 in granules localized to the post-synaptic
terminal (Figure 4-4).
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Neurexin (NRX) is an adhesion molecule at pre-synaptic terminal that binds to
Neuroligin (NL) at post-synaptic terminal. Neuroligins expressed in non-neuronal cells can
trigger pre-synaptic development (Scheiffele et al., 2000). The reverse experiment of NRX
expressed on non-neuronal cells co-cultured with neurons can also induce post-synaptic
development (Graf et al., 2004).
We performed an artificial synapse formation assay to set up a method for further
research on new synapse. Neurons were co-transfected with NL1-RFP construct (NL1 coding
sequence, +A2+B variant) and the LifeAct-Cerulean vector (LA-Cerulean) (Figure 4-5, A).
LifeAct highlighted the morphology of the neuron by binding to F-actin. The transfected neurons
were co-cultured with HEK293 cells transfected with NRX-GFP. Artificial synapses formed
between HEK293 cells expressing NRX-GFP and neurons expressing both LA-Cerulean and
NL1-RFP (pointed by arrow in Figure 4-5, A). The neurexins on HEK293 cells bind to
neuroligin molecules on neurons and trigger formation of artificial synapses in minutes. The
NRX-GFP accumulates at the presynapse on HEK293 cells, while NL1-RFP and LifeActCerulean accumulate at the postsynapse on neurons. The accumulation of LifeAct-Cerulean at
the post synaptic terminal of the artificial synapse represents the accumulation of F-Actin. It
makes sense that there are more structural proteins accumulated in new synapses.
To determine the similarity between artificial synapses and real synapses, the artificial
synapse formation assay was performed with neurons transfected with the PSD95-RFP vector
and NL1-Cerulean. These neurons were then co-cultured with HEK293 cells transfected with
Neurexin-GFP. PSD95-RFP accumulates at the post-synaptic terminal of the artificial synapse
(Figure 4-5, B). The appearance of PSD95 at the post-synaptic terminal is a sign of its similarity
compared to real synapse. Neurons treated with the translation inhibitor anisomycin before co-
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culture, are still able to form artificial synapses (Figure 4-5, C). This suggests that artificial
synapse formation is not translation-dependent.
With the knowledge of synaptic localization of NL1 protein and the dendritic localization
of Nl1 mRNA, it is natural to further investigate whether the Nl1 3’UTR is also localized to
synapses for local translation. Artificial synapse formation assay was performed with neurons
transfected with the Nl1 3’ UTR MS2 system and LifeAct-Cerulean. Nl1 3’UTR (red)
accumulated at the postsynapse of artificial synapse (Figure 4-6 A). Time-lapse images were
captured after NRX-GFP transfected HEK293 cells were co-cultured with transfected neurons
(Figure 4-6, B). Arrows point to the locations of artificial synapses where Nl1 3’ UTR get
accumulated at the post-synaptic terminal over time (Figure 4-6, C).
Co-culture of HEK293 cells transfected with myr-GFP does not trigger the formation of
an artificial synapse and no subsequent accumulation of Nl1 3’ UTR (Figure 4-6, D). As control
experiments, the same assay was performed using MS2-Gapdh mRNA (whole mRNA containing
5’ UTR, CDS and 3’ UTR) and MS2-CamK2 3’ UTR (Figure 4-6, E). Gapdh mRNA is known to
majorly stay in cell body, CamK2 3’ UTR is a known FMRP target, and also localizes to
dendrites (Mayford et al., 1996). The top panel shows the merge of images from the Cy3 channel
(MS2-MCP), CFP channel (NL1-Cerulean), and GFP channel (NRX-GFP in HEK293). The
bottom panel shows Cy3 only. The quantification of the region of interest (Lapidus et al.) shows
the Gapdh mRNA and CamK2 3’ UTR do not concentrate at artificial synapses like the Nl1 3’
UTR (Figure 4-6, F). Since the arbitrary identification of ROI could be inaccurate, the NL1Cerulean signal was used to normalize the data (Figure 4-6, G), which shows that Gapdh
mRNAs do not concentrate at artificial synapses.

86

Our assumption was that the more NL1-Cerulean signal found at the artificial synapse,
the bigger the postsynapses are, and therefore the more the synaptic mRNA present.
Normalization of data represents mRNAs accumulated at artificial synapse normalized to
artificial synapse amount (NL1-Cerulean). Whether or not CamK2 3’ UTR is accumulated in the
artificial synapse may be arguable, but Gapdh mRNA does not accumulate at the artificial
synapse. Therefore, we suggest that the Nl1 3’ UTR is transported and accumulates at the postsynaptic terminal of artificial synapses.

4.5

Translation regulated through Nl1 3’ UTR
To determine how translation is regulated through the Nl1 3’ UTR, a neuron-specific

luciferase assay was performed. Dual synapsin luciferase vector pDS-LUC-Nl1 3’ UTR was
constructed by cloning Nl1 3’UTR to pDS-LUC vector (Figure 4-7, A). Transfection and a
luciferase assay were performed in the same way as the Fmr1 3’ UTR luciferase assay described
previously (Chapter 3). The Firefly luciferase/Renilla luciferase ratio of pDS-LUC-Nl1 3’ UTR
was normalized to the Firefly luciferase/Renilla luciferase ratio of pDS-LUC blank vector
(Figure 3-5, C). The normalized expression ratio shows the translational regulation through Nl1 3’
UTR. Results show the basal levels of translation regulated through the Nl1 3’ UTR are the same
in wild type and Fmr1 KO mouse hippocampal neurons (Figure 4-7, B). There is a significant
increase with DHPG stimulation in wild type neurons while a decrease in KO.
To examine local translation, we performed a Fluorescence Recovery After
Photobleaching (FRAP) experiment using a myristoylated-destabilized-RFP-based translation
reporter (deTagRFP) as previous described (Chapter3). Myristoylation allows the protein to bind
the membrane near its translation site thereby reduces diffusion in cytoplasm. The destabilized
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peptide is a target of the protein degradation machinery. Therefore, any new fluorescence that
appears at the bleached site represents new locally translated protein.
We constructed a myristoylated-destabilized-RFP-Nl1 3’ UTR vector (Figure 4-8, A).
Neurons were transfected with myr-deTagRFP-Nl1 3’ UTR vector and LA-Cerulean.
Immunofluorescent photos of the same neuron were taken before and after BDNF treatment.
After BDNF treatment, both the deTagRFP signal and Cerulean signal increased. Relative
expression is expressed as the ratio of deTagRFP-Nl1 3’ UTR/Cerulean normalized by ratio of
deTagRFP/Cerulean, similar to the calculation of luciferase assay. The predominant expression
of reporters was localized in cell bodies and the locally translated reporter in processes stay
where they are translated. Therefore, cell bodies and processes were quantified and analyzed
respectively (Figure 4-8, C and D). There is no significant difference in cell bodies between wild
type and Fmr1 KO hippocampal neurons. However, there is more myr-deTagRFP expression in
the Fmr1 KO processes (Figure 4-8, D). The relative expression in both wild type and Fmr1 KO
neurons are decreased by BDNF treatment (Figure 4-8, C, D).
Fragile X mental retardation proteins are believed to be a major a translation repressor,
although little is known about the mechanism of translational regulation. The unphosphorylated
FMRP is associated with actively translating polyribosomes while a fraction of phosphorylated
FMRP associates with stalled polyribosomes (Ceman, Zhang, Johnson, & Warren, 2003). This
result suggests that translational regulation by FMRP is controlled by switching its
phosphorylation status.
To examine if the phosphorylation status of FMRP affects its RNA binding ability under
physiological conditions, the two FMRP mutants, S499A (the phosphorylation inhibition mutant)
and S499D (the phosphorylation mimic) were used (Figure 4-9, A). The deTagRFP density in the
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dendrites was quantified and compared (Figure 4-9, B). The mean deTagRFP intensity in
dendrites is much lower in S499D FMRP co-transfection. This further confirmed that FMRP
regulate translation through Nl1 3’ UTR.

4.6

Local translation regulated through Nl1 3’ UTR
With the knowledge of Nl1 3’ UTR dendritic/synaptic localization, further experiment

was performed to confirm its local translation. Hippocampal neurons of WT mice were
transfected with myr-deTagRFP vectors, Cerulean, and PSD95-GFP on DIV 6-7 and imaged
approximately 48 hrs later. The myr-deTagRFP-Gapdh vector with Gapdh (5’ UTR-CDS-3’
UTR) which localizes to the cell body, was used as a control. PSD 95-GFP is a post-synaptic
terminal marker of excitatory synapse. Regions where deTagRFP is expressed at PSD 95-GFP
positive sites were chosen for FRAP since PSD 95-GFP positive sites are the potential postsynaptic terminal. The chosen region of a dendrite was photobleached by 405 nm light for 0.5
sec. Images were acquired before (time point -01 min) and after bleaching (00 min to 30 min).
Local translation in this region was assayed by observing recovery of fluorescence after
photobleaching. Experiment with the Nl1 3'-UTR untreated, treated with BDNF, protein
translation inhibitor Cycloheximide (CHX, inhibit protein translation by interfering with the
translocation step in protein synthesis) and with BDNF+CHX are indicated. Representative
FRAP images before bleaching, after bleaching and 30 min after bleaching are shown by
rainbow contrast pictures, (Figure 4-10, A). The hotspots in deRFP-Gapdh did not recover after
bleaching (Figure 4-10, B). The hotspots in deRFP-Nl1 3’ UTR got recovered. When deRFP-Nl1
3’ UTR was treated with BDNF, there is a robust recovery. But when the neurons are treated
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with CHX (50 nM) for 1h before FRAP, the recovery of deTagRFP hotspots was inhibited,
regardless whether BDNF was present or not (Figure 4-10, C).
Myr-deTagRFP-Nl1 3’ UTR was co-transfected with PSD95-GFP to WT hippocampal
neurons on ~DIV 7 and images were taken 24~48 h after transfection (Figure 4-11). Arrows
point to the co-localization of deTagRFP with PSD95-GFP, representing local translation of
myr-deTagRFP at post-synaptic terminal. Therefore, the Nl1 3’ UTR is sufficient to guide the
transcript to post-synaptic terminal, then the mRNA with Nl1 3’ UTR is locally translated there.

4.7

Local translation at artificial synapse
Neurons transfected with myr-deTagRFP-Nl1 3’ UTR (deR-Nl1 3’U) and LifeAct-

Cerulean (LA-CRL) were co-cultured with Neurexin-GFP transfected to HEK293cells (Figure
4-12, A). The arrow points to an artificial synapse site formed between HEK293 cell and
hippocampal neuron, where local translation of deTagRFP occurred. The time represents time
passed since the start of co-culturing. A region of artificial synapses was chosen for
quantification. Quantification of this region shows an increased amount of deTagRFP at this site,
compared to a dendrite in the nearby area (Figure 4-12, B). The light intensity of the nearby
dendrite area did not change significantly, while the intensity of hot spot was increased. Another
example shows local translation at the tip of a dendrite/spine which is the post-synaptic terminal
of the artificial synapse (Figure 4-12, C). The deTagRFP blank vector shows much less
deTagRFP at artificial synapse (Figure 4-12, D). Anisomycin is a translation inhibitor interfering
with protein synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Neurons
transfected with LifeAct-Cerulean and Nl1-RFP (coding sequence) were treated with anisomycin
1 h before co-culturing with Neurexin-GFP transfected HEK293 cells. The artificial synapse
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formation was not affected as proved before (Figure 4-5, C). The local translation of myrdeTagRFP-Nl1 3’ UTR at post-synaptic terminal was inhibited by anisomycin. This further
proved that the dendritic hotspot in Figure 4-12 A, C were local translated instead of diffused
from cytoplasm. The relative expression level of myr-deTagRFP in myr-deTagRFP-Nl1 3’ UTR
transfected vector was significantly reduced by anisomycin treatment (Figure 4-12, F). The
translation inhibitor anisomycin is not supposed to affect RNP transport/accumulation, so the
difference is caused by local translation.

4.8

Conclusion
The results presented here indicate the functions of Nl1 3' UTR in both mRNA transport

and translational regulation. Nl1 3' UTR was pulled down by FLAG-FMRP from lysate of cotransfected HEK293 cells, despite this interaction could be direct or indirect. Using MS2-MCP
system, we observed Nl1 3’ UTR RNP granules localized to dendrites and synapses. FMRP cotransported with Nl1 3' UTR in mRNP granules to dendrites. The phosphorylation of FMRP at
S499 had no effect on the RNA binding ability of FMRP with Nl1 3’ UTR in neuron. With the
help of artificial synapse formation assay, we observed accumulation of MS2-Nl1 3’ UTR to
artificial synapse over time.
The Synapsin promoter luciferase vector enable us to perform neuron specific luciferase
assay with Nl1 3’ UTR in mice hippocampal neurons. Result shows the relative expression level
of reporter with Nl1 3’ UTR has similar level of expression at basal state. But with DHPG
stimulation, the relative expression of reporter with Nl1 3’ UTR got increased in WT, while it got
decreased in Frm1 KO hippocampal neurons. The lack of FMRP regulation resulted in the lack
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of positive response of Nl1 3’ UTR to DHPG stimulation in reporter translation. The luciferase
assay provide a view of global translational regulation through Nl1 3’ UTR within neuron.
Presumably, mRNAs move to their destination in dendrites, local translation occurs there
under regulation. With the myristoylated-destabilized-RFP-based translation reporter myrdeTagRFP, we captured clear evidence of this process. Artificial synapse formation assay
showed local translation of reporter deTagRFP on site over time. Translation inhibitors
effectively inhibited the recovery of deTagRFP in FRAP experiment, also inhibited formation of
hotspots in the artificial synapse. The two phosphorylation mutant S499A and S499D showed
relieving or repressing of translation of myr-deTagRFP reporter as expected. The same
experiment on Fmr1 3’ UTR does not show hot spot of local translation triggered by artificial
synapse formation (data not shown).
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Figure 4-1
FMRP binds Nl1 3’ UTR in HEK293 cells
(A) QGRS (Quadruplex forming G-Rich Sequences) prediction of Nl1 3’ UTR. QGRS
prediction
of
two
G-rich
region
was
predicted
using
QGRS
Mapper
(http://bioinformatics.ramapo.edu/QGRS/index.php).
(B) Plasmid map of pmirGLO-Nl1 3’ UTR. Nl1 3’ UTR was cloned from cDNA of whole
mouse brain to pmirGLO vector MCS between SacI and SalI.
(C) PCR detecting mRNA pulled down in anti-FLAG full down. HEK293 cells were cotransfected with pmirGLO-Nl1 3’ UTR/pmirGLO vectors and pcDNA3_FLAG-FMRP for IP.
RNA were extracted from beads after IP for RT-PCR. Expected Firefly luciferase amplicon is
500 bp, N19 amplicon is 379 bp, Renilla amplicon is 308 bp. PCR shows Firefly luciferase-Nl1 3’
UTR mRNA was pulled down (lane 1), but not Firefly luciferase mRNA itself (lane 3). Positive
control N19 region of Fmr1 3’ UTR was pulled down as expected (lane 5). Renilla luciferase
mRNA was not pulled down as expected (lane 2 and lane 4). See Figure 3-1 for primer test.
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Figure 4-2
Nl1 3’ UTR transport in dendrites
(A) Nl1 3’ UTR granule moving in hippocampal neuron processes. Hippocampal neurons
were co-transfected with RSV-MS2-Nl1 3’ UTR and MCP-TagRFP on DIV 6-7. Live imaging
was done the second day. Timeframe photos of representative neuron processes show transport
of Nl1-3’ UTR granules in processes. Arrow points to the moving granule. Scale bar is 5μm.
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(B) MS2-Nl1 3’UTR moving velocity. Moving velocity of the Nl1 3’ UTR granule in (A) was
measured. Left in (A) was assigned as positive.
(C) FISH of MS2-Nl1 3’ UTR transfected neuron. Hippocampal neurons were co-transfected
with RSV-MS2-Nl1 3’ UTR and MCP-TagRFP on DIV 6-7. Neurons were fixed for FISH the
second day. MAP2-Rab-Cy5 was used to stain neuron dendrites. MS2 probe was used to detect
MS2-Nl1 3’ UTR mRNA. Probed dendritic MS2-Nl1 3’ UTR was pointed by arrows in the
merge photo. Scale bar is 5 μm.
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Figure 4-3
Co-localization and co-transport of Nl1 3’ UTR with FMRP
(A) Co-localization of MS2-Nl1 3’ UTR and GFP-FMRP. WT hippocampal neurons were cotransfected with RSV-MS2-Nl1 3’ UTR, MCP-TagRFP and GFP-FMRP on DIV 6-7. Live
imaging was done the second day. Representative photo of merged Cy3, GFP, and DIC channels
shows co-localization of GFP-FMRP and Nl1 3’ UTR in granules, pointed by arrows. Scale bar
is 2μm.
(B) Co-transport of MS2-Nl1 3’ UTR and GFP-FMRP. Time frames of video taken from
transfection in (A) shows co-transport of MS2-Nl1 3’ UTR and GFP-FMRP neuron processes.
Scale bar is 2μm.
(C) FMRP phosphorylation mutations does not affect their co-localization with MS2-Nl1 3’
UTR. WT hippocampal neurons were co-transfected with RSV-MS2-Nl1 3’ UTR, MCP-TagRFP,
LifeAct-Cerulean and GFP-FMRP (wt, or S499D, or S499A) on DIV 6-7. Photos were taken the
second day. Arrows point to the GFP-FMRP (wt, or S499D, or S499A) and Nl1 3’ UTR colocalized granules in cell processes. Scale bar is 5μm.

MS2-Nl1 3’ UTR PSD-95

Figure 4-4
Post-synaptic localization of Nl1 3’ UTR
Hippocampal neurons were co-transfected with RSV-MS2-Nl1 3’ UTR, MCP-TagRFP and
PSD 95-GFP on DIV 6-7. Live imaging was done the second day. Representative photo of
merged Cy3, GFP, and DIC channels shows co-localization of GFP-FMRP and Nl1 3’ UTR in
granules, pointed by arrows. Co-transfection of MS2-Nl1 3’ UTR, MCP-RFP and PSD 95-GFP
in hippocampal neuron. Co-localization of PSD95-GFP and MS2-Nl1 3’ UTR shows Nl1 3’ UTR
localize to post synaptic terminal of excitatory synapse. Scale bar is 2μm.
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Figure 4-5
Artificial synapse formation assay
(A) Artificial synapse formation assay. HEK293 cells expressing NRX-GFP were co-cultured
with hippocampal neurons transfected with pDS_hNL1-mRFP_LifeAct-Cerulean for 1h. Arrow
points to artificial synapse formed between HEK293 cell and neuron. NRX-GFP accumulates in
the pre-synaptic terminal (first frame, green). Both LA-Cerulean (frame 2, blue) and NL1-RFP
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(frame 3, red) accumulates on the post-synaptic terminal. The arrow in merge photo (frame 4)
points to artificial synapse formed between HEK293 and neuron. Scale bar is 2μm.
(B) Artificial synapse formation assay with PSD95-RFP transfected neuron. HEK293 cells
transfected with NRX-GFP were co-cultured with neuron transfected with NL1-Cerulean and
PSD95-TagRFP. NRX-GFP accumulates in the pre-synaptic terminal (first frame, green). Both
NL1-Cerulean (frame 2, blue) and post-synaptic marker PSD95-RFP (frame 3, red) accumulates
on the post-synaptic terminal. The arrow in merge photo (frame 4) points to artificial synapse
formed between HEK293 and neuron. Scale bar is 2 μm.
(C) Artificial synapse formation assay is protein translation independent. Neurons were
treated with 50μm anisomycin 1h before artificial synapse assay as (A). Protein translation
inhibitor anisomycin does not affect artificial synapse formation. The arrow in merge photo
(frame 4) points to artificial synapse formed between HEK293 and neuron in the presence of
anisomycin. Scale bar is 2 μm.
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Figure 4-6
Nl1 3’ UTR accumulate at artificial synapse
(A) MS2-Nl1 3’ UTR accumulate at artificial synapse. HEK293 cells expressing NRX-GFP
were co-cultured with hippocampal neurons transfected with MCP-TagRFP and MS2-Nl1 3’
UTR for 1h. Artificial synapse formed between HEK293 (frame 1, green) and neuron (frame2,
blue). MS2-Nl1 3’ UTR accumulated in post-synaptic terminal (frame 3, red). Arrow points to
the MS2-Nl1 3’ UTR accumulated at the artificial synapse (frame 4, merge). Scale bar is 2μm.
(B) Time frame of MS2-Nl1 3’ UTR accumulate at artificial synapse. A time frame video
was taken in the same transfection in (A). MS2-Nl1 3’ UTR signal (red) increases at artificial
synapse over time. Arrows points to artificial synapse formed between HEK293 cells and neuron.
Scale bar is 2μm.
(C) Quantification of MS2-Nl1 3’ UTR accumulated at artificial synapse over time in (B).
Results show mean intensity of Nl1 3’ UTR signal at artificial synapse pointed in (B) over time
(±SEM).
(D) Myr-GFP does not trigger MS2 accumulation. HEK293 cells transfected with myr-GFP
(myristoylation consensus sequence-GFP) does not trigger formation of artificial synapse and
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therefore does not cause accumulation of Nl1 3’ UTR at the site the neuron in touch with HEK
cells. Scale bar is 5μm.
(E) Comparison of Nl1 3’ UTR, CamK2-3’ UTR and Gapdh-mRNA accumulation at
artificial synapse. Scale bar is 5μm. HEK293 cells expressing NRX-GFP were co-cultured with
hippocampal neurons transfected with MCP-TagRFP and MS2-Nl1 3’ UTR, or MS2-CamK2-3’
UTR, or Gapdh-3’ UTR for 1h. Top frames show merge of HEK293 cells expressing NRX-GFP
(green), MS2-RNA (red) and NL1-CRL (NL1-Cerulean, blue). Bottom frames show MS2-RNA
only. Scale bar is 2μm.
(F) Quantification of target mRNA at artificial synapse. Results shows mean MS2-RNA
signal at artificial synapse in (E) (±SEM). ****p< 0.0001 (Student’s t test).
(G) Quantification of mRNA (relative) at artificial synapse. Results shows mean MS2-RNA
signal (normalized to NL1-Cerulean) at artificial synapse in (E) (±SEM). ns (non-significant)
p≥0.05, ***p< 0.001 (Student’s t test).
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Figure 4-7
Neuron specific luciferase assay of Nl1 3’ UTR.
(A) Plasmid map of pDS-LUC_Nl1 3’ UTR vector. Nl1 3’ UTR was cloned to pDS-LUC
vector after the Firefly luciferase.
(B) Neuron specific luciferase assay of Nl1 3’ UTR. Hippocampal neurons were transfected
with pDS-LUC_Nl1 3’ UTR on DIV 6-7. Transfected neurons were collected 24h after
transfection for luciferase assay. Results shows mean of relative expression level of Firefly
luciferase regulated through Nl1 3’ UTR in WT and Fmr1 KO hippocampal neurons, in the
absence or presence of DHPG, n=4 (±SEM). For DHPG treated sample, neuron culture was
treated with 100 μM (RS)-3, 5-DHPG for 20min before collection. ns (non-significant) p≥ 0.05,
*p< 0.05. **p< 0.01 (Student’s t test).
This is Ratio of Firefly luciferase/Renilla luciferase normalized
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Figure 4-8
myr-deTagRFP-Nl1 3’ UTR expression in HEK293 and neuron
(A) Plasmid map of pcDNA3.1+Myr-deTagRFP_Nl1 3’ UTR vector. Myr-deTagRFP was
constructed by fusing myristoylation consensus sequence to 5’ of TagRFP and destabilizing
sequence to 3’. Nl1 3’ UTR was placed downstream of myr-deTagRFP.
(B) Myr-deTagRFP_Nl1 3’UTR expression in hippocampal neuron. WT and Fmr1 KO
hippocampal neurons were transfected with pcDNA3.1+Myr-deTagRFP_Nl1 3’ UTR and
pcDNA-Cerulean. Photo of the same neuron was taken before and after BDNF stimulation. Top
fames show before stimulation, lower panel shows after BDNF stimulation. Scale bar is 10 μm.
(C) (D) Relative expression ratio of myr-deTagRFP Nl1 3’ UTR in neuron cell body and
processes. Light intensity ratio TagRFP/Cerulean of myr-deTagRFP Fmr1 3’UTR was
normalized to myr-deTagRFP blank vector. Results shows mean of more than 12 neurons, 3-4
dendrites per neuron (±SEM). ns (non-significant) p≥0.05, ** p<0.01, *** p<0.001, ****
p<0.0001 (Student’s t test).
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Figure 4-9
FMRP mutants in translational regulation
(A) Phosphorylation status of FMRP regulate deTagRFP-Nl1 3’ UTR expression.
Hippocampal neurons were co-transfected with LA-Cerulean, myr-deTagRFP-Fmr1 3'UTR and
GFP-FMRP S499A (phosphorylation mimic mutant) or S499D (phosphorylation inhibition
mutant) on DIV 6-7. Live imaging was done the second day. Representative photo of CFP, GFP,
Cy3, and merged channels shows the expression of reporter deTagRFP in neuron processes with
either S499A or S499D. Scale bar is 2um.
(B) Relative expression level of deTagRFP with GFP-FMRP S499A and S499D. Relative
expression of deTagRFP in (A) was quantified. Results shows mean of relative expression of
deTagRFP normalized to GFP-FMRP (S499A) or GFP-FMRP (S499D) (±SEM). More than 11
neurons, 2-3 processes per neuron were quantified. ** p<0.01 (Student’s t test). Scale bar is 2μm.
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Figure 4-10 FRAP of deTagRFP-Nl1 3’ UTR
(A) FRAP experiment of deTagRFP with different 3’ UTRs and different treatment.
Hippocampal neurons were transfected with PSD95-GFP, Cerulean, myr-deTagRFP-Gpadh
mRNA or myr-deTagRFP-Nl1 3’ UTR on DIV 6-7. BDNF and CHX were used to treat neuron
culture of myr-deTagRFP-Nl1 3’ UTR transfection before FRAP. 405nm laser was applied to
chosen region of dendrites in transfected neuron. Fluorescence recovery was recorded and
presented as rainbow photos. In myr-deTagRFP-Nl1 3’ UTR transfected neuron, bleached region
has hot spot recovered. Representative photos on 1 min before bleach are shown as merged
image of CFP channel, GFP channel, and Cy3 channel (top row). Hot spots with both PSD 95GFP and deTagRFP were chosen for bleaching, which are pointed by arrows. Representative
photos on 1 min before bleach, 1 min and 30 min after bleaching are shown from the second row
to the fourth row as rainbow photo. The recorded recovery of hot spots were observed in myrdeTagRFP-Nl1 3’ UTR transfection (second column) and myr-deTagRFP-Nl1 3’ UTR
transection treated with BDNF (fourth column). There was no such hot spot recovery in myrdeTagRFP-Gapdh mRNA vector (first column). The recovery was inhibited in myr-deTagRFPNl1 3’ UTR treated with protein translation inhibitor CHX, or myr-deTagRFP-Nl1 3’ UTR
transfection treated with both BDNF and CHX (third and fifth column).
(B) (C) deTagRFP fluorescence recovery of FRAP experiment overtime. Graph shows
accumulative recovery of more than 8 hot spots over time of (A) normalized to the fluorescence
on the hotspot before bleaching (±SEM). X axis represent time, Y axis represent deTagRFP
fluorescence. *p<0.05, **p<0.01 (Two way ANOVA).
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deRFP-Nl1 3’UTR
GFP-PSD95

Figure 4-11 Post-synaptic expression of deTagRFP-Nl1 3’ UTR
Hippocampal neurons were transfected with myr-deTagRFP 3’ UTR and post-synaptic marker
PSD 95-GFP on DIV 6. Live images were taken the second day. Arrows point to synapse where
deTagRFP expresses. Scale bar is 5μm.
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(A) Time frame of myr-deTagRFP-Nl1 3’ UTR local translation at artificial synapse.
Artificial synapse formation assay trigger local translation of myr-deTagRFP-Nl1 3’ UTR.
HEK293 cells transfected NRX-GFP were cultured with hippocampal neuron transfected with
myr-deTagRFP and LACRL (LifeAct-Cerulean). Local translation of myr-deTagRFP-Nl1 3’
UTR was triggered at artificial synapse formed between HEK cell and neuron. The arrow points
to a representative region have local translation. Scale bar is 2 μm.
(B) Quantification of translation at artificial synapse in (B) overtime. Cy3 intensity of two
positions in (A) was quantified overtime (72 min). The myr-deTagRFP local translation of myrdeTagRFP-Nl1 3’ UTR in the red box where HEK293 cell expressing NRX-GFP increases over
time.
(C) Local translation of myr-deTagRFP at artificial synapse. The same experiment like
60min after co-culturing. Scale bar is 2μm.
(D) Artificial synapse formation assay with deTagRFP blank vector. Artificial synapse
formation assay was performed with HEK293 cells transfected with NRX-GFP and hippocampal
neuron transfected with myr-deTagRFP blank vector. Representative photo shows limited
expression of deTagRFP at artificial synapse. Scale bar is 2μm.
(E) Local translation of myr-deTagRFP-Nl1 3’ UTR is translation dependent. Protein
synthesis inhibitor anisomycin inhibited local translation at artificial synapse. Neurons were
treated with 50μM anisomycin 1h before artificial synapse assay before artificial synapse.
(F) Comparison of local translation at artificial synapse in regular luciferase and
anisomycin treated one. Results shows relative deTagRFP expression normalized to LifeActCerulean at artificial synapse region (±SEM). 55 artificial synapse regions were measured. ****p
< 0.0001 (Student’s t test).
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CHAPTER

5

ABNORMAL NEUROLIGIN1 MRNA ALTERNATIVE SPLICING IN FMR1 KO MICE
HIPPOCAMPUS
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5.1

Introduction
Neuroligins (NL) are a family of neural adhesion molecules (Sudhof, 2008). Located at

the post-synaptic membrane, they bind to a pre-synaptic counterpart, Neurexins (NRX)
(Ichtchenko et al., 1995). There are four neuroligin isoforms in rodents (Nl1-Nl4) and five
isoforms in humans (NL1-NL5) (Baudouin & Scheiffele, 2010). It is suggested that alternative
splicing of neuroligins produces variants that bind differentially to variants of neurexins
(Ichtchenko et al., 1995) (Boucard et al., 2005). To clarify, the isoforms here represent different
genes transcribed from different promoter, the variants represents alternative splicing products of
the same pre-mRNA.
Four neuroligin alternative splice variants derived from two splice sites (A and B) have
been reported: +A+B, +A∆B, ∆A+B, and ∆A∆B (Ichtchenko et al., 1995). The major splice
variant is ∆A+B, which contains only splice site B. Splice site B of NL1 is a key switch for NL1
variants binding to NRX variants (Boucard et al., 2005). Neuroligin 1 with or without splice site
B has different binding ability to different Neurexin variants. The regulation of RNA alternative
splicing may affect the balance between different variants, which may further affect synapse
formation and functions.
There are two variations of splice site A of Nl1, A1 and A2 (Bolliger et al., 2008). Most
reports have used A2 to represent splice site A and ignored splice site A1. Both A1 and A2 are
60 nucleotides in length and are named in the order of their orientation in the pre-mRNA, with
A1 closer to the 5’ end. The A1 variant translates to VKRISKECARKPGKKICRKG and the A2
variant translates to GPLTKKHTDDLGDNDGAEDE (Bolliger et al., 2008).
The short peptide of splice site A1 and A2 have different charges under physiological
condition. Peptide of A1 is basic, while peptide of A2 is acidic (Figure 1-8). Since recognition
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and binding between NL and NRX is charge dependent (Koehnke et al., 2010), spice site A1 and
A2 may play different roles in synapse formation, maintenance, and signal transduction.
Although spice site B functions in NRX-NL binding, the function of spice site A has not been
elucidated.
We wanted to know if there is a difference in NL variants in wild type versus Fmr1 KO
synaptosomes. Difference of NL1 abundance in WT and KO synaptosomes were assayed with
Western blot (Figure 5-1). Synaptosomes were prepared from the hippocampus of wild type
(P14) and Fmr1 KO mice. In the wild type sample, we observed one band migrating at
approximately 117 kDa. However, the Fmr1 KO sample produced two bands (unpublished data
by Valerie Drouet). Previous reports from Drosophila research describe an interaction between
dFMRP and the RNA editing protein, dADAR (Bhogal et al., 2011). This was the first report of
FMRP function in the nucleus and first report of FMRP function on RNA processing. Although
RNA editing and RNA alternative splicing are different (see Chapter 1), the difference of NL1
western blot between WT and Fmr1 KO gives a possibility that FMRP may play a role in Nl1
RNA processing. Since Nl1 is under regulation of alternative splicing, the second band in our
western blot could be a shorter variant (~95 kDa) (Figure 5-1).
To test the hypothesis that abnormal alternative splicing of Nl1 produces the unknown
band observed in western blot, Nl1 alternative splicing variants were examined at the RNA level
in the hippocampus of wild type and Fmr1 KO mice.

5.2

Abnormal alternative splicing in Fmr1 KO mice
We designed primers (named F and R) to amplify variants of Nl1 alternative splicing

(Figure 5-2, A). The expected products and length of expected products were shown based on the
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schematic of Nl1 gene. Nl1 variants were amplified from cDNA of wild type (P14) mouse
hippocampus by RT-PCR with F and R primers. Three bands were found between 396-510 bp
(DNA ladder not shown) as expected (Figure 5-2, B). The three bands were cut and cloned to
TOPO TA vector for sequencing. Sequencing of the smallest band was confirmed to be the major
Nl1 variant, ∆A+B. The largest band was confirmed to be a combination of +A1+B and +A2+B
variants. All the attempts to sequence the middle band failed. But our calculations show that the
size of the middle band fits the expectation of the +AΔB variant (472bp).
The same F and R primers were used for the Nl1 variants pattern with cDNA derived
from the hippocampus of WT and Fmr1 KO mice at P7, P14 and P21 (postnatal 7, 14, 21)
(Figure 5-2, C). Only at P14, but not P7 or P21, we observed a significantly increased amount of
the larger band (representing the +A+B variant) in the Fmr1 KO, and a decrease in the smaller
band (∆A+B) in the Fmr1 KO compared to wild type (Figure 5-2, C and D). This result suggests
that the abnormal ratio of Nl1 variants changes during development and P14 is a crucial stage.
The expression of the middle band +A∆B (including +A1∆B and +A2∆B) are similar in wild
type and Fmr1 KO mice (Figure 5-2, E).
It is obvious that the absence of FMRP is the possible cause of the Nl1 variant difference
in P14 mouse hippocampus between WT and Fmr1 KO mouse. To prove the connection of
FMRP to this phenomenon FMRP in wild type neurons was knocked down to mimic the Fmr1
KO neurons. Fmr1 siRNAs was transfected to wild type hippocampal neurons on DIV 6-7.
Approximately 85 % of FMRP was knocked down at 48 h post-transfection (Figure 5-2, F and
G). Only two bands instead of three were amplified in PCR of neuron culture samples (Figure
5-2 H). This pattern differs from the three bands in amplifications performed using hippocampus
and may be the result of different environments of neurons in vivo and in vivo. The smallest band
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was confirmed by sequencing to be the ∆A+B variant. However, the abundance of the largest
band was too low to sequence. Nevertheless, we were able to see a change in the pattern of Nl1
variants, presented as a top band/bottom band ratio (Figure 5-2, H and I). In Fmr1 KO
hippocampus on P14, the top band/bottom band ratio is higher, which means the major variant is
+A+B (Figure 5-2, C and D). In the FMRP RNAi experiment, the top band/bottom band ratio is
increased in wild type hippocampal neurons (Figure 5-2, H and I). These results show that
knockdown of FMRP using siRNAs mimics the variant pattern of N11 in the Fmr1 KO
hippocampus.
Next, we asked if the presence of FMRP could rescue the PCR pattern of Nl1 variants
observed in Fmr1 KO neurons. We transfected hippocampal neurons of Fmr1 KO mice (P0)
with a Flag-tagged FMRP vector. F/R primers were used to access the Nl1 variant pattern. The
top band/bottom band ratio is decreased with Flag-FMRP transfection (Figure 5-2, J and K).
Thus, the introduction of FMRP into the Fmr1 KO neurons resulted in PCR pattern that
mimicked the Nl1 variant expression pattern observed in wild-type hippocampus at P14. The
FMRP expression in Fmr1 KO neuron rescued the Fmr1 KO neuron to make the Nl1 variant
patter more normal.

5.3

PCR of Nl1 +A+B variants
As shown in previous results, we observed more +A+B expression (top band) in the

Fmr1 KO hippocampus than in wild type at P14. Since +A+B is comprised of both +A1+B and
+A2+B, we designed primers (A1, A2 and B) to examine which one of these variations
contributes more to the elevated level of variant +A+B (Figure 5-2, C). Results show that the
level of +A1+B in P14 Fmr1 KO hippocampus increased while the level of +A2+B decreased
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(Figure 5-3, B and C). So the increased +A+B expression in the Fmr1 KO hippocampus at P14 is
due to increased amounts of the +A1+B variant.
The +A1+B and +A2+B variant pattern the FMRP RNAi experiment and Fmr1 KO
neuron rescue experiment should be consistent with the hippocampus result. The Nl1 variant
PCR pattern showed the same trend as P14 hippocampus (Figure 5-3, D-G). The FMRP RNAi
modified the variant pattern more like FMRP KO, while the rescue by expression of FMRP did
the opposite.
Nl2 is a known FMRP target. There is only splice site A in Nl2 which result in two
variants, Nl2 containing splice site A (Nl2 (A)) and without splice site A (Nl2 (∆A)). Adding
together, it is called Nl2 (total). There is no significant Nl2 (A)/total Nl2 (total) ratio difference
between WT and Fmr1 KO at P7, P14 or P21 (Figure 5-4).

5.4

Discovery of new alternative splicing variant of Nl1 +SSA1+SSA2+SSB
The variant PCR experiments with primer A1 as forward primer and primer B as reverse

primer shows an unknown band in wild type P14 hippocampus if the bands are properly
separated on an agarose gel (Figure 5-5, A). The extra band was isolated for sequencing. It
turned out to be a new variant of Nl1 +A1+A2+B (Figure 5-5, B). This is a novel variant and we
report it here for the first time (Figure 5-5, C). This variant only showed up in hippocampus of
WT mice but not in Fmr1 KO at P14 (Figure 5-5, A). It is also slightly visible in the Figure 5-3
D, top panel.

5.5

Neuron rescue by Nl1 variant expression
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If the absence of FMRP can result in the “abnormal” splicing pattern of Nl1, and
abnormal synapse size and number, maybe there is connection between the two defects. Since
Nl1 is synaptic adhesion molecules, it is possible that abnormal Nl1 variant pattern contributes to
the abnormal synapse size and number more or less. Synapsin is a pre-synaptic marker for the
synapse. Wild type and Fmr1 KO hippocampal neurons were stained with anti-synapsin antibody
to label the synapse (Figure 5-6, A). We observed smaller synapse sizes and numbers in Fmr1
KO neurons compared to wild type (Figure 5-6, B and C).
Previous results show that there is less ∆A+B in Fmr1 KO hippocampus compared to
wild type (Figure 5-2, C and D), and less +A2+B in Fmr1 KO compared to wild type (Figure 5-3,
B and C). So if the lower level ∆A+B and +A2+B in Fmr1 KO hippocampus is the cause of the
abnormal synapse size and number, expression of this these two Nl1 variants in Frm1 KO neuron
may be able to rescue the anomalies. Fmr1 KO hippocampal neurons were transfected with Nl1
variants ∆A+B or +A2+B to determine if synapse number and size could be rescued (Figure 5-6,
A). Both vectors increased synapse number in Fmr1 KO neurons, with +A2+B having a greater
effect than ∆A+B (Figure 5-6, B). However, only ∆A+B increased synapse size (Figure 5-6, C).
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) is composed

of four types of subunits, GluA1-4, also called Glutamate receptor 1-4 (GluR1-4) (Shi et al.,
1999). According to previous reports, the internalization of AMPAR is increased in FXS because
absence of FMRP relieves the translation of FMRP targets. FMRP targets include proteins
responsible for AMPAR receptor internalization (Sidorov et al., 2013). Previous research
reported misregulated expression of GluA2 in Fmr1 KO neuron in response to stimulation but
not at basal state (Muddashetty, Kelic, Gross, Xu, & Bassell, 2007).
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To further look into the roles these two Nl1 variants ∆A+B or +A2+B playing in neurons,
we looked into if the expression of these two variants could rescue the surface AMPARs, since
only the surface AMPARs are the “functional” receptors. We stained surface GluA2 and internal
GluA2 to compare wild type and Fmr1 KO hippocampal neurons (Figure 5-7, A). Our results
show less surface GluA2 on Fmr1 KO neurons and neither the expression ∆A+B nor +A2+B
rescues the amount of surface GluA2 (Figure 5-7, B). In the Nl1 +A2+B variant transfection
there is even less surface GluA2 (Figure 5-7, B). Internal GluA2 amounts do not appear to be
affected in Fmr1 KO neurons, and Nl1 variant transfection does not change internal GluA2
amounts (Figure 5-7, B). Therefore, it may not be the decreased amounts of ∆A+B or +A2+B in
Fmr1 KO neurons that account for decreased AMPAR on the neuron surface.

5.6

β-NRX-FC staining of WT and Fmr1 KO hippocampal neurons.
Neuroligins are the major target of β-NRX in dendrites. Since previous results show the

Nl1 variant patterns are different in WT and Fmr1 KO hippocampal neurons, the neurexin
binding to the post-synaptic terminal should be affected. Therefore β-NRX binding on the
surface of wild type and Fmr1 KO neurons was accessed. A β-Nrx-FC protein was made to stain
WT and Fmr1 KO neurons. β-Nrx binds to Nls on the post-synaptic terminal on dendrites. The
peptide called fragment crystallizable region of antibody (FC) can recognize and bound protein
A. Fluorescence labeled protein A can be used to stain neurons bound by β-Nrx-FC (Figure 5-8,
A). β-Nrx-FC vector was constructed and transfected to HEK293 cells. A signal peptide at the Nterminus β-Nrx-FC allowed the protein to be secreted into the medium. The medium containing
secreted β-NRX-FC was collected with protein A magnetic beads and then eluted from the beads
for neuronal surface staining. After WT and Fmr1 KO hippocampal neurons were incubated with
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β-NRX-FC, fluorescent Protein A was used to label β-NRX-FC on the neuron. Wild type and
Fmr1 KO neurons were examined for the fluorescent hotspot size and numbers. Results showed
protein A-stained hotspots in WT and Fmr1 KO neurons (Figure 5-8, B). There is less hotspots
in Fmr1 KO neurons (Figure 5-8, C), and these hotspots are also smaller in Fmr1 KO neurons
(Figure 5-8, D). Therefore, the absence of FMRP affects NRX binding the targeting proteins on
the post-synaptic terminal, including Neuroligins.

5.7

Conclusion
For the first time, FMRP was found to be involved in RNA splicing, although there needs

further research to know the mechanism, like whether the involvement is direct or indirect. An
abnormal Nl1 alternative splicing pattern was found in hippocampus of P14 Fmr1 KO mice.
Since it is only found in hippocampus on P14 but not P7 or P21, so this abnormal alternative
splicing pattern of Nl1 is development dependent. In the Nl1 splicing PCR, the Fmr1 KO shows
an elevated level of +A+B variant (+A1+B and +A2+B) and a decreased level of ∆A+B variant.
To further validate that this abnormal pattern is caused by the absence of FMRP, FMRP in WT
hippocampal neuron was knocked down by RNAi to mimic the Fmr1 KO neuron, and Fmr1 KO
neuron was rescued by expressing FMRP in Fmr1 KO neuron to mimic WT neuron. Although
the Nl1 variant PCR pattern were different in neuron culture and hippocampus, and the
knockdown and rescue experiment both showed the same trend in WT hippocampus and Fmr1
KO hippocampus. FMRP decreased the largest band (+A+B, including both +A1+B and +A2+B)
in hippocampus and top band (unknown, too tiny to separate for sequencing) in neuron culture
(RNAi knockdown and FMRP over expression); FMRP increased the smallest band ΔA+B in
both hippocampus and neuron culture (RNAi knockdown and FMRP over expression). On the
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contrary, the known FMRP target Nl2 splicing was not affected in Fmr1 KO mice hippocampus
(Figure 5-4).
To further investigate which +A+B (+A1+B or +A2+B) contributed to the +A+B
increase in Fmr1 KO hippocampus, variant specific primers were used to amplify +A1+B and
+A2+B variants of Nl1 (Figure 5-3). The +A1+B variant increased in Fmr1 KO mice
hippocampus, while the +A2+B variant decreased. RNAi knockdown of FMRP increased
+A1+B and decreases the amount of +A2+B (Figure 5-3, D and E). So the knockdown of FMRP
made the neuron more like “Fmr1 KO”. In the Fmr1 KO neurons transfected with FMRP, the
+A1+B variant was decreased, while the +A2+B was increased. Overexpression of FMRP turned
the variant PCR pattern to more “wild-type” (Figure 5-3, F and G). All these evidence showed
that FMRP affected alternative splicing of Nl1, changed the balance of different variants of Nl1.
A new alternative splicing variant was found when A1/B primers were used for +A1+B
variant. Extra cycles in PCR and proper agarose gel running are needed to separate the new band
from +A1+B. The new band is much dimmer but bigger than the +A1+B band. Sequencing of
the new band shows it is +A1+A2+B. This variant was not reported before probably because of
its low abundance and such tiny difference in length from the other variants. Abundance and
importance may not be positively related. Although the abundance of this variant is low, it may
be crucial to normal physiology since this variant was not found in KO hippocampus at P14.
Sample from hippocampus of younger or older mice was not tested to detect this new variant.
This variant is slightly visible in PCR of +A1+B of WT neuron culture (Figure 5-3, D). All
possible alternative splicing variants are presented in Figure 5-9.
The size and number of Synapsin hot spot in Fmr1 KO hippocampal neurons are fewer
and smaller compared to WT. Since the amount of +A2+B and ∆A+B Nl1 variants in Fmr1 KO
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hippocampus were decreased, it is possible the lack of these two Nl1 variants (+A2+B and ∆A+B)
caused the anomalies in Fmr1 KO neurons, at least partially. Both Nl1 (+A2+B) and Nl1 (∆A+B)
were used to transfect Fmr1 KO hippocampal neurons to compare to WT. The pre-synaptic
marker Synapsin staining shows less synapses and smaller synapse in Fmr1 KO neurons. Both
+A2+B and ∆A+B can increase Synapsin stained hot spots. NL1 +A2+B have stronger effect
than NL1 ∆A+B in increasing synapse number. Only +A2+B can rescue synapse size.
There is less surface GluA2 in Frm1 KO neurons compared to WT, while there is no
significant difference in internal GluA2. The surface GluA2 amount and surface/internal GluA2
ratio could not be rescued by expression of NL +A2+B and ∆A+B two variants.
The β-NRX-FC staining of wild type and Fmr1 KO mice shows smaller and fewer
hotspot size and numbers in Fmr1 KO hippocampal neurons. This means the NRX binding
proteins on the post-synaptic terminal is reduced in size and number, possibly NLs.
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NL1

117 kD
~95 kD

DM1α

57 kD

Figure 5-1
NL1 expression in synaptosomes of hippocampus
Western blot using NL1 and DM1α antibodies were used to probe target proteins (P14 WT and
Fmr1 KO mice). On band is observed in the wild type samples while two bands are observed in
the Fmr1 KO samples (unpublished data, Valerie Drouet).
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(A) Schematic of Neuroligin1 and primers designed to amplify splice variants. Primers at
upstream and downstream of spice site A and B were designed to amplify all possible alternative
splicing variants of Nl1. Expected amplification products of Nl1 variant PCR and expected
length are presented.
(B) PCR products of Nl1 variants from wild type (P14) hippocampus. Sequencing confirms
the top band is +A+B (+A1+B and +A2+B) variant; middle band has the expected size of +AΔB
(including +A1ΔB and +A2ΔB); lower band is confirmed as ΔA+B. The ΔAΔB variant was not
detected.
(C) PCR of Nl1 variants from mouse hippocampus at different ages. RNA was extracted
from P7, P14 and P21 mouse hippocampus from wild type and Fmr1 KO mice for cDNA
synthesis. Semi-quantitative PCR was performed to assess the relative expression of each variant
normalized to β-actin.
(D) Quantitation of top band/bottom band ratio in (C). Results show mean ratio of top band
to bottom band. There is a significant difference between the top/bottom band ratios in
hippocampus at P1 (n=3, ±SEM, * p<0.05) (Student’s t test).
(E) Relative expression of middle band. Results show mean relative expression of middle band,
normalized to β-actin in (C) (n=3, ±SEM) (non-significant, p≥0.05) (Student’s t test).
(F) siRNA knock down of FMRP in hippocampal neurons. Wild type hippocampal neurons
were transfected Fmr1 siRNA to knock down FMRP. Western blot shows FMRP and β-actin
expression in FMRP knock down samples compared to negative control (wild type neurons
transfected with scrambled siRNA).
(G) Quantification of FMRP knockdown. Approximately 85% of FMRP was knocked down
using siRNAs.
(H) Nl1 PCR variants in wild type hippocampal neuron with FMRP knocked down. Two
bands are observed in variant PCRs of hippocampal neurons in culture when FMRP knocked
down by siRNAs. Β-actin was amplified as internal control.
(I) Quantification of PCR product in (H). Results show mean mRNA amount of top band and
bottom band, which are normalized to β-actin (n=3, ±SEM, ** p<0.01) (Student’s t test).
(J) Nl1 variant PCR of Fmr1 KO neuron transfected with Flag-FMRP vector. Cultured
hippocampal neurons (P0) culture were transfected with Flag-FMRP at DIV 6-7. Nl1 variant
PCR shows the top band/bottom band ratio is decreased by FMRP overexpression (n=3, ±SEM,
** p<0.01) (Student’s t test).
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Figure 5-3
Nl1 A1B A2B PCR
(A) Primer design for Nl1 +A+B variants. Primers were designed to detect +A1+B and +A2+B
variants of +A+B. The expected PCR product is 427 bp.
(B) Nl1 variant PCR of +A1+B and +A2+B using wild type and Fmr1 KO hippocampal
RNA at P14. Β-actin was amplified as an internal control.
(C) Quantitation of the relative expression. of variants +A1+B and +A2+B in (B). Results
shows mean relative RNA amount of variant +A1+B and variant +A2+B in wild type and Fmr1KO (P14) hippocampus, normalized to β-actin RNA (n=3, ±SEM, * p<0.05) (Student’s t test).
(D) Nl1 variant PCR of +A1+B and +A2+B in WT hippocampal neurons with FMRP
knocked down.
(E) Relative expression of variants +A1+B and +A2+B in (D). Results show mean relative
RNA amounts of variant +A1+B and variant +A2+B in wild type hippocampal neurons and wild
type l neurons with Fmr1 knocked down (n=3, ±SEM, * p<0.05) (Student’s t test).
(F) Nl1 PCR variants of +A1+B and +A2+B in Fmr1 KO hippocampal neurons and Fmr1
KO hippocampal neurons transfected with an FMRP expression vector.
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(G) Relative expression of variants +A1+B and +A2+B in (F). Results show mean relative
RNA amount of variant +A1+B and variant +A2+B in (F) normalized to β-actin ( n=3, ±SEM, *
p<0.05) (Student’s t test).
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Nl2 variants are not affected in Fmr1 KO mice
(A) Variant PCR primer design for Nl2 variants quantification. Nl2 has only one alterative
splice site A, which could be present or absent in the mature mRNA. Primers were designed in
the SS A and downstream for variant detection. Primers of Nl2 amplifying the total Nl2 are
presented.
(B) Variant PCR of Nl2 variant Nl2 (A) and total Nl2. Primers in (A) were used to detect
variant Nl2 (A) that contains SS A. Another pair of primers out of splice site was used to detect
total mRNA amount of Nl2.
(C) Relative expression of Nl2 in (B). Results shows mean of the relative amount of Nl2+A
variant in Nl2 (total) (n=3, ±SEM) (non-significant, p≥0.05) (Student’s t test). There is no
significant difference in Nl2 mRNA variants between WT and Fmr1 KO on P7, P14 and P21.
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New variant: A1A2B
(A) Discovery of new alternative splicing variant in Nl1. Nl1 Variant PCR with A1 forward
primer and B reverse primer shows a different pattern compared to P14 WT and Fmr1 KO
hippocampus. There was only one band in KO hippocampus (+A1+B) but there is one unknown
band in WT hippocampus (around 50 bp longer).
(B) Sequencing results of top band in (A). Sequencing result of the unknown band
(Washbourne et al.) in (A) shows a transcript with both A1 and A2 next to each other).
(C) New Nl1 variant +A1+A2+B schematic. The arrangement of SS A1, SS A2 and SS B are
presented as an explanation of the unknown band in (A).
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Figure 5-6
Nl1 variants expression affect synapse number and size differently
(A) Fmr1 KO neuron synapse rescue experiment (IF). Different neuroligin variants were
transfected to Fmr1 KO hippocampal neurons to rescue Synapsin I staining puncta number. IF
staining was performed to hippocampal neuron of WT, Fmr1 KO, and Fmr1 KO transfected with
empty vector (pcDNA3), or with Nl1∆A+B variant vector, or with +A2+B variant vector. Presynaptic marker Synapsin I antibody was used to probe synapses, and dendritic marker MAP2
antibody was used to label dendrites.
(B) Quantification of synapse number in (A). Both ∆A+B and +A2+B can rescue the synapse
number, but to different level. Results shows mean of average synapse number of more than 25
neurons, 2-4 dendrites per neuron (±SEM). Both Nl1 ∆A+B and +A2+B variants can save the
synapse number in Fmr1 KO hippocampal neuron. ns (non-significant) p≥0.05, *p < 0.05, **p <
0.01, ****p < 0.0001, (Student’s t test).
(C) Quantification of synapse size in (A). Results shows mean of average synapse size of more
than 25 neurons, 2-4 dendrites per neuron (±SEM). Only +A2+B variant can save the synapse
size. ns (non-significant) p≥0.05, **p < 0.01, ***p < 0.001, (Student’s t test).
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Figure 5-7
Nl1 variants affect surface GluA2 amount
(A) Surface GluA2 staining of Fmr1 KO neuron is rescue by Nl1 variants (IF). IF of
surface/internal GluA2 in WT and Fmr1 KO hippocampal neurons shows amount of GluA2 on
the surface on the dendrites and in the dendrites. There are KO neurons transfected with Nl1
variant ∆A+B or Nl1 variant +A2+B. Dendritic marker MAP2 was used to highlight dendrites.
(B) External GluA2 density in (A). Results show the mean intensity of GluA2 on the surface of
dendrites (±SEM). Surface GluA2 in KO hippocampal neurons is a significantly lower than in
WT. ∆A+B variant expression does not change the external GluA2 amount, while +A2+B
variant expression even decrease the GluA2 amount. More than 13 neurons, 4-6 dendrites per
neuron were quantified. *p < 0.05, **p < 0.01 (Student’s t test).
(C) Internal GluA2 density in (A). There is no significant difference between KO and the
others (±SEM) (Student’s t test).
(D) Ratio of external GluA2 to internal GluA2 in (A). There is a significant decrease in
+A2+B variant transfected neuron (±SEM). **p < 0.0001 (Student’s t test).
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NRX-FC staining of WT and KO neuron
(A) β-NRX-FC /protein A staining design. β-NRX-FC construct was made to produce β-NRXFC from HEK293 cells. Overexpressed β-NRX-FC was purified for the protein A staining.
(C) Mean
NRX-FC
hotspot
number difference
WT KO
Nrx-FC
hotspots
number in WT and KO hippocampal neuron. More
than 20 neurons, 2-4 neuron processes were taken. (±SEM)**p < 0.01 (Student’s t test).
(D) Average NRX-FC hotspot area difference in WT and KO hippocampal neuron. More
than 20 neurons, 2-4 neuron processes were taken. (±SEM)**p < 0.01 (Student’s t test).
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Figure 5-9
All possible variants of Neuroligin1
All possible variants of Nl1 alternative splicing. Possible variant +A1+A2+B, +A1+A2 and
+A1∆B have not been reported yet. +A1+A2+B were discovered for the first time in this thesis.
+A2+B, +A2∆B, ∆A+B and ∆A∆B were the variants reported frequently. ∆A+B is the
predominant variant.
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Fragile X Syndrome (FXS) is the most widespread single-gene cause of autism and most
frequent genetic cause of mental retardation, caused by the loss of functional fragile X mental
retardation protein 1 (FMRP). FMRP is widely expressed in virtually all cells types, with an
especially high level in neuronal cells in the brain and in the testis (Sethna, Moon, & Wang,
2014). This means FMRP has general functions in all cell types, and plays special roles in
neurons. As a RNA binding protein, FMRP potentially regulates many target genes in many
ways and plays a critical role in the neuron. Increasing amount of evidence show that FMRP is
like a “Swiss army knife” in neurons, which plays multiple roles in gene expression, translational
regulation and signal transduction. The research on FMRP in the past two decades has led to
significant advances in understanding the molecular events in FXS. Despite the growing data
achieved on the roles FMRP plays in physiology and in neuronal plasticity, details regarding
behaviors of FMRP remain to be elucidated.
The majority of FXS is caused by the increase of the CGG trinucleotide repeat in the 5’
untranslated regions (5' UTR) of fragile X mental retardation 1 (FMR1) gene. The abnormal
increased CGG repeats, especially the full mutation with more than 200 repeats, cause
hypermethylation of that region. Eventually the hypermethylation diminishes FMRP expression
at the transcription level (Fu et al., 1991) (Pieretti et al., 1991) (Bell et al., 1991). Other types of
FXS include mutation in key positions of FMRP. One patient has an I340N mutation in the K
Homology 2 (KH2) domain of FMRP which is one of the three RNA binding domains in FMRP
(De Boulle et al., 1993) (Y. Feng, Absher, et al., 1997). Another patient has a R138Q mutation in
the nuclear export signals (NES) of FMRP (Collins et al., 2010). These two mutations give hints
about the key roles FMRP may play. One is its RNA binding ability, which is well known and
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widely studied. The other is the functions of FMRP in the nucleus, which has been
underestimated in the past.
The majority of FMRP research has focused on its roles in the cytoplasm in the past,
probably because FMRP predominantly localizes in the cytoplasm. FMRP is widely recognized
as a RNA binding protein. RNA binding proteins are important to control functions of target
RNAs, like RNA transcription, RNA processing (including splicing and RNA editing), nuclear
export, mRNA stability and translational regulation, almost all aspects of RNA during its whole
life. FMRP is involved in the life of its target mRNAs in many ways, including its transport,
stability and especially translational regulation (Sethna et al., 2014). The absence of FMRP
causes many abnormal phenomena in neurons and the nervous system. From the morphological
point of view, FXS patients and Fmr1 KO mice both show abnormal dendritic spine shape and
spine numbers (Bagni & Greenough, 2005). From the physiological point of view, the absence of
FMRP causes exaggerated long-term depression (LTD), one type of long-term plasticity
important for learning and memory (Huber et al., 2002). From the molecular point of view, the
transports of some FMRP target mRNAs are altered and the protein translations of these targets
are abnormal. The mGluR theory of FXS explained the possible roles FMRP plays in synaptic
plasticity (Bear et al., 2004). Based on this theory, loss of FMRP relieves translation of “LTD”
proteins and results in the exaggerated LTD in the hippocampus of Fmr1 KO mice. One
interesting target is its own mRNA Fmr1 (C. T. Ashley, Jr. et al., 1993), so we chose it as one
research target in this thesis. Many FMRP targets are involved in autism, like Neuroligin (Nl)
and Neurexin (Nrx). Neuroligin1 is another target studied in thesis because of its involvement in
autism.
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This thesis is devoted to explore FMRP function in both the cytoplasm and the nucleus.
In the cytoplasm aspect, this thesis studied the 3’ UTR of Fmr1 and Nl1 because the 3’ UTR is
usually a critical target of mRNA regulation. At the mRNA level, we confirmed the binding of
target 3’ UTRs by FMRP. Then we studied the subcellular localization of target 3’ UTRs. At the
protein level, we studied the FMRP translational regulation on reporter genes with target 3’ UTR
and local translation of reporters with target 3’ UTRs. In the nucleus aspect, we discovered an
abnormal alternative splicing pattern related to FMRP and studied the changes of Nl1 variants
caused by the absence of FMRP.

FMRP and Fmr1 3’ UTR
In this study, we have presented evidence that FMRP binds the 3’ UTR of Fmr1, and
regulates translation of reporters with the Fmr1 3’ UTR. The Fmr1 3’ UTR transported to
dendrites of hippocampal neurons and a reporter with the Fmr1 3’ UTR was locally translated in
dendrites.
We confirmed the proposed binding of FMRP to Fmr1 3’ UTR. Fmr1 mRNA is the
target of its own protein FMRP. FMRP may target more than one region in its target mRNA,
either in the coding or untranslated region. A purine quartet motif in the Fmr1 coding region is
known to be bound by FMRP (Schaeffer et al., 2001). The N19 segment containing this region
was used as the positive control of FMRP target in this thesis. But whether Fmr1 3’ UTR is a
target of FMRP is arguable. It was reported as an FMRP target achieved by UV cross-linking
(Brown et al., 1998). Another report proposed that the major FMRP binding site (FBS) only
localizes in the RGG box in the 3’ of the Fmr1 coding region, not in its 3’ UTR (Schaeffer et al.,
2001). Our immunoprecipitation (IP) result shows that Fmr1 3’ UTR was pulled down by
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FLAG-FMRP from HEK239 cell lysate (Figure 3-1). This result is not achieved by using UV
cross-linking, so the interaction between FMRP and Fmr1 3’UTR may be either direct or indirect.
Further experiments in this thesis were designed to investigate Fmr1 3’UTR behaviors and
regulation on it by FMRP based on the knowledge of this interaction.
To study FMRP’s role in translational regulation, we studied the effects of FMRP on
reporter genes carrying the Fmr1 3’ UTR, as well as its effect on global translation in HEK293
cells. Previous publications showed that the phosphorylation status of FMRP may be a switch of
its translational regulation, with phosphorylated FMRP being associated with stalled ribosomes,
and dephosphorylated FMRP associated with active translation (Ceman, O'Donnell, et al., 2003).
The luciferase assay of Fmr1 3’ UTR in HEK293 cells with transfection of FMRP or FMRP
phosphorylated mimic mutant S499D or FMRP dephosphorylated mimic mutant S499A showed
phosphorylation status of FMRP can adjust translational regulation activity of FMRP. A strong
inhibition of reporter translation by FMRP (S499D) was expected, and the data showed that in
fact, FMRP (S499D) strongly inhibited reporter gene translation (Figure 3-5, D). Although
FMRP (S499A) which is the dephosphorylated mimic mutant, showed higher translation of the
reporter gene than FMRP (S499D), it showed decreased translation compared to WT FMRP, in
contrast to our initial expectations. We believe it is the lack of regulation ability of FMRP
(S499A) hindered the expression of reporter luciferase. In other words, functional FMRP with
regulation ability through phosphorylation/dephosphorylation is important to target gene
expression. That is why we believe the best description of FMRP is as a translation regulator
instead of an inhibitor, because it is not only repressing translation under all circumstances, but
also can upregulate translation sometimes. The optimal regulation would allow the proper gene
expressed at the right time in the right place responding to specific stimuli with the proper
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strength. We used a myristoylated-destabilized-TagRFP reporter to visualize local translation,
which can also provide another view of global translation by measuring RFP fluorescence. In
HEK293 cells, we observed a decrease in myr-deTagRFP expression with all 3’ UTRs we tested
(Fmr1, Nl1, CanK2) except β-Actin 3’ UTR (Figure 3-6, C and D).
We invented a neuron specific luciferase system for a neuron specific translation assay
and investigated the translational regulation of FMRP on Fmr1 3’ UTR in hippocampal neurons.
Since FMRP is widely expressed in almost all cell types, the influence of endogenous FMRP
from HEK293 cells can not be avoided in the HEK293 luciferase assay. The best platform to
differentiate the expression regulated through target 3’ UTR in the presence or absence of FMRP
are WT and Fmr1 KO mouse hippocampal neurons. To exclude the influence of glia cells in the
neuronal culture which can also express FMRP, a neuron specific dual Synapsin promoter vector
was invented. The dual Synapsin promoter luciferase vector enables luciferase assay in neuron
cells specifically without interference from the highly abundant glial cells routinely exist in the
neuron cultures. At the basal level, the reporter with Fmr1 3’ UTR has a higher expression level
in Fmr1 KO neurons compared to WT (Figure 3-5, E). The lack of FMRP regulation relieves the
translational suppression of its target gene in Fmr1 KO neuron. With DHPG stimulation, reporter
gene Firefly luciferase expression is increased in WT hippocampal neuron but the Fmr1 KO
neuron does not respond to the stimulation. This suggests that the stimulation of Fmr1 3’ UTR
translation by DHPG is fulfilled through FMRP. This is the FMRP translational regulation
mentioned before, instead of just translation inhibitor.
We observed the dendritic localization of MS2-Fmr1 3’ UTR RNP granules, with the
help of the non-invasive mRNA labelling method, the MS2-MCP system. This result shows the
Fmr1 3’ UTR contains enough information to guide the transport of the whole reporter transcript
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to the proper destination, just like the zip-code sequence in the β-Actin 3’UTR. The Fmr1 3’
UTR was co-transported in neuronal processes with FMRP, which is consistent with the previous
pull down result showing that FMRP binds Fmr1 3’ UTR. One important role of 3’ UTR of
many genes is targeting mRNA to specific subcellular compartments. For decades, it was
believed that mRNAs are translated in the cell body near the nucleus, and then mature proteins
were transported to their destination and execute their function there. After the discovery of
translational machinery at the base of dendritic spines (Steward & Levy, 1982), evidence
accumulated shows the existence of local translation and the significant roles local translation
plays in cell, especially in neurons. The theory of synaptic tagging proposed that neural signals at
synapses cause subsequent plasticity-related product trafficking that is essential for synaptic
plasticity (Frey & Morris, 1998), and the transport of mRNAs to synapses fulfills the physical
requirement of local translation.
We observed local translation of reporters carrying the Fmr1 3’ UTR. FMRP mediated
local translation can be activated in dendrites in response to stimulation (Weiler et al., 1997). The
luciferase assay can only provide a result of the global translational regulation in the whole cell,
which is mostly contributed by the cell body. Thus, to focus on local translation in synpases that
may be regulated through target 3’ UTRs, we used fluorescence recovery after photobleaching
(FRAP) on neurons transfected with myristoylated-destabilized-TagRFP with Fmr1 3’ UTR.
Results showed new protein was locally synthesized in the dendrites after photo bleaching of
pre-existing TagRFP. Since FMRP plays an important role in local translation, local translation
of FMRP itself is critical because new FMRP translated locally could regulate its targets mRNA
translation on site immediately.
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FMRP and Neuroligin1 3’ UTR
In this study, we have presented the evidence that Nl1 3’ UTR was transported to
dendrites and post-synaptic terminals of hippocampal neurons, and that reporters with Nl1 3’
UTR are locally translated in dendrites and post-synaptic terminals; we also showed that FMRP
binds the Nl1 3’ UTR, and regulates translation of reporters with the Nl1 3’ UTR.
There are several reasons why we became interested in Nl1. NEUROLIGIN (NL) is a
family of post-synaptic terminal transmembrane proteins, which recognize and bind to their presynaptic counterpart NEUREXIN (NRX). One important function of NLs and NRXs is that they
recognize each other, bind to each other, and trigger synapse formation (Sudhof, 2008)
(Scheiffele et al., 2000). Since the mRNA of several Nl and Nrx have already been proved to be
FMRP targets, and several Nl and Nrx isoforms have been found to be involved in autism
(Jamain et al., 2003) (J. Feng et al., 2006) (Sudhof, 2008), it is possible that FMRP influences
Nls in some pathway to cause autism. So either abnormal Nls themselves or absence of FMRP
regulation on Nls could have pathogenic consequences. Over expression of eIF4E or relief of
eIF4E (by knocking out of the eukaryotic translation initiation factor 4E-binding protein 2, 4EBP2) can cause overexpression of Neuroligin, which breaks the excitation-to-inhibition balance
and also causes Autism Spectrum Disorders (ASD) like phenotypes (Gkogkas et al., 2012).
FMRP has been shown to repress translation through facilitating eIF4E binding (Napoli et al.,
2008). These findings suggest a link between FMRP and NL1 in ASD, which makes it important
to clarify the role of FMRP in regulating Nl1 expression, particularly its regulation on local
translation of Nl1 in the post-synaptic terminal.
We predicted and confirmed the binding of FMRP to the Nl1 3’ UTR. Nl1 was not found
as a target of FMRP in a high-throughput sequencing combined with crosslinking
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immunoprecipitation (HITS-CLIP) experiment, in which Nl2, Nl3 and all three Nrxs were found
to be FMRP targets (Darnell et al., 2011). However, it was found to be an FRMP target in
another report (Dahlhaus & El-Husseini, 2010). We found two G-rich region in Nl1 3’ UTR by
QGRS (Quadruplex forming G-Rich Sequences) prediction, which are potential FMRP binding
regions. In fact, in our studies, Nl1 3’UTR was pulled down in the same immunoprecipitation (IP)
experiment as Fmr1 3’ UTR in HEK293 cells by FLAG-FMRP. This result narrowed down the
FMRP target region in Nl1 to its 3’ UTR, although we do not know whether this binding is direct
or indirect.
We studied the localization of Nl1 3’ UTR in hippocampal neurons, and found that it
localized to dendrites and synapses. Using the MS2-MCP system, we observed dendritic
localization of the Nl1 3’ UTR (Figure 4-2) and its co-transport with FMRP (Figure 4-3). As we
expected, the phosphorylation mutants of FMRP (S499A, S499D) did not interfere with the
dendritic localization of Nl1 3’ UTR and the co-transport of FMRP with Nl1 3’ UTR. Since NL1
protein localized to post-synaptic terminals, we suspect that NL1 may be translated on site at
where it is needed. Local translation of a gene requires the localization of its mRNA transported
to its destination first. To narrow down the subcellular localization of Nl1 3’ UTR, cotransfection of neurons with the MS2-MCP system and post-synaptic marker post synaptic
density protein 95 (PSD95-GFP) showed that some Nl1 3’ UTR granules in fact co-localize with
PSD95 in post-synaptic terminals (Figure 4-4), showing that the 3’ UTR of Nl1 is sufficient to
localize a reporter mRNA to functional post-synaptic terminals. Artificial synapse formation
assay also showed Nl1 3’ UTR accumulation at the post-synaptic terminal of artificial synapses
(Figure 4-6).
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In FRAP experiments using the myr-deTagRFP local translation reporter, we found that
the Nl1 3’ UTR was sufficient to enable local translation of the reporter in post-synaptic
terminals (Figure 4-10). As expected, the translation inhibitor CHX inhibited the recovery in
fluorescence following photobleaching, indicating that the observed increase in fluorescence
under normal conditions (no CHX) was in fact due to local translation. We found that local
translation of myr-deTagRFP-Nl1 3’ UTR can also be triggered in the post-synaptic terminal of
artificial synapses (Figure 4-12). However, we performed the same artificial synapse formation
assay with myr-deTagRFP-Fmr1 3’ UTR, but no local translation was observed (unpublished
data). This means that the Fmr1 3’ UTR and Nl1 3’ UTR are differentially regulated in terms of
local translation. We proposed that at the synapse, NLs are needed between pre-synaptic and
post-synaptic terminals, especially at new synapses. So the mRNAs for these synaptic proteins
are likely transported to the appropriate destination. Then they simply wait for signals that will
promote local translation, such as a new synapse forming. Although FMRP was reported to be
locally translated in dendrites in response to stimulation of Gp1 mGluR, apparently this type of
stimulation is different from the signals of new synapse formation. The new synapse needs
protein synthesis of many genes especially structural proteins, and it may not need FMRP, which
may inhibit translation of many genes at the new synapse, explaining our observed results.
We also investigated the role of the Nl1 3’ UTR on general translational regulation and in
FMRP-specific regulation. To study the effects of this 3’ UTR on general translational regulation
of reporter mRNAs, we used the myr-deTagRFP translation reporter in HEK293 cells (Figure
3-6). The results show that the Nl1 3’UTR repressed translation of the reporter, compared to the
blank reporter. To exclude the effects of endogenous FMRP in HEK293 and glia cells, the
effects of the Nl1 3’ UTR on translational regulation was studied with our neuron specific dual
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luciferase system in WT and Fmr1 KO hippocampal neurons (Figure 4-7). The experiment
shows that reporter expression is similar between WT and Fmr1 KO mouse hippocampal
neurons at the basal state. Interestingly, translation was increased in WT neurons after DHPG
stimulation but not in Fmr1 KO neurons, suggesting that Nl1 3’ UTR may be downstream of
Gp1 mGluR signaling regulated by FMRP. The translational regulation pattern of Nl1 3’ UTR
and Fmr1 3’ UTR are different. In the basal state, the Fmr1 3’ UTR showed a higher level of
translation in Fmr1 KO neurons, while the basal level of expression of the reporter with Nl1 3’
UTR is similar in WT and Fmr1 KO neurons (Figure 3-5) (Figure 4-7) . This difference could
represent the different nature of FMRP and NEUROLIGIN proteins. For FMRP, it may require a
relatively constant basal level of expression to regulate local translation at post-synaptic
terminals. New synapse formation is unlikely to trigger local translation of FMRP, because
elevated expression of many genes including FMRP targets are required as building blocks for
new synapse. Expression of FMRP may enhance repression of these genes. For NL1, more NL1
is needed for synapse formation, maturation and enhancement after recognition between presynaptic and post-synaptic terminals, so more NL1 will be translated, probably locally at the base
of spines. So the basal level expression regulated through Nl1 3’ UTR between WT and Fmr1
KO neurons are similar, since there is no stimulation like new synapse formation. In other words,
FMRP is constantly needed to maintain homeostasis while NL1 is more needed during
synaptogenesis. The difference of transitional regulation through Fmr1 3’ UTR and Nl1 3’ UTR
reflect the difference in the role of their proteins. Synaptic genes like Nl1 may be regulated as the
model in Figure 6-1.
Taken together, our results of FMRP and its targets provide a new role of Nl1 3' UTR and
Fmr1 3' UTR in mRNA transport and translation regulation. We showed that FMRP interacts
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with the Nl1 and Fmr1 3’ UTRs by immunoprecipitation from cell lysates. We also showed that
the Nl1 3' UTR and Fmr1 3' UTR contain enough localization information to guide the mRNAs
to dendrites, and specifically to post-synaptic terminals in the case of Nl1. Further, FMRP was
co-transported with both Nl1 3' UTR and Fmr1 3' UTR in mRNP granules to dendrite, but the
phosphorylation status of FMRP had no effect on this co-transport. After the mRNAs arrive to
their destination in dendrites, local translation could happen there under regulation. The hotspot
of deTagRFP has shown local translation in the dendrites, especially in the post-synaptic
terminal.

The role of FMRP in splicing:
In this study, we discovered an abnormal alternative splicing pattern of Nl1 mRNA in
Fmr1 KO hippocampus and studied the Nl1 variant changes in the absence of FMRP. This
research was triggered by an extra band found in western blots for NL1 from synaptosomes
prepared from hippocampus at P14 compared to WT (Figure 5-1). With the knowledge that there
are several Nl1 alternative splicing variants, the extra band in western blot was thought to be a
product of alternative splicing in Fmr1 KO mouse hippocampus.
We found an abnormal Nl1 splicing pattern hippocampus in Fmr1 KO. Nl1 variant
specific RT-PCR was performed on the mRNA from P7, P14 and P21 hippocampi of WT and
Fmr1 KO mice (Figure 5-2, C). Based on previous reports and all possible combination, there
should be 6 Nl1 variants with 4 different lengths: +A1+B and +A2+B (the longest variants with
the same length), +A1ΔB and +A2ΔB (the second longest variants with the same length), ΔA+B
(the third longest variant, the most abundant variant) and ΔAΔB (the shortest variant). The
ΔAΔB variant reported as one of 4 Nl1 variants is either too low in abundance to be detected in

144

the PCR or too small to be separated from variant ΔA+B, since the difference between ΔA+B
and

ΔAΔB

is

the

27nt

splice

site

B.

Although

splice

site

A1

(SS

A1,

VKRISKECARKPGKKICRKG) and splice site A2 (SS A2, GPLTKKHTDDLGDNDGAEDE)
have been reported in Nl1 as well as Nl3 (Koehnke et al., 2010) (Bollinger, 2008 #561), most
reports of Nl1 just used SS A in the description of Nl1 (using SS A2 sequence). Only very few
reports used SS A1 as SS A (Comoletti et al., 2003), or presented both SS A1 and SS A2. SS A2
was used as SS A most of the time probably because the abundance of +A2+B is more than
+A1+B in our neuron culture, although the abundance are similar in hippocampus at P14 (Figure
5-2, Figure 5-3). The variant pattern difference of Nl1 mRNA in hippocampus was only observed
on the P14, so this phenomenon is development dependent. Although the Nl1 variant pattern
returns to normal in Fmr1 KO hippocampus at P21, we believe that the aberrant variant
expression may have irreparable consequences on hippocampal development. The variant pattern
change in the Fmr1 KO hippocampus was increase of the longest variants +A+B (containing
both +A1+B and +A2+B) and decrease of the third longest variant (ΔA+B). In contrast, the
variant expression pattern of the FMRP target Nl2 was not affected, so this change is Nl1 specific.
To be more specific, in P14 Fmr1 KO hippocampus, the mRNA abundance of +A1+B variant
increased, while the mRNA abundance of +A2+B and ΔA+B decreased. The ΔA+B is the major
variant of Nl1 mRNA based on previous publications, and we found this to be the case in WT
hippocampus in our experiment but not in Fmr1 KO hippocampus at P14.
The difference in variant mRNA pattern can not perfectly explain the extra band in the
western blot of Fmr1 KO hippocampus based on the mRNA difference. Although more mRNA
of one gene does not necessarily mean more protein will be translated, we still assume the ΔA+B
NL1 is the major form NL1 protein in this case (Figure 5-1). The extra band (95kD) found in
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western blot of Fmr1 KO hippocampus synaptosomes is smaller in molecular weight than the
major band (117kD). If this smaller band in western blot is a translation product of a shorter
mRNA variant because of decreased number of amino acids, the size differences in mRNA
should be much more than splice site A (SS A) (60 bp). But the increased variant in Fmr1 KO is
+A1+B, decreased variant is ΔA+B, The difference is 60 bp SS A1. The difference between
ΔA+B and ΔAΔB is the 9AA splice site B, which is less than 1kD. The difference between the
major band (117 kD) and the unexpected extra band (95 kD) in western blot of Fmr1 KO
hippocampus is 22 kD. So the different in AA can not explain the difference. Although the extra
band in Fmr1 KO hippocampus is the reason we started this research and we did find anomalies
in alternative splicing at the mRNA level, we still have no evidence to show this extra band is
caused directly by abnormal alternative splicing.
Another possible explanation of the extra band in western blot is protein modification. It
has been shown that NL1 has two bands in western blot due to glycosylation and the ratio of
these two bands changes during development (Comoletti et al., 2003). It is possible that the extra
band we saw in Fmr1 KO is not glycosylated while the major band with bigger molecule weight
is glycosylated. We predicted an N-glycosylation consensus sequences in SS B, which may
explain the extra band in western blot. The hypothesis is that Fmr1 KO hippocampus on P14
contains certain amount of ΔAΔB variant while WT does not. Thus, Nl1 variant ΔAΔB without
SS B does not contain this N-glycosylation consensus sequences, and they migrate with a lower
molecular weight than variants which contain SS B. This is just one hypothesis we got from the
western blot and variant specific PCR of Nl1. There are still questions that can not be answered
by this hypothesis, such as the fact that we observed +AΔB (including +A1ΔB and +A2ΔB)
variants by PCR which do not contain the SS B. If our hypnosis is correct, this variant without
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SS B should not contain the N-glycosylation in SS B and appears as a band lower than the major
band in the western blot of synaptogenesis of hippocampus. But we did not see this band in the
western blot of WT (Figure 5-1). So there is still a lot work to do to relate the variant pattern
difference in mRNA and the protein difference in western blot between WT and Fmr1 KO
hippocampus, especially at P14.
We found that Nl1 variants have different functional roles during synaptogenesis, and
that expression of specific Nl1 variants can rescue some defects of Fmr1 KO hippocampal
neurons. Previous reports found more excitatory synapses in WT than KO, and opposite for
inhibitory synapses in the hippocampus (Dahlhaus & El-Husseini, 2010). Over expression of
FMRP in Fmr1 KO hippocampal neurons decrease synapsin puncta (Pfeiffer & Huber, 2007). In
our results, Fmr1 KO hippocampal neuron shows less synapsin puncta (Figure 5-6). Since
variants +A2+B and ΔA+B were decreased in Fmr1 KO hippocampus, expressing them may
correct some anomalies in Fmr1 KO. Some properties of Fmr1 KO neurons were rescued by
expression of some of these variants (Figure 5-6). Another difference is the abundance of Nl1
variant +A1+B, which was increased in Fmr1 KO hippocampus. The splice site SS B is a key
switch for recognizing and binding NRX (Baudouin & Scheiffele, 2010). It is already known the
interaction between NL and NRX is charge dependent (Koehnke et al., 2010), suggesting that
these two NL1 variants may have different physiological roles during neuronal development (SS
A1 is positive, SS A2 is negative) (Figure 1-8). More experiments need to be done to show what
difference these two splice sites (SS A1 and SS A2) have in physiology.
We also discovered a new splicing variant of Nl1: +A1+A2+B in WT hippocampus at
P14. We did not check other age. This is the first time this variant was discovered. There was no
evidence of the existence or function of this variant probably because of its low abundance
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(Figure 5-5). More experiments need to be done to understand its function. It is interesting this
variant was not found in Fmr1 KO hippocampus at P14. Higher abundance does not necessarily
mean bigger significance. It is possible the absence of this variant is a cause of anomalies in
Fmr1 KO hippocampal neurons, at least partially. Further research are needed to investigate the
physiological significance of this variant.
Our results clearly relate the Nl1 variant pattern differences in hippocampus of WT and
Fmr1 KO mice to FMRP (Figure 5-2, Figure 5-3). We have 3 hypotheses to explain the
difference in Nl1 variants caused by FMRP: splicing regulation, mRNA stability control or
FMRP regulation on transcription factors.
Splicing regulation: The NLS and NES enable FMRP to localize in both the nucleus and
cytoplasm. Most research about FMRP in the past has focused on its roles in the cytoplasm and
its roles in RNA biding, RNA transport, translational regulation. Not much has been done on its
roles in the nucleus. Among these limited research of FMRP in the nucleus, FMRP has been
found to bind pre-mRNA in nucleus when it is transcribed (Kim et al., 2009). Drosophila fragile
X homolog (dFMR1) has been shown to get involved in RNA editing in the nucleus (Bhogal et
al., 2011). One recent report found FMRP gets involved in the DNA damage response (Alpatov
et al., 2014). Most heterogeneous nuclear riboncucleoproteins (hnRNPs) localize and function in
the nucleus. It is currently not known whether the binding of FMRP-hnRNP occurs in the
nucleus or cytoplasm. Considering FMRP partially localizes in the nucleus and its RNA binding
ability, it is possible that FMRP function in nucleus and may have a role in RNA processing. Our
finding suggests FMRP is involved in splicing of specific gene. Adding together, we think
FMRP plays a more important role in nucleus than we thought.
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Stability control of mRNA: FMRP has been shown to be involved in the regulation of
PSD-95 and Nxf1 mRNA stability in the hippocampus (Zalfa et al., 2007). The 4 variants of Nl1
share the same 3' UTR and most of the coding sequence. But the variants differ a lot in the 5'
UTR which is 1.3 kb in variants +A+B (+A1+B and +A2+B) and around 400 bp in the others,
based on the information of Nl1 in National Center for Biotechnology Information (NCBI).
Details of which variant has which 5’UTR is not known. The Nl1 5' UTR is a potential
regulation target for regulating stability of the mRNA. If FMRP target different Nl1 5’ UTR
hence regulate the stability of Nl1 variants differently, then the actual amount of one variant
would be changed depending on the absence or presence of FMRP, which explains our
observation.
FMRP regulation on transcription factors: FMRP also targets mRNAs of several
transcription factors (Darnell et al., 2011). It is not so clear what is the physiological meaning of
the translational regulation by FMRP on nuclear proteins, since the proteins translated from most
of its targets localize in cytoplasm. Apparently, the abundance of these proteins may affect RNA
processing activities.

Further directions:
The thesis focused on the research of FMRP and Neuroligin1. We have found that FMRP
has an important role in cytoplasmic mRNA transport and translation, and discovered a role for
FMRP in the nucleus as well. Although we have a lot of discoveries on their functions and
behaviors, there are still a lot need to do in the future to understand the roles they play in FXS
and cognition.
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We have found that FMRP has an important role in cytoplasmic mRNA transport and
translation, and discovered a role for FMRP in the nucleus as well. It is unclear whether FMRP
interactions with target mRNAs are continuous from the nucleus until their final destination in
the cytoplasm, but the importance of FMRP’s nuclear role has certainly been underestimated in
the past. A role for FMRP in the nucleus would be of importance due to the following reasons.
First, FMRP may affect splicing on other genes besides Nl1. If FMRP is involved in
alternative splicing, this event would happen before its involvement regulating target mRNA
stability, transport and translation. Thus, the earlier and the more upstream control is exerted on a
gene, the more important this regulation is for the target gene. Considering that more than 80%
of human genes undergo alternative splicing, it is possible that at least part of the pathogenicity
of FXS is a result of the abnormal alternative splicing. If this hypothesis is true, then there will
be many genes with altered splicing patterns in the absence of FMRP. To study this hypothesis,
more genes should be tested for the abnormal splicing, like the known FMRP targets, and
especially ones with alternative splicing, like other Nl isoforms besides Nl1, all Nrxs isoforms
and Fmr1 itself. If the alternative splicing of other genes is also changed in Fmr1 KO mice, this
would strengthen the argument that FMRP has an important role in alternative splicing. In fact,
this may lead to a new era of FMRP research focusing on its roles in the nucleus and a new
theory of how loss of functional FMRP causes the disease, namely the “altered splicing theory of
FXS”.
Second, previous reports showed that Drosophila FMR1 was involved in dADAR RNA
editing, but it is unknown whether FMRP is also involved in RNA editing in mammals. If it is,
whether or not this influence in RNA editing would affect splicing by editing critical splice sites
for recognition by splicing machinery should be studied. The first experiments to test this
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hypothesis should focus on determining whether FMRP and ADAR (and other RNA editing
enzymes) physically interact via immunoprecipitation. It is possible that FMRP may play a role
in alternative splicing through RNA editing: if a key splice site is edited through RNA editing by
FMRP directly or indirectly, then the splicing pattern would be changed. If this is the case,
carefully scrutinizing the Nl1 DNA sequence and linking it to the mature variants will help to
determine which type of RNA editing happening in Neuroligin1. After all, there is also other
types of RNA editing besides A-I conversion, and there are specific enzyme responsible for each
type of editing.
Third, it is still unclear how the life cycle of FMRP looks like. It is possible the journey
of FMRP and its targets start in the nucleus. So far, there is no solid evidence showing FMRP
and its target mRNAs exporting from the nucleus to the cytoplasm. If this event is observed, then
we can know more about when and where FMRP begins to get involved in RNA binding and
gene expression regulation. New microscopic technology and RNA labeling technique may help
us to observe this process.
In the cytoplasm phase, we have captured the transport of Nl1 3’ UTR mRNAs to
synapses and the co-transport of mRNAs with FMRP. We have not yet visualized an mRNP
containing both mRNA and FMRP moving to synapses, an important step towards understanding
activity-dependent mRNA transport during synaptic plasticity. It seems that stimulation in the
form of synapse formation is enough to trigger Nl1 expression in WT but not in Fmr1 KO
neurons (unpublished data). Using different combinations of fluorescent proteins in live imaging
experiments can help us to visualize the co-transport of FMRP with its targets to synapses upon
stimulation. We found that the Fmr1 and Nl1 3’ UTR are localized to dendrites, and that the Nl1
3’ UTR is specifically localized to synapses. Similar to the case of the zip-code region in the β-
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Actin 3’ UTR, it would be interesting to study the 3’ UTRs of Fmr1 and Nl1 in more detail to
identify specific sequences that are responsible for dendritic/synaptic targeting. In this thesis, the
phosphorylation of FMRP did not interfere with the basal dendritic localization of Nl1 3’ UTR.
However, previous reports provided evidence that the phosphorylation of FMRP affects the
dynamics of RNP granules of some of its targets under stimulation. Thus, it’s possible that
stimulation may cause FMRP-containing RNPs to slow down and anchor at synapses upon
synaptic stimulation. This would require techniques to robustly image and analyze moving RNP
granules containing Fmr1 and Nl1 3’ UTR.
In the translational regulation aspect, we have observed that FMRP regulates global
translation of target mRNAs, and that 3’ UTRs are sufficient to allow local. The next step would
be to study in detail the role of FMRP in regulating local translation of mRNAs through
regulation of their 3’ UTR – both in basal and stimulated conditions. It seems the stimulation like
synapse formation is enough to trigger Nl1 expression in WT but not in Fmr1 KO (unpublished
data).
The FMRP in the dendrites can be classified as soma translated and local translated. It is
translated immediately in dendrites after stimulation and we also observed FMRP transported to
dendrites. We believe there are differences between FMRP translated from different site. They
may target different mRNAs and regulate translation differently. It would be to tell the difference
between them.
In the Neuroligin research, we found a new splice variant +A1+A2+B, also we found the
expression of variants +A1+B, +A2+B and ΔA+B are different in WT and Fmr1 KO mice. It is
unknown how these variants differ in neuron physiology like synaptogenesis and synaptic
plasticity. More experiments are needed to distinguish the functions of these Nl1 variants. The
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physiological difference between Nl1 variants may further explain the roles of FMRP in FXS.
Also, we still do not know whether the changes in mRNA variants are the cause of the difference
of proteins in western blot of synaptosomes from hippocampus of WT and Fmr1 KO mouse. We
do not know the physiological effect caused by the protein bands either. For the splicing part, we
found Nl1 variant +A2+B abundance increased in Fmr1 KO hippocampus. To understand the
function of this variant, overexpression of this variant in WT should be able to switch the neuron
to be more like Fmr1 KO neurons.
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Figure 6-1
FMRP targets local translation model
Stimulation like new synapse formation or neurotransmitter on the post-synaptic terminal can
send retrograde signals to cell body and trigger anterograde co-transport of target mRNA and
FMRP to base of spine. FMRP is regulated by local stimulation through phosphorylation and
dephosphorylation. When FMRP is dephosphorylated, the target gene is locally translated at the
post-synaptic terminal.
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